Immunoengineering through cancer vaccines – A personalized and multi-step vaccine approach towards precise cancer immunity

During the last decade anti-tumor immune-therapy has opened novel opportunities to efficiently combat cancer progression. The introduction of DC- and CAR T-cell based therapies as well as the successful application of antibody-based inhibitor of immune checkpoints (CTLA-4, PD1 and PDL1) have boosted...

Full description

Saved in:
Bibliographic Details
Published inJournal of controlled release Vol. 289; pp. 125 - 145
Main Authors Lybaert, Lien, Vermaelen, Karim, De Geest, Bruno G., Nuhn, Lutz
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 10.11.2018
Online AccessGet full text

Cover

Abstract During the last decade anti-tumor immune-therapy has opened novel opportunities to efficiently combat cancer progression. The introduction of DC- and CAR T-cell based therapies as well as the successful application of antibody-based inhibitor of immune checkpoints (CTLA-4, PD1 and PDL1) have boosted the field and led to an overall benefit for many patients. In situ cancer vaccination is an attractive strategy to further improve the therapeutic outcome, especially towards a more personalized and individually tailored immune response against the patient’s mutanome. Nanoparticle-based delivery platforms can assist in combination treatments e.g. with multiple immune stimulatory signales (PAMPs and DAMPs) to increase the probability of evoking broader and all-embracing cytotoxic and memory T-cell responses. In this review, various approaches and hurdles of cancer vaccination are discussed including the beneficial contributions of the thriving field of nanoparticle design and functionalization, which may further boost the development of cancer immunotherapeutics. [Display omitted]
AbstractList During the last decade anti-tumor immune-therapy has opened novel opportunities to efficiently combat cancer progression. The introduction of DC- and CAR T-cell based therapies as well as the successful application of antibody-based inhibitor of immune checkpoints (CTLA-4, PD1 and PDL1) have boosted the field and led to an overall benefit for many patients. In situ cancer vaccination is an attractive strategy to further improve the therapeutic outcome, especially towards a more personalized and individually tailored immune response against the patient's mutanome. Nanoparticle-based delivery platforms can assist in combination treatments e.g. with multiple immune stimulatory signales (PAMPs and DAMPs) to increase the probability of evoking broader and all-embracing cytotoxic and memory T-cell responses. In this review, various approaches and hurdles of cancer vaccination are discussed including the beneficial contributions of the thriving field of nanoparticle design and functionalization, which may further boost the development of cancer immunotherapeutics.
During the last decade anti-tumor immune-therapy has opened novel opportunities to efficiently combat cancer progression. The introduction of DC- and CAR T-cell based therapies as well as the successful application of antibody-based inhibitor of immune checkpoints (CTLA-4, PD1 and PDL1) have boosted the field and led to an overall benefit for many patients. In situ cancer vaccination is an attractive strategy to further improve the therapeutic outcome, especially towards a more personalized and individually tailored immune response against the patient’s mutanome. Nanoparticle-based delivery platforms can assist in combination treatments e.g. with multiple immune stimulatory signales (PAMPs and DAMPs) to increase the probability of evoking broader and all-embracing cytotoxic and memory T-cell responses. In this review, various approaches and hurdles of cancer vaccination are discussed including the beneficial contributions of the thriving field of nanoparticle design and functionalization, which may further boost the development of cancer immunotherapeutics. [Display omitted]
Author De Geest, Bruno G.
Nuhn, Lutz
Vermaelen, Karim
Lybaert, Lien
Author_xml – sequence: 1
  givenname: Lien
  surname: Lybaert
  fullname: Lybaert, Lien
  organization: Department of Pharmaceutics, Ghent University, Ghent, Belgium
– sequence: 2
  givenname: Karim
  surname: Vermaelen
  fullname: Vermaelen, Karim
  organization: Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium
– sequence: 3
  givenname: Bruno G.
  orcidid: 0000-0001-9826-6170
  surname: De Geest
  fullname: De Geest, Bruno G.
  email: br.degeest@ugent.be
  organization: Department of Pharmaceutics, Ghent University, Ghent, Belgium
– sequence: 4
  givenname: Lutz
  surname: Nuhn
  fullname: Nuhn, Lutz
  email: lutz.nuhn@mpip-mainz.mpg.de
  organization: Max-Planck-Institute for Polymer Research, Mainz, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30223044$$D View this record in MEDLINE/PubMed
BookMark eNqFkMFuEzEQhi3UiqaFRwD5yGWX8Trr2CdUVRQqVeJSzpbXniSOdu3F3i1qxaHvwBvyJDhKwpXTHOab-We-S3IWYkBC3jGoGTDxcVfvbAwJ-7oBJmtQNYB6RRZMrni1VKo9I4vCyYqLVl2Qy5x3ANDy5eo1ueDQNByWywX5dTcMc4gYNj4gJh82dNqmOG-21JpgMdFHY23pZfrn5Te9piOmHIPp_TM6aoKjw9xPvsoTjieUmnFM0dgtneJPk1ymY0LrM55W-n2mn57ekPO16TO-PdYr8v3288PN1-r-25e7m-v7ypbjpwqlZLwzDGUD2Fm3QiGtdEzwRrTCKNFJEIY3FkEq2xrV7Tvl1_XKKdEofkU-HPaWs37MmCc9-Gyx703AOGfdMFCct1y1BW0PqE0x54RrPSY_mPSkGei9eL3TR_F6L16D0kV8mXt_jJi7Ad2_qZPpAnw6AFgeffSYdLYeiw7ni5xJu-j_E_EXsq2cBw
CitedBy_id crossref_primary_10_3389_fonc_2024_1389775
crossref_primary_10_3390_cells9092021
crossref_primary_10_1002_adtp_202300076
crossref_primary_10_1016_j_jconrel_2023_12_007
crossref_primary_10_1021_jacs_1c03772
crossref_primary_10_1007_s12274_021_3525_6
crossref_primary_10_1002_adhm_202100299
crossref_primary_10_1002_ange_201905687
crossref_primary_10_1002_mabi_202100356
crossref_primary_10_3389_fphar_2021_679602
crossref_primary_10_1021_acs_biomac_0c00205
crossref_primary_10_1038_s41413_023_00246_z
crossref_primary_10_1002_advs_202402935
crossref_primary_10_1002_macp_202300199
crossref_primary_10_1016_j_eurpolymj_2024_113150
crossref_primary_10_1021_acsnano_1c02103
crossref_primary_10_1021_acsnano_1c10709
crossref_primary_10_1016_j_trecan_2023_02_004
crossref_primary_10_3389_fphar_2019_00751
crossref_primary_10_1002_marc_202100829
crossref_primary_10_1016_j_eurpolymj_2020_109481
crossref_primary_10_3389_fcell_2020_607209
crossref_primary_10_3389_fimmu_2020_620374
crossref_primary_10_1002_anie_201905687
crossref_primary_10_1021_acsnano_3c02273
crossref_primary_10_3389_fonc_2019_00720
crossref_primary_10_1093_jleuko_qiad051
crossref_primary_10_1002_advs_202401539
crossref_primary_10_1021_jacs_3c08511
crossref_primary_10_1021_acs_biomac_1c00440
crossref_primary_10_1186_s12920_022_01411_9
Cites_doi 10.1056/NEJMoa1001294
10.1038/s41467-017-01651-9
10.1093/intimm/dxw021
10.2217/nnm.14.199
10.1016/j.biotechadv.2016.04.005
10.1007/s11596-010-0354-3
10.1002/ijc.27801
10.1172/JCI74894
10.1046/j.1440-1711.2000.00906.x
10.1016/j.molmed.2015.05.005
10.1016/j.it.2016.09.006
10.1038/cddis.2013.207
10.1021/acsnano.6b08152
10.1007/s00018-008-8228-6
10.1038/s41551-018-0236-8
10.1021/mp200394t
10.1124/pr.114.009456
10.1007/s10555-011-9270-7
10.1007/s00428-015-1787-7
10.1189/jlb.0812397
10.1038/nri3156
10.1016/j.coph.2013.05.017
10.1073/pnas.1104264108
10.1586/erv.12.35
10.1158/0008-5472.CAN-12-0569
10.1097/CCO.0b013e3283380939
10.1016/S0065-2776(10)05003-0
10.1038/gt.2013.35
10.1158/0008-5472.CAN-10-2907
10.1038/ni1102-991
10.1155/2013/764706
10.1016/S1470-2045(12)70006-2
10.1002/anie.201509935
10.1007/s00005-011-0129-y
10.1080/2162402X.2017.1386829
10.4161/onci.21205
10.1007/s00262-006-0183-1
10.1097/MOU.0b013e3283381793
10.1111/cas.13072
10.1111/j.1600-065X.2008.00610.x
10.1016/j.apsb.2015.05.007
10.1016/j.smim.2008.09.006
10.1158/0008-5472.CAN-13-2685
10.1002/adhm.201200441
10.1038/nature22991
10.1016/j.coi.2015.11.009
10.1586/14760584.3.4.403
10.3389/fonc.2013.00049
10.1038/nature23003
10.2147/IJN.S33666
10.1002/ijc.21163
10.4161/21624011.2014.967147
10.1186/1479-5876-8-84
10.1158/1078-0432.CCR-15-1362
10.1007/s00432-007-0315-9
10.1136/gut.2009.194472
10.4049/jimmunol.180.11.7249
10.1158/1078-0432.CCR-14-1716
10.1021/mp100067u
10.1172/JCI79915
10.1097/PPO.0b013e3181eb33d7
10.1038/nrurol.2010.71
10.1038/cgt.2009.39
10.1111/j.1365-2567.2010.03255.x
10.1016/j.coi.2014.01.004
10.1007/s00262-013-1396-8
10.1016/j.vaccine.2016.06.080
10.1016/j.imlet.2010.06.001
10.1021/acs.bioconjchem.8b00319
10.1002/eji.201344272
10.1158/1078-0432.CCR-14-3145
10.1111/joim.12091
10.1034/j.1600-065X.2002.18809.x
10.1189/jlb.1107774
10.1038/nri2173
10.1007/s00345-015-1615-3
10.1615/CritRevImmunol.v30.i4.30
10.1200/JCO.2012.47.7521
10.1016/j.it.2013.10.001
10.1158/0008-5472.CAN-11-3687
10.1111/imr.12432
10.3389/fimmu.2014.00360
10.1073/pnas.1600816113
10.1016/j.coi.2011.12.011
10.1158/2326-6066.CIR-13-0180
10.1039/C3TB21317J
10.1002/biot.200500044
10.1158/0008-5472.CAN-07-1882
10.1016/j.vaccine.2011.09.061
10.1016/j.biomaterials.2018.03.026
10.1002/adfm.201402303
10.3389/fphar.2013.00028
10.18632/oncotarget.8698
10.1126/scitranslmed.aan3682
10.1002/advs.201700050
10.1021/acs.nanolett.5b05030
10.1016/j.it.2012.02.006
10.1517/17425247.2014.901308
10.1016/j.smim.2010.02.004
10.1586/14760584.2013.811195
10.4161/21645515.2014.982996
10.1007/s00262-011-1011-9
10.1158/0008-5472.CAN-11-4062
10.1182/blood-2006-03-006403
10.3390/vaccines3020344
10.1136/bmj.h988
10.3349/ymj.2017.58.3.489
10.1126/scitranslmed.aaa4306
10.1080/2162402X.2015.1016700
10.1021/acs.biomac.6b00685
10.2217/nnm.14.193
10.1002/path.4287
10.1097/COC.0000000000000239
10.1038/nri2343
10.1002/ijc.29481
10.1111/j.1600-065X.2008.00718.x
10.1007/s00262-008-0532-3
10.1186/s12916-016-0623-5
10.1002/adfm.201802540
10.1371/journal.pone.0067904
10.1016/j.ejca.2016.06.028
10.1146/annurev.immunol.22.012703.104803
10.2515/therapie/2010069
10.2217/nnm-2016-0275
10.1016/j.coi.2016.07.005
10.1002/JLB.5MIR0917-351R
10.1186/s12943-018-0804-2
10.1016/j.coi.2009.05.018
10.1016/j.smim.2015.11.002
10.1021/nn205099c
10.1016/j.cell.2014.03.047
10.1016/j.it.2011.12.001
10.1158/0008-5472.CAN-07-2593
10.1038/nm976
10.1097/CJI.0b013e3181d32f01
10.4161/21645515.2014.980686
10.1016/j.coi.2010.11.013
10.18632/oncotarget.9910
10.1002/eji.201041235
10.1371/journal.pone.0152500
10.1016/j.cytogfr.2015.01.001
10.1002/anie.200902564
10.1038/jid.2012.283
10.1021/acs.nanolett.6b01994
10.1002/ijc.21303
10.1002/chem.201400256
10.4049/jimmunol.1701188
10.1111/cas.12621
10.1016/j.ccell.2016.03.009
10.1093/intimm/dxw014
10.1158/0008-5472.CAN-10-2820
10.1186/2051-1426-2-S3-O15
10.1016/j.semcancer.2007.06.009
10.1016/j.vaccine.2010.09.077
10.1182/blood-2009-09-246124
10.1073/pnas.1533209100
10.1158/1940-6207.CAPR-14-0094
10.4161/21645515.2014.973317
10.1016/j.jconrel.2017.05.012
10.1038/ncomms13720
10.1002/adhm.201400460
10.1146/annurev-immunol-030409-101243
10.1097/PPO.0b013e318233e5b2
10.1016/j.coi.2011.03.007
10.3389/fimmu.2018.00398
10.1007/s00432-008-0395-1
10.1038/nrc.2016.36
10.1111/j.1749-6632.2009.04939.x
10.1016/j.immuni.2016.04.020
10.1093/intimm/dxw027
10.3389/fonc.2014.00142
10.1158/0008-5472.CAN-11-4094
10.1158/1940-6207.CAPR-10-0040
10.1016/j.nano.2017.10.013
10.1158/0008-5472.CAN-06-0488
10.1146/annurev-immunol-031210-101324
10.1158/1535-7163.MCT-15-0742
10.1053/j.seminoncol.2012.02.007
10.1021/nn502975r
10.1038/nature14011
10.1038/ncomms8556
10.2217/imt.13.102
10.3389/fimmu.2014.00603
10.1007/s10549-011-1470-x
10.1038/nri1707
10.1016/S1470-2045(16)00099-1
10.1016/j.ccr.2013.12.004
10.1056/NEJMoa1406498
10.1155/2011/430394
10.1080/08830180902978120
10.1038/nri1961
10.4149/neo_2016_517
10.1002/eji.200425887
10.3389/fimmu.2015.00482
10.1111/jdv.13968
10.3389/fimmu.2015.00663
10.1038/ncomms13193
10.1007/s00428-016-1910-4
10.1210/en.2009-1082
10.1038/icb.2016.81
10.3389/fimmu.2016.00032
10.1016/j.jconrel.2016.05.033
10.1002/adma.201200446
10.1002/ccr3.596
10.4161/bioe.24666
10.1111/j.0022-202X.2004.23535.x
10.18632/oncotarget.2222
10.1053/j.seminoncol.2015.05.011
10.1093/carcin/bgh283
10.1080/1061186X.2016.1236112
10.2217/nnm-2016-0174
10.1038/nrd4591
10.21037/atm.2016.07.11
10.1016/j.jconrel.2015.02.006
10.1111/j.1365-2796.2010.02317.x
10.1016/j.tibtech.2016.01.005
10.1586/14760584.2013.811188
10.1186/s40425-015-0089-6
10.1158/1078-0432.CCR-16-2677
10.1021/bi901546e
10.1126/science.aaf1490
10.1016/j.ccell.2014.12.001
10.3389/fimmu.2015.00310
10.1016/j.coi.2009.03.011
10.1158/1078-0432.CCR-15-1433
10.1038/nature18300
10.4049/jimmunol.167.9.4844
10.1007/s10120-011-0090-9
10.1016/j.semcancer.2015.03.004
10.1038/nbt.3371
10.1056/NEJMoa1302369
10.1186/2051-1426-1-10
10.3390/cancers6031670
10.1038/nri.2016.107
10.1089/ars.2013.5378
10.1158/1078-0432.CCR-14-1711
10.1016/j.immuni.2016.05.002
10.1038/nature13904
10.1111/j.1365-2567.2007.02587.x
10.1080/2162402X.2015.1086862
10.1016/j.immuni.2013.07.004
10.1021/nn305466z
10.1016/j.celrep.2016.03.037
10.1073/pnas.0809818106
10.18632/oncotarget.6884
10.3389/fimmu.2014.00182
10.4161/21624011.2014.953407
10.1016/j.ejca.2015.08.021
10.1038/s41551-016-0011
10.1093/annonc/mdx760.002
10.1073/pnas.1209367109
10.1126/science.aaf2834
10.1182/blood-2012-09-452078
10.1038/nri3133
10.1002/anie.201200048
10.1586/erv.10.141
10.1158/2326-6066.CIR-14-0036
10.1016/j.it.2016.01.002
10.1038/nmat3775
10.1097/PPO.0b013e3181eb3343
10.1200/JCO.2005.01.109
10.3390/vaccines3030662
10.1016/j.str.2011.02.004
10.1586/14760584.2013.836320
10.1038/nm.4086
10.1016/j.immuni.2014.10.019
10.1016/j.jconrel.2015.03.029
10.1002/adma.201803397
10.1053/j.seminoncol.2014.09.004
10.3389/fonc.2018.00049
10.1111/j.0105-2896.2006.00391.x
10.1080/21645515.2015.1105415
10.4161/onci.27058
10.1586/14760584.6.6.925
10.1016/j.bcmd.2005.03.003
10.1002/anie.201304212
10.1038/nrc2326
10.1007/978-1-4614-5915-6_9
10.1586/14760584.2014.911093
10.1007/s00262-014-1549-4
10.1038/nri3845
10.1016/j.smim.2015.10.007
10.3747/co.19.945
10.1038/cti.2016.22
10.1038/sj.bjc.6605820
10.1007/s00109-015-1376-x
10.1126/science.aaa6204
10.1038/nrc3239
10.1038/nrclinonc.2011.157
10.1200/JCO.2015.60.8448
10.3892/ol.2013.1616
10.1002/adma.200801478
10.1016/j.prp.2009.10.001
10.1016/j.biomaterials.2017.09.014
10.1046/j.1365-2796.2003.01140.x
10.1038/nrc3245
10.1146/annurev.immunol.25.022106.141609
10.1038/cddis.2015.162
10.1016/j.lungcan.2016.04.021
10.1021/acs.bioconjchem.6b00277
10.1002/ijc.25270
10.1111/j.1600-0463.2008.01163.x
10.1016/j.immuni.2004.07.017
10.1016/j.coi.2015.12.007
10.1007/s00262-008-0536-z
10.1158/1078-0432.CCR-15-1509
10.1182/blood-2008-01-135319
10.1038/nri2510
10.1126/scitranslmed.3009980
10.1517/14712598.2014.927432
10.1007/s00262-011-1046-y
10.1189/jlb.2MR0316-117RR
10.4161/21624011.2014.954829
10.1038/nm0302-274
10.1002/chem.201403942
10.2217/imt-2015-0002
10.1038/nrc776
10.1039/B914943K
10.1126/science.aaa4971
10.1038/cti.2016.6
10.1172/JCI45817
10.1007/s00262-011-1178-0
10.1158/2159-8290.CD-16-0146
10.1126/scitranslmed.3006504
10.1186/1479-5876-10-205
10.1021/acsnano.5b07973
10.1038/nbt.3398
10.1172/JCI80005
10.1039/c3cs35470a
10.1186/1471-2407-14-486
10.1080/2162402X.2016.1232237
10.1158/1078-0432.CCR-15-1849
10.1016/j.ccell.2015.02.015
10.1038/nbt1332
10.1038/nature13954
10.1016/j.virol.2014.12.033
10.7150/ijbs.7.651
10.1038/nrc1886
10.1016/j.smim.2010.02.001
10.1101/gr.165985.113
10.1038/nrc2734
10.1038/nrc3258
10.1016/j.jconrel.2006.01.006
10.1084/jem.20112321
10.1007/s00262-012-1321-6
10.1200/JCO.2010.30.5037
10.1007/s00281-013-0367-7
10.1155/2016/6058147
10.1016/j.coi.2013.12.005
10.1158/1078-0432.CCR-14-2468
10.1016/j.immuni.2015.11.024
10.1038/sj.bjc.6601331
10.1345/aph.1P651
10.1592/phco.31.8.813
10.1016/j.ymeth.2006.05.016
10.1021/cb500079s
10.1186/1479-5876-11-148
10.1002/ijc.26411
10.4269/ajtmh.2012.11-0525
10.4161/hv.20474
10.1039/c3cs60039d
10.1038/cdd.2016.5
10.1007/978-1-4939-6445-1_10
10.1002/cam4.371
10.3389/fimmu.2014.00197
10.1056/NEJMoa1003466
10.1111/j.0105-2896.2004.00139.x
10.1007/s11864-016-0434-0
10.1126/science.aaa1348
10.1016/S1471-4906(02)02281-0
10.1056/NEJMoa020177
10.1038/nri3862
10.1016/j.coi.2013.03.004
10.1016/S0065-230X(08)60240-7
10.1111/nyas.12756
10.3389/fimmu.2017.00828
10.1002/adma.201402996
10.1038/nm1100
10.1158/1078-0432.CCR-11-0482
10.1038/nature06175
10.1172/JCI86892
10.1007/s00262-007-0343-y
10.2174/0929867324666170320114359
10.1038/32588
10.1186/s12916-015-0455-8
10.1016/j.tvjl.2013.06.005
10.1371/journal.pone.0143080
10.2147/OTT.S119362
10.1021/acs.chemmater.6b05062
ContentType Journal Article
Copyright 2018 Elsevier B.V.
Copyright © 2018 Elsevier B.V. All rights reserved.
Copyright_xml – notice: 2018 Elsevier B.V.
– notice: Copyright © 2018 Elsevier B.V. All rights reserved.
DBID NPM
AAYXX
CITATION
7X8
DOI 10.1016/j.jconrel.2018.09.009
DatabaseName PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-4995
EndPage 145
ExternalDocumentID 10_1016_j_jconrel_2018_09_009
30223044
S0168365918305285
Genre Journal Article
Review
GroupedDBID ---
--K
--M
.~1
0R~
1B1
1RT
1~.
1~5
4.4
457
4G.
53G
5GY
5VS
7-5
71M
8P~
9JM
AABNK
AABXZ
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AATCM
AAXUO
ABFNM
ABFRF
ABJNI
ABMAC
ABOCM
ABYKQ
ABZDS
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ADBBV
ADEZE
AEBSH
AEFWE
AEKER
AENEX
AEZYN
AFKWA
AFRZQ
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AIEXJ
AIKHN
AITUG
AJOXV
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
AXJTR
BKOJK
BLXMC
C45
CS3
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
HMT
IHE
J1W
KOM
M34
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
RIG
RNS
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SPC
SPCBC
SSM
SSP
SSZ
T5K
TEORI
~G-
AAHBH
AAXKI
AKRWK
NPM
.GJ
29K
3O-
AAQXK
AAYOK
AAYXX
ABXDB
ACNNM
ADMUD
AFJKZ
AHHHB
ASPBG
AVWKF
AZFZN
CITATION
D-I
FEDTE
FGOYB
G-2
HVGLF
HZ~
R2-
SEW
SPT
WUQ
7X8
ID FETCH-LOGICAL-c365t-e8813ba1e820ebcd7e68c8d1632656a96b806a32ce089c5a9b6326053f7d96293
IEDL.DBID .~1
ISSN 0168-3659
IngestDate Sat Oct 26 01:21:54 EDT 2024
Thu Sep 26 21:51:44 EDT 2024
Wed Oct 16 00:51:29 EDT 2024
Fri Feb 23 02:33:26 EST 2024
IsPeerReviewed true
IsScholarly true
Language English
License Copyright © 2018 Elsevier B.V. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c365t-e8813ba1e820ebcd7e68c8d1632656a96b806a32ce089c5a9b6326053f7d96293
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ORCID 0000-0001-9826-6170
PMID 30223044
PQID 2109335395
PQPubID 23479
PageCount 21
ParticipantIDs proquest_miscellaneous_2109335395
crossref_primary_10_1016_j_jconrel_2018_09_009
pubmed_primary_30223044
elsevier_sciencedirect_doi_10_1016_j_jconrel_2018_09_009
PublicationCentury 2000
PublicationDate 2018-11-10
PublicationDateYYYYMMDD 2018-11-10
PublicationDate_xml – month: 11
  year: 2018
  text: 2018-11-10
  day: 10
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Journal of controlled release
PublicationTitleAlternate J Control Release
PublicationYear 2018
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Burnette (bb1410) 2011; 71
Fox, Haensler (bb0795) 2013; 12
Tarhini (bb1570) 2013; 2013
Vlkova (bb1100) 2014; 5
Karagiannis, Iriguchi, Kaneko (bb1145) 2016; 28
Kreiter, Diken, Selmi, Türeci, Sahin (bb0385) 2011; 23
Quesnel (bb0070) 2008; 116
Disis (bb0265) 2014; 41
Ribas (bb1555) 2005; 23
Shen (bb2055) 2015; 3
Prendergast (bb1190) 2014; 63
Dunn, Koebel, Schreiber (bb0110) 2006; 6
Oki, Younes (bb0975) 2004; 3
Cottin, Niedrig, Domingo (bb0830) 2013; 12
Weir (bb2115) 2014; 3
Lynn (bb0895) 2015; 33
Zhou (bb1095) 2009; 28
Biswas, Allavena, Mantovani (bb0175) 2013; 35
de Souza Apostólico, Santos Lunardelli, Coirada, Boscardin, Santoro Rosa (bb0780) 2016; 2016
Slingluff, The (bb0375) 2011; 17
Liu (bb1210) 2010; 115
Draghiciu, Lubbers, Nijman, Daemen (bb1340) 2015; 4
De Coen, Vanparijs, Risseeuw, Lybaert, Louage, De Koker, Kumar, Grooten, Taylor, Van Calenbergh, Nuhn, De Geest (bb0755) 2016; 11
Su, Chen, Shieh, Yeh, Su (bb1350) 2012; 7
Benne, van Duijn, Kuiper, Jiskoot, Slutter (bb0635) 2016; 234
Mlecnik, Bindea, Pagès, Galon (bb1730) 2011; 30
Nuhn, De Koker, Van Lint, Zhong, Catani, Combes, Deswarte, Li, Lambrecht, Lienenklaus, Sanders, David, Tavernier, De Geest (bb0915) 2018
Shah, O'Hagan, Amiji, Brito (bb0670) 2014; 9
Brown (bb1915) 2014; 24
De Geest, Willart, Hammad, Lambrecht, Pollard, Bogaert, De Filette, Saelens, Vervaet, Remon, Grooten, De Koker (bb0695) 2012; 6
Bühler, Gietzen, Reuter, Kappel, Fischer, Decker, Schäffel, Koynov, Bros, Tubbe, Grabbe, Schmidt (bb0765) 2014; 20
Taiakina, Dal Pra, Bristow (bb1960) 2014; 772
Vandenberk, Belmans, Van Woensel, Riva, Van Gool (bb0935) 2016; 6
Mueller, Ahmed (bb1150) 2009; 106
Yata, Takahashi, Tan, Nahatsuji, Ohtsuki, Murakami, Imahori, Umeki, Shiomi, Takakura (bb0950) 2017; 146
Glaffig, Palitzsch, Hartmann, Schüll, Nuhn, Gerlitzki, Schmitt, Frey, Kunz (bb0440) 2014; 20
Davis (bb0260) 2000; 78
Roohi, Hojjat-Farsangi (bb1260) 2017; 25
Steinman, Banchereau (bb0305) 2007; 449
McGranahan (bb1690) 2016; 351
Gajewski, Fuertes, Spaapen, Zheng, Kline (bb1645) 2011; 23
Yang, Jeang, Yang, Wu, Hung (bb0450) 2014; 10
Fan, Moon (bb0640) 2015; 3
Baba, Sato-Matsushita, Kanamoto, Itoh, Oyaizu, Inoue, Kawakami, Tahara (bb2005) 2010; 8
Mukherjee (bb2030) 2009; 1950
Kaiser, Gaidzik, Westerlind, Kowalczyk Hobel, Schmitt, Kunz (bb0425) 2009; 48
Maus, June (bb0405) 2016; 22
Nuhn, Hartmann, Palitzsch, Gerlitzki, Schmitt, Zentel, Kunz (bb0435) 2013; 52
Chowdhury (bb1875) 2016; 7
Li, Xu, Zou, Wang (bb2100) 2010; 30
Jing (bb1950) 2015; 8
Chen, Xu, Liang, Wang, Peng, Liu (bb0960) 2016; 7
Grabbe, Haas, Diken, Kranz, Langguth, Sahin (bb0530) 2016; 11
Shrotriya, Walsh, Bennani-Baiti, Thomas, Lorton (bb1945) 2015; 10
Perl (bb1245) 2015; 1346
Bencherif, Sands, Ali, Li, Lewin, Braschler, Shih, Verbeke, Bhatta, Dranoff, Mooney (bb0575) 2015; 6
Corthay (bb0090) 2014; 5
Diniz, Sales, Silva, Ferreira (bb2050) 2016; 15
Ophir, Bobisse, Coukos, Harari, Kandalaft (bb0360) 2016; 1865
Wang, Smith, Yin (bb0865) 2013; 42
Nars, Kaneno (bb1085) 2013; 132
Schaer, Murphy, Wolchok (bb1450) 2012; 24
Leffers (bb1815) 2010; 103
Shurin, Tourkova, Kaneno, Shurin (bb2125) 2009; 1950
bb1685
Mayanagi (bb2025) 2015; 106
Kim, Emi, Tanabe (bb0055) 2007; 121
Joffre, Nolte, Sporri, Reise Sousa (bb0720) 2009; 227
Facciabene, Motz, Coukos (bb0205) 2012; 72
Rivoltini (bb1015) 2002; 188
Madjd, Spendlove, Pinder, Ellis, Durrant (bb1995) 2005; 117
Wang (bb1675) 2004; 10
McKinney, Smith (bb1135) 2016; 94
Mazor, Pankov, Song, Costello (bb0080) 2016; 29
Zolnik, González-Fernández, Sadrieh, Dobrovolskaia (bb0235) 2010; 151
Spranger, Gajewski (bb1635) 2015; 3
Rundqvist, Johnson (bb1965) 2013; 274
Zeng (bb1880) 2016; 7
Kim, Bae (bb0185) 2016; 2016
Galluzzi, Buqué, Kepp, Zitvogel, Kroemer (bb0920) 2017; 17
Petersen, Dickgreber, Hermans (bb0330) 2010; 30
Kantoff (bb0620) 2010; 363
Reck (bb1680) 2017; 28
Zhang, Zheng (bb0980) 2013; 6
Dowling, Mansell (bb0735) 2016; 5
Ogino (bb1980) 2006; 66
Raza Zaidi, Merlino (bb1110) 2011; 17
Nakakubo (bb1775) 2003; 89
bb0015
Yuan, Liu, Fu, Chen (bb1930) 2012; 37
Lybaert, De Vlieghere, De Rycke, Vanparijs, De Wever, De Koker, De Geest (bb0550) 2014; 24
Clayton, Mitchell, Court, Linnane, Mason, Tabi (bb1060) 2008; 180
Ihara (bb1650) 2012; 72
Hiramoto (bb1285) 2014; 7
Liu, Cao (bb0150) 2016; 94
Garrido, Cabrera, Aptsiauri (bb1075) 2010; 127
Mesenheimer (bb2135) 2017; 23
Gilboa, Vieweg (bb0595) 2004; 199
Zhang (bb1865) 2016; 107
Bernal, Ruiz-Cabello, Concha, Paschen, Garrido (bb1070) 2012; 61
Vinay (bb1020) 2015; 35
Fridman, Pagès, Sautès-Fridman, Galon (bb1745) 2012; 12
McGranahan (bb1920) 2016; 351
Gibney (bb2085) 2015; 21
Traynor (bb1505) 2011; 68
Rabinovich, Gabrilovich, Sotomayor (bb0095) 2007; 25
Yu, Tang, Sun (bb1255) 2017; 58
Saito (bb1845) 2016; 22
bb0010
Cui, Osada, Imaizumi, Kataoka, Nakano (bb0485) 2015; 206
González-Navajas, Lee, David, Raz (bb1390) 2012; 12
Pardoll (bb1495) 2012; 12
Mohr, Kappel, Kramer, Bros, Grabbe, Zentel (bb0750) 2016; 11
Porembka (bb1305) 2012; 61
bb0005
Turcotte (bb1985) 2014; 2
Farkona, Diamandis, Blasutig (bb1715) 2016; 14
Cicchelero, de Rooster, Sanders (bb0565) 2014; 13
Marvel, Gabrilovich (bb1270) 2015; 125
Morse (bb2020) 2008; 112
Lee (bb1325) 2012; 131
Raedler (bb1520) 2015; 8
Nivolumab approved for Lung Cancer (bb1510) 2015; 5
Birnbaum (bb1705) 2014; 157
Soliman, Mediavilla-Varela, Antonia (bb1200) 2010; 16
Corrales, Gajewski (bb1385) 2015; 21
Tagliamonte, Petrizzo, Tornesello, Buonaguro, Buonaguro (bb0395) 2014; 10
Wesolowski, Markowitz, Carson (bb1335) 2013; 1
Kashimura (bb1835) 2012; 15
Igney, Krammer (bb0125) 2002; 2
Schildberg, Klein, Freeman, Sharpe (bb1525) 2016; 44
Leifer, Medvedev (bb0860) 2016; 100
Irvine, Swartz, Szeto (bb0645) 2013; 12
Powles (bb1890) 2014; 515
Sheng Sow, Mattarollo (bb2110) 2013; 2
Suckow, Heinrich, Rosen (bb0570) 2007; 6
Hanson, Irvine (bb0875) 2017; 1494
Kyte (bb0585) 2016; 5
Deering, Kommareddy, Ulmer, Brito, Geall (bb0470) 2014; 11
Barrett, Teuwen (bb0840) 2009; 21
Rutella, Danese, Leone (bb0165) 2006; 108
Hartmann, Nuhn, Palitzsch, Glaffig, Stergiou, Gerlitzki, Schmitt, Kunz, Zentel (bb0445) 2015; 4
Spranger, Bao, Gajewski (bb1630) 2014; 2
De Koker (bb0685) 2011; 40
Palucka, Banchereau (bb0775) 2012; 12
Frick, Domogalla, Baier, Wurm, Mailaender, Landfester, Steinbrink (bb1475) 2016; 10
Rodell, Arlauckas, Cuccarese, Garris, Li, Ahmed, Kohler, Pittet, Weissleder (bb1375) 2018; 2
Xiang (bb0675) 2006; 40
Yang (bb1395) 2014; 25
Xu (bb1860) 2015; 8
Mittal, Gubin, Schreiber, Smyth (bb0075) 2014; 27
Anguille (bb0295) 2015; 67
Ko, Kim (bb1315) 2016; 98
Bertrand, Kostine, Barnetche, Truchetet, Schaeverbeke (bb1560) 2015; 13
Schreiber, Raez, Rosenblatt, Podack (bb1025) 2010; 22
Clayton, Tabi (bb1055) 2005; 34
Marrack, McKee, Munks (bb0785) 2009; 9
Antonarakis, Drake (bb2010) 2010; 20
Fruci, Benevolo, Cifaldi, Lorenzi, Lo Monaco, Tremante, Giacomini (bb1010) 2012; 19
Shimoji (bb1870) 2016; 98
Reimers (bb1830) 2014; 14
Anassi, Ndefo (bb0630) 2011; 36
Smith (bb0890) 2016; 34
Mancini, Stutts, Ryu, Tom, Esser-Kahn (bb0850) 2014; 9
Salmon (bb1655) 2012; 122
Sierro (bb2130) 2011; 41
Hutchinson (bb0580) 2010; 7
Iclozan, Antonia, Chiappori, Chen, Gabrilovich (bb2045) 2013; 62
Gonzalez (bb0985) 2014; 10
Toth, Skwarczynski (bb0240) 2014; 9
Vacchelli (bb1215) 2014; 3
Wang (bb1825) 2016; 63
Rizvi (bb1710) 2015; 348
Kirilovsky (bb1800) 2016; 28
Murphy, Travers, Walport, Janeway (bb0255) 2012
Demoulin, Herfs, Delvenne, Hubert (bb1365) 2013; 93
Genard, Lucas, Michiels (bb1360) 2017; 8
Kim (bb0880) 2016; 27
De Geest, Willart, Lambrecht, Pollard, Vervaet, Remon, Grooten, De Koker (bb0690) 2012; 51
Ilie, Hofman, Dietel, Soria, Hofman (bb1885) 2016; 468
Mahoney, Rennert, Freeman (bb1490) 2015; 14
Mao (bb1785) 2016; 11
Pranchevicius, Vieira (bb0380) 2013; 4
Zarour (bb1155) 2016; 22
Shen, Krauthäuser, Fischer, Hobernik, Abassi, Dzionek, Nikolaev, Voltz, Diken, Krummen, Montermann, Tubbe, Lorenz, Strand, Schild, Grabbe, Bros (bb0770) 2016; 11
Ishii, Takahashi, Soroosh, Sugamura (bb1465) 2010; 105
Angell, Galon (bb1765) 2013; 25
Renovanz, Kim (bb0340) 2014; 4
Wu, Drake, Huang, Chiu, Zheng (bb1120) 2015; 4
Montana (bb0805) 2010; 65
Wang, Wang, Zhang, Yu, Wen, Hu, Ye, Bomba, Hu, Liu, Dotti, Gu (bb1605) 2018; 10
Johansson, Hamzah, Payne, Ganss (bb1670) 2012; 109
Vesely, Kershaw, Schreiber, Smyth (bb0050) 2011; 29
Panni, Linehan, DeNardo (bb1420) 2013; 5
de Gruijl, van den Eertwegh, Pinedo, Scheper (bb0600) 2008; 57
Garg, Romano, Rufo, Agostinis (bb0930) 2016; 23
Ou (bb2105) 2008; 134
Chiang, Coukos, Kandalaft (bb0460) 2015; 3
Janikashvili, Bonnotte, Katsanis, Larmonier (bb0160) 2011; 2011
Hirosue, Kourtis, van der Vlies, Hubbell, Swart (bb0700) 2010; 28
Mahmoud (bb1780) 2011; 29
Reddy, Rehor, Schmoekel, Hubbell, Swartz (bb0660) 2006; 112
Galon (bb1755) 2014; 232
Dunn, Old, Schreiber (bb0040) 2004; 22
Bhullar, Lagarón, McGowan, Parmar, Jha, Hubbard, Rupasinghe (bb0020) 2018; 17
Wilson, Keller, Manganiello, Cheng, Lee, Opara, Covertine, Stayton (bb0740) 2013; 7
Rahimian, Fransen, Kleinovink, Christensen, Amidi, Hennink, Ossendorp (bb0415) 2015; 203
Dane, Irvine (bb0900) 2015; 33
Lu, Robbins (bb0320) 2016; 28
Horvat (bb1565) 2015; 33
Hossain (bb1320) 2015; 21
Chang, Ferrone (bb1040) 2007; 56
Lybaert, Ryu, Nuhn, De Rycke, De Wever, Chon, Esser-Kahn, De Geest (bb0560) 2017; 29
Nuhn, Van Hoecke, Deswarte, Schepens, Li, Lambrecht, De Koker, David, Saelens, De Geest (bb0910) 2018; 178
Thomas, Lorenzetti, Spragins, Jackson, Williamson (bb0835) 2012; 86
Pico de Coana, Choudhury, Kiessling (bb1535) 2015; 21
Walsh (bb1970) 2014; 21
Preuss (bb0140) 2014; 2
Galluzzi, Kroemer, Eggermont (bb1515) 2014; 3
Chen (bb0725) 2016; 12
O'Hagan, Ott, De Gregorio, Seubert (bb0790) 2012; 30
Kosmides, Sidhom, Fraser, Bessell, Schneck (bb1615) 2017; 11
Weiner, Surana, Murray (bb0290) 2010; 3
Zulfiqar, Mahroo, Nasir, Farooq, Jalal, Rashid, Asghar (bb1220) 2017; 10
Nefedova (bb1330) 2007; 67
Zhang (bb1770) 2003; 348
Phan (bb1550) 2003; 100
Thibodeau, Bourgeois-Daigneault, Lapointe (bb0115) 2012; 1
Botos, Segal, Davies (bb0855) 2011; 19
Duan, Chan, Lin (bb0945) 2018
Myc, Gamian, Myc (bb0280) 2011; 59
Vandenberck, Belmans, Van Woensel, Riva, Van Gool (bb0995) 2016; 6
Wang, Ye, Hochu, Sadeghifar, Gu (bb1600) 2016; 16
Fu (bb2065) 2015
Clayton (10.1016/j.jconrel.2018.09.009_bb1055) 2005; 34
Raedler (10.1016/j.jconrel.2018.09.009_bb1520) 2015; 8
Myc (10.1016/j.jconrel.2018.09.009_bb0280) 2011; 59
Leifer (10.1016/j.jconrel.2018.09.009_bb0860) 2016; 100
Rahimian (10.1016/j.jconrel.2018.09.009_bb0415) 2015; 203
Camacho (10.1016/j.jconrel.2018.09.009_bb1580) 2015; 4
Wilson (10.1016/j.jconrel.2018.09.009_bb1005) 2018; 14
Kusmartsev (10.1016/j.jconrel.2018.09.009_bb2060) 2003; 63
Schumacher (10.1016/j.jconrel.2018.09.009_bb0510) 2015; 348
Galon (10.1016/j.jconrel.2018.09.009_bb1760) 2014; 30
Schildberg (10.1016/j.jconrel.2018.09.009_bb1525) 2016; 44
Hirosue (10.1016/j.jconrel.2018.09.009_bb0700) 2010; 28
Liontos (10.1016/j.jconrel.2018.09.009_bb1910) 2016; 4
Culver (10.1016/j.jconrel.2018.09.009_bb1500) 2011; 45
LeBlanc (10.1016/j.jconrel.2018.09.009_bb0130) 2002; 8
Ilie (10.1016/j.jconrel.2018.09.009_bb1885) 2016; 468
Weed (10.1016/j.jconrel.2018.09.009_bb1295) 2015; 21
Dunn (10.1016/j.jconrel.2018.09.009_bb0045) 2004; 21
Tarhini (10.1016/j.jconrel.2018.09.009_bb1570) 2013; 2013
Leffers (10.1016/j.jconrel.2018.09.009_bb1815) 2010; 103
Somersan (10.1016/j.jconrel.2018.09.009_bb0970) 2001; 167
Saga (10.1016/j.jconrel.2018.09.009_bb0810) 2013; 2013
Anguille (10.1016/j.jconrel.2018.09.009_bb0295) 2015; 67
Zarour (10.1016/j.jconrel.2018.09.009_bb1155) 2016; 22
Liu (10.1016/j.jconrel.2018.09.009_bb0390) 2003; 253
Nagtegaal (10.1016/j.jconrel.2018.09.009_bb1725) 2012; 9
Zhang (10.1016/j.jconrel.2018.09.009_bb1230) 2016; 7
Lynn (10.1016/j.jconrel.2018.09.009_bb0895) 2015; 33
Nivolumab approved for Lung Cancer (10.1016/j.jconrel.2018.09.009_bb1510) 2015; 5
Wolchok (10.1016/j.jconrel.2018.09.009_bb1905) 2013; 369
Ishii (10.1016/j.jconrel.2018.09.009_bb1465) 2010; 105
Mittal (10.1016/j.jconrel.2018.09.009_bb0075) 2014; 27
Sengupta (10.1016/j.jconrel.2018.09.009_bb0100) 2010; 206
Moon (10.1016/j.jconrel.2018.09.009_bb0245) 2012; 24
Yu (10.1016/j.jconrel.2018.09.009_bb0135) 2009; 9
Boyman (10.1016/j.jconrel.2018.09.009_bb0220) 2012; 12
van Montfoort (10.1016/j.jconrel.2018.09.009_bb0650) 2014; 5
Calcinotto (10.1016/j.jconrel.2018.09.009_bb1665) 2012; 1950
Neller (10.1016/j.jconrel.2018.09.009_bb0365) 2008; 20
Nishikawa (10.1016/j.jconrel.2018.09.009_bb1435) 2014; 27
Zamarron (10.1016/j.jconrel.2018.09.009_bb0145) 2011; 7
Antonarakis (10.1016/j.jconrel.2018.09.009_bb2010) 2010; 20
Spranger (10.1016/j.jconrel.2018.09.009_bb1115) 2016; 28
Genard (10.1016/j.jconrel.2018.09.009_bb1360) 2017; 8
Xu (10.1016/j.jconrel.2018.09.009_bb1860) 2015; 8
Schreiber (10.1016/j.jconrel.2018.09.009_bb1025) 2010; 22
González-Navajas (10.1016/j.jconrel.2018.09.009_bb1390) 2012; 12
Shimoji (10.1016/j.jconrel.2018.09.009_bb1870) 2016; 98
Ascierto (10.1016/j.jconrel.2018.09.009_bb1810) 2012; 131
Kaiser (10.1016/j.jconrel.2018.09.009_bb0425) 2009; 48
Draghiciu (10.1016/j.jconrel.2018.09.009_bb1340) 2015; 4
Bruttel (10.1016/j.jconrel.2018.09.009_bb1030) 2014; 5
Fuertes Marraco (10.1016/j.jconrel.2018.09.009_bb1140) 2015; 6
McGranahan (10.1016/j.jconrel.2018.09.009_bb0085) 2004; 27
Hasmim (10.1016/j.jconrel.2018.09.009_bb1045) 2015; 6
Nefedova (10.1016/j.jconrel.2018.09.009_bb1330) 2007; 67
Traynor (10.1016/j.jconrel.2018.09.009_bb1505) 2011; 68
Nuhn (10.1016/j.jconrel.2018.09.009_bb0435) 2013; 52
Alving (10.1016/j.jconrel.2018.09.009_bb0820) 2012; 11
Nuhn (10.1016/j.jconrel.2018.09.009_bb0905) 2016; 113
Aaes (10.1016/j.jconrel.2018.09.009_bb0925) 2016; 15
Horn (10.1016/j.jconrel.2018.09.009_bb1795) 2016; 34
Heller (10.1016/j.jconrel.2018.09.009_bb0490) 2017; 258
Garg (10.1016/j.jconrel.2018.09.009_bb0940) 2017; 6
Blank (10.1016/j.jconrel.2018.09.009_bb1740) 2016; 352
McGranahan (10.1016/j.jconrel.2018.09.009_bb1920) 2016; 351
Mahoney (10.1016/j.jconrel.2018.09.009_bb1490) 2015; 14
Kirilovsky (10.1016/j.jconrel.2018.09.009_bb1800) 2016; 28
Klebanoff (10.1016/j.jconrel.2018.09.009_bb0275) 2006; 211
Taiakina (10.1016/j.jconrel.2018.09.009_bb1960) 2014; 772
Diniz (10.1016/j.jconrel.2018.09.009_bb2050) 2016; 15
Nars (10.1016/j.jconrel.2018.09.009_bb1085) 2013; 132
Sierro (10.1016/j.jconrel.2018.09.009_bb2130) 2011; 41
Kranz (10.1016/j.jconrel.2018.09.009_bb0535) 2016; 534
Salgter-Jäger (10.1016/j.jconrel.2018.09.009_bb0590) 2013; 2
Cicchelero (10.1016/j.jconrel.2018.09.009_bb0565) 2014; 13
Buchbinder (10.1016/j.jconrel.2018.09.009_bb1585) 2016; 39
van Rooij (10.1016/j.jconrel.2018.09.009_bb0515) 2013; 31
Suckow (10.1016/j.jconrel.2018.09.009_bb0285) 2013; 198
Kono (10.1016/j.jconrel.2018.09.009_bb1080) 2013; 4
Phan (10.1016/j.jconrel.2018.09.009_bb1550) 2003; 100
Munn (10.1016/j.jconrel.2018.09.009_bb1180) 2016; 37
Kerkar (10.1016/j.jconrel.2018.09.009_bb0200) 2012; 72
Macri (10.1016/j.jconrel.2018.09.009_bb0615) 2016; 5
Yang (10.1016/j.jconrel.2018.09.009_bb1395) 2014; 25
Glaffig (10.1016/j.jconrel.2018.09.009_bb0440) 2014; 20
Palitzsch (10.1016/j.jconrel.2018.09.009_bb0430) 2016; 55
Vesely (10.1016/j.jconrel.2018.09.009_bb0050) 2011; 29
Liu (10.1016/j.jconrel.2018.09.009_bb0150) 2016; 94
Morse (10.1016/j.jconrel.2018.09.009_bb2020) 2008; 112
De Koker (10.1016/j.jconrel.2018.09.009_bb0685) 2011; 40
Knee (10.1016/j.jconrel.2018.09.009_bb1445) 2016; 67
Shen (10.1016/j.jconrel.2018.09.009_bb0770) 2016; 11
Le (10.1016/j.jconrel.2018.09.009_bb0545) 2010; 16
Croft (10.1016/j.jconrel.2018.09.009_bb1460) 2010; 28
Lutz (10.1016/j.jconrel.2018.09.009_bb0155) 2002; 23
Lee (10.1016/j.jconrel.2018.09.009_bb1325) 2012; 131
Roohi (10.1016/j.jconrel.2018.09.009_bb1260) 2017; 25
Soliman (10.1016/j.jconrel.2018.09.009_bb1200) 2010; 16
Corrales (10.1016/j.jconrel.2018.09.009_bb1385) 2015; 21
Hutchinson (10.1016/j.jconrel.2018.09.009_bb0580) 2010; 7
Mandal (10.1016/j.jconrel.2018.09.009_bb1590) 2016; 6
Ladoire (10.1016/j.jconrel.2018.09.009_bb1850) 2011; 60
Tosolini (10.1016/j.jconrel.2018.09.009_bb1805) 2011; 71
Garrido (10.1016/j.jconrel.2018.09.009_bb1075) 2010; 127
Lu (10.1016/j.jconrel.2018.09.009_bb0320) 2016; 28
Ogino (10.1016/j.jconrel.2018.09.009_bb1980) 2006; 66
Angell (10.1016/j.jconrel.2018.09.009_bb1765) 2013; 25
Rabinovich (10.1016/j.jconrel.2018.09.009_bb0095) 2007; 25
Cui (10.1016/j.jconrel.2018.09.009_bb0485) 2015; 206
Mao (10.1016/j.jconrel.2018.09.009_bb1785) 2016; 11
Horvat (10.1016/j.jconrel.2018.09.009_bb1565) 2015; 33
Alloatti (10.1016/j.jconrel.2018.09.009_bb0680) 2016; 272
Wilson (10.1016/j.jconrel.2018.09.009_bb0740) 2013; 7
O'Hagan (10.1016/j.jconrel.2018.09.009_bb0790) 2012; 30
Shen (10.1016/j.jconrel.2018.09.009_bb2055) 2015; 3
Salmon (10.1016/j.jconrel.2018.09.009_bb1655) 2012; 122
Aguiar (10.1016/j.jconrel.2018.09.009_bb1900) 2016; 8
Pico de Coana (10.1016/j.jconrel.2018.09.009_bb1535) 2015; 21
Chowdhury (10.1016/j.jconrel.2018.09.009_bb1875) 2016; 7
Scheffold (10.1016/j.jconrel.2018.09.009_bb0225) 2005; 35
Pranchevicius (10.1016/j.jconrel.2018.09.009_bb0380) 2013; 4
Garrido (10.1016/j.jconrel.2018.09.009_bb1035) 2016; 39
Wang (10.1016/j.jconrel.2018.09.009_bb1825) 2016; 63
Maus (10.1016/j.jconrel.2018.09.009_bb0405) 2016; 22
Jing (10.1016/j.jconrel.2018.09.009_bb1950) 2015; 8
Reiman (10.1016/j.jconrel.2018.09.009_bb0105) 2007; 17
Ribas (10.1016/j.jconrel.2018.09.009_bb1555) 2005; 23
Nakakubo (10.1016/j.jconrel.2018.09.009_bb1775) 2003; 89
Davis (10.1016/j.jconrel.2018.09.009_bb0260) 2000; 78
Chang (10.1016/j.jconrel.2018.09.009_bb1040) 2007; 56
Lassi (10.1016/j.jconrel.2018.09.009_bb2015) 2010; 22
Tagliamonte (10.1016/j.jconrel.2018.09.009_bb0395) 2014; 10
Hiramoto (10.1016/j.jconrel.2018.09.009_bb1285) 2014; 7
Croci (10.1016/j.jconrel.2018.09.009_bb0035) 2007; 56
Walsh (10.1016/j.jconrel.2018.09.009_bb1970) 2014; 21
Fox (10.1016/j.jconrel.2018.09.009_bb0795) 2013; 12
Rundqvist (10.1016/j.jconrel.2018.09.009_bb1965) 2013; 274
Geall (10.1016/j.jconrel.2018.09.009_bb0495) 2012; 109
Watson (10.1016/j.jconrel.2018.09.009_bb1990) 2006; 118
de Lecea (10.1016/j.jconrel.2018.09.009_bb1925) 2016; 31
Chao (10.1016/j.jconrel.2018.09.009_bb1440) 2018; 200
Chen (10.1016/j.jconrel.2018.09.009_bb0725) 2016; 12
Spranger (10.1016/j.jconrel.2018.09.009_bb1640) 2016; 5
Zeng (10.1016/j.jconrel.2018.09.009_bb1880) 2016; 7
Spranger (10.1016/j.jconrel.2018.09.009_bb1635) 2015; 3
Laoui (10.1016/j.jconrel.2018.09.009_bb0745) 2016; 7
Yuan (10.1016/j.jconrel.2018.09.009_bb2070) 2011; 60
Nuhn (10.1016/j.jconrel.2018.09.009_bb0915) 2018
Reissfelder (10.1016/j.jconrel.2018.09.009_bb1790) 2015; 125
Suckow (10.1016/j.jconrel.2018.09.009_bb0570) 2007; 6
Cook (10.1016/j.jconrel.2018.09.009_bb1425) 2013; 13
Deng (10.1016/j.jconrel.2018.09.009_bb1415) 2014; 41
De Geest (10.1016/j.jconrel.2018.09.009_bb0690) 2012; 51
Garg (10.1016/j.jconrel.2018.09.009_bb0930) 2016; 23
Mahmoud (10.1016/j.jconrel.2018.09.009_bb1780) 2011; 29
Boczkowski (10.1016/j.jconrel.2018.09.009_bb2040) 2009; 16
McGranahan (10.1016/j.jconrel.2018.09.009_bb1690) 2016; 351
Califano (10.1016/j.jconrel.2018.09.009_bb1290) 2015; 21
Kashimura (10.1016/j.jconrel.2018.09.009_bb1835) 2012; 15
De Geest (10.1016/j.jconrel.2018.09.009_bb0695) 2012; 6
Miyoshi (10.1016/j.jconrel.2018.09.009_bb2095) 2016; 4
Duncan (10.1016/j.jconrel.2018.09.009_bb0230) 2011; 8
Poh (10.1016/j.jconrel.2018.09.009_bb1430) 2018; 8
Smith (10.1016/j.jconrel.2018.09.009_bb0890) 2016; 34
Spranger (10.1016/j.jconrel.2018.09.009_bb1620) 2013; 5
Yata (10.1016/j.jconrel.2018.09.009_bb0950) 2017; 146
Topalian (10.1016/j.jconrel.2018.09.009_bb1855) 2016; 16
Irvine (10.1016/j.jconrel.2018.09.009_bb0645) 2013; 12
Platten (10.1016/j.jconrel.2018.09.009_bb1195) 2012; 72
Casella (10.1016/j.jconrel.2018.09.009_bb0825) 2008; 65
Hodi (10.1016/j.jconrel.2018.09.009_bb1545) 2010; 363
Janikashvili (10.1016/j.jconrel.2018.09.009_bb0160) 2011; 2011
Hossain (10.1016/j.jconrel.2018.09.009_bb1320) 2015; 21
De Sanctis (10.1016/j.jconrel.2018.09.009_bb1275) 2016; 1865
Tureci (10.1016/j.jconrel.2018.09.009_bb0505) 2016; 22
Spranger (10.1016/j.jconrel.2018.09.009_bb1630) 2014; 2
Weir (10.1016/j.jconrel.2018.09.009_bb2115) 2014; 3
Wu (10.1016/j.jconrel.2018.09.009_bb0870) 2014; 6
Jia (10.1016/j.jconrel.2018.09.009_bb1935) 2015; 137
Emeagi (10.1016/j.jconrel.2018.09.009_bb1310) 2013; 20
Baitsch (10.1016/j.jconrel.2018.09.009_bb1165) 2012; 33
Kim (10.1016/j.jconrel.2018.09.009_bb0055) 2007;
References_xml – volume: 14
  start-page: 486
  year: 2014
  ident: bb1830
  article-title: Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study
  publication-title: BMC Cancer
  contributor:
    fullname: Reimers
– volume: 117
  start-page: 248
  year: 2005
  end-page: 255
  ident: bb1995
  article-title: Total loss of MHC class I is an independent indicator of good prognosis in breast cancer
  publication-title: Int. J. Cancer
  contributor:
    fullname: Durrant
– volume: 22
  start-page: 1875
  year: 2016
  end-page: 1884
  ident: bb0405
  article-title: Making better chimeric antigen receptors for adoptive T-cell therapy
  publication-title: Clin. Cancer Res.
  contributor:
    fullname: June
– volume: 33
  start-page: 435
  year: 2010
  end-page: 441
  ident: bb1840
  article-title: Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoImmune-therapy
  publication-title: J. Immunother.
  contributor:
    fullname: Correale
– volume: 8
  start-page: 108
  year: 2008
  end-page: 120
  ident: bb0465
  article-title: DNA vaccines: precision tools for activating effective immunity against cancer
  publication-title: Nat. Rev. Cancer
  contributor:
    fullname: Stevenson
– volume: 7
  start-page: 13720
  year: 2016
  ident: bb0745
  article-title: The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity
  publication-title: Nat. Commun.
  contributor:
    fullname: Laoui
– volume: 132
  start-page: 2471
  year: 2013
  end-page: 2478
  ident: bb1085
  article-title: Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immune-therapy
  publication-title: Int. J. Cancer
  contributor:
    fullname: Kaneno
– volume: 28
  start-page: 35
  year: 2016
  end-page: 44
  ident: bb1145
  article-title: Reprogramming away from the exhausted T cell state
  publication-title: Semin. Immunol.
  contributor:
    fullname: Kaneko
– volume: 16
  start-page: 304
  year: 2010
  end-page: 310
  ident: bb0545
  article-title: Cellular vaccine approaches
  publication-title: Cancer J.
  contributor:
    fullname: Jaffee
– ident: bb0010
– volume: 9
  start-page: 2607
  year: 2014
  end-page: 2609
  ident: bb0240
  article-title: The immune system likes nanotechnology
  publication-title: Nanomedicine
  contributor:
    fullname: Skwarczynski
– volume: 14
  start-page: 1411
  year: 2014
  end-page: 1425
  ident: bb1480
  article-title: Induced regulatory T cells in inhibitory microenvironments created by cancer
  publication-title: Expert. Opin. Biol. Ther.
  contributor:
    fullname: Whiteside
– volume: 61
  start-page: 1373
  year: 2012
  end-page: 1385
  ident: bb1305
  article-title: Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth
  publication-title: Cancer Immunol. Immunother.
  contributor:
    fullname: Porembka
– volume: 8
  start-page: 2101
  year: 2011
  end-page: 2141
  ident: bb0230
  article-title: Nanomedicine(s) under the microscope
  publication-title: Mol. Pharm.
  contributor:
    fullname: Gaspar
– volume: 188
  start-page: 97
  year: 2002
  end-page: 113
  ident: bb1015
  article-title: Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction
  publication-title: Immunol. Rev.
  contributor:
    fullname: Rivoltini
– volume: 348
  start-page: 124
  year: 2015
  end-page: 128
  ident: bb1710
  article-title: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
  publication-title: Science
  contributor:
    fullname: Rizvi
– volume: 6
  start-page: 925
  year: 2007
  end-page: 937
  ident: bb0570
  article-title: Tissue vaccines for cancer
  publication-title: Expert Rev. Vaccines
  contributor:
    fullname: Rosen
– volume: 6
  year: 2016
  ident: bb0935
  article-title: Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines
  publication-title: Front. Immunol.
  contributor:
    fullname: Van Gool
– volume: 2011
  start-page: 430394
  year: 2011
  ident: bb0160
  article-title: The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance
  publication-title: Clin. Dev. Immunol.
  contributor:
    fullname: Larmonier
– volume: 274
  start-page: 105
  year: 2013
  end-page: 112
  ident: bb1965
  article-title: Tumour oxygenation: implications for breast cancer prognosis
  publication-title: J. Intern. Med.
  contributor:
    fullname: Johnson
– volume: 67
  start-page: 11021
  year: 2007
  end-page: 11028
  ident: bb1330
  article-title: Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells
  publication-title: Cancer Res.
  contributor:
    fullname: Nefedova
– volume: 23
  start-page: 286
  year: 2011
  end-page: 292
  ident: bb1645
  article-title: Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment
  publication-title: Curr. Opin. Immunol.
  contributor:
    fullname: Kline
– volume: 8
  start-page: 523
  year: 2008
  end-page: 532
  ident: bb0210
  article-title: How regulatory T cells work
  publication-title: Nat. Rev. Immunol.
  contributor:
    fullname: Workman
– year: 2018
  ident: bb0915
  article-title: Nanoparticle-conjugate TLR7/8 agonist localized immunotherapy provokes safe antitumoral responses
  publication-title: Adv. Mater.
  contributor:
    fullname: De Geest
– volume: 133
  start-page: 509
  year: 2013
  end-page: 517
  ident: bb1820
  article-title: BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma
  publication-title: J. Investig. Dermatol.
  contributor:
    fullname: Mann
– volume: 12
  start-page: 125
  year: 2012
  end-page: 135
  ident: bb1390
  article-title: Immunomodulatory functions of type I interferons
  publication-title: Nat. Rev. Immunol.
  contributor:
    fullname: Raz
– volume: 68
  start-page: 768
  year: 2011
  ident: bb1505
  article-title: Ipilimumab approved for metastatic melanoma
  publication-title: Am. J. Health-System Pharmacy
  contributor:
    fullname: Traynor
– volume: 6
  year: 2014
  ident: bb0870
  article-title: Rational design of small molecules as vaccine adjuvants
  publication-title: Sci. Transl. Med.
  contributor:
    fullname: Wu
– volume: 7
  start-page: 55765
  year: 2016
  end-page: 55770
  ident: bb1955
  article-title: Elevated serum C-reactive protein level predicts a poor prognosis for recurrent gastric cancer
  publication-title: Oncotarget
  contributor:
    fullname: Kong
– volume: 13
  start-page: 595
  year: 2013
  end-page: 601
  ident: bb1425
  article-title: Tumour-associated macrophages and cancer
  publication-title: Curr. Opin. Pharmacol.
  contributor:
    fullname: Hagemann
– volume: 9
  start-page: 1385
  year: 2010
  end-page: 1398
  ident: bb0800
  article-title: Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine
  publication-title: Expert Rev. Vaccines
  contributor:
    fullname: Faust
– volume: 42
  start-page: 4859
  year: 2013
  end-page: 4866
  ident: bb0865
  article-title: Targeting Toll-like receptors with small molecule agents
  publication-title: Chem. Soc. Rev.
  contributor:
    fullname: Yin
– volume: 21
  start-page: 1516
  year: 2014
  end-page: 1554
  ident: bb1970
  article-title: The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities
  publication-title: Antioxid. Redox Signal.
  contributor:
    fullname: Walsh
– volume: 9
  start-page: 119
  year: 2012
  end-page: 123
  ident: bb1725
  article-title: Has the new TNM classification for colorectal cancer improved care?
  publication-title: Nat. Rev. Clin. Oncol.
  contributor:
    fullname: Schmoll
– volume: 10
  start-page: 909
  year: 2004
  end-page: 915
  ident: bb2000
  article-title: Cancer immunotherapy: moving beyond current vaccines
  publication-title: Nat. Med.
  contributor:
    fullname: Restifo
– volume: 178
  start-page: 643
  year: 2018
  end-page: 651
  ident: bb0910
  article-title: Potent anti-viral vaccine adjuvant based on pH-degradable nanogels with covalently linked small molecule imidazoquinoline TLR7/8 agonist
  publication-title: Biomaterials
  contributor:
    fullname: De Geest
– volume: 63
  start-page: 789
  year: 2016
  end-page: 798
  ident: bb1825
  article-title: Regulatory T cells are an important prognostic factor in breast cancer: a systematic review and meta-analysis
  publication-title: Neoplasma
  contributor:
    fullname: Wang
– volume: 4
  start-page: 264
  year: 2016
  ident: bb1910
  article-title: DNA damage, tumor mutational load and their impact on immune responses against cancer
  publication-title: Ann. Transl. Med.
  contributor:
    fullname: Dimopoulos
– volume: 28
  start-page: 22
  year: 2016
  end-page: 27
  ident: bb0320
  article-title: Cancer Immune-therapy targeting neoantigens
  publication-title: Semin. Immunol.
  contributor:
    fullname: Robbins
– volume: 7
  start-page: 301
  year: 2010
  ident: bb0580
  article-title: Significant overall survival advantage for RCC patients treated with autologous tumor lysate vaccine
  publication-title: Nat. Rev. Urol.
  contributor:
    fullname: Hutchinson
– volume: 14
  start-page: 237
  year: 2018
  end-page: 246
  ident: bb1005
  article-title: Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy
  publication-title: Nanomedicine (NMB)
  contributor:
    fullname: Kim
– volume: 108
  start-page: 1435
  year: 2006
  end-page: 1440
  ident: bb0165
  article-title: Tolerogenic dendritic cells: cytokine modulation comes of age
  publication-title: Blood
  contributor:
    fullname: Leone
– volume: 98
  start-page: 69
  year: 2016
  end-page: 75
  ident: bb1870
  article-title: Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)
  publication-title: Lung Cancer (Amsterdam, Netherlands)
  contributor:
    fullname: Shimoji
– volume: 112
  start-page: 26
  year: 2006
  end-page: 34
  ident: bb0660
  article-title: In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles
  publication-title: J. Control. Release
  contributor:
    fullname: Swartz
– volume: 20
  start-page: 12405
  year: 2014
  end-page: 12410
  ident: bb0765
  article-title: Selective uptake of cylindrical Poly(2-Oxazoline) brush-AntiDEC205 antibody-OVA antigen conjugates into DEC-positive dendritic cells and subsequent T-Cell activation
  publication-title: Chem. Eur. J.
  contributor:
    fullname: Schmidt
– volume: 11
  start-page: 2479
  year: 2016
  end-page: 2488
  ident: bb0755
  article-title: pH-degradable mannosylated nanogels for dendritic cell targeting
  publication-title: Biomacromolecules
  contributor:
    fullname: De Geest
– volume: 5
  start-page: 360
  year: 2014
  ident: bb1030
  article-title: Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune-escape?
  publication-title: Front. Immunol.
  contributor:
    fullname: Wischhusen
– volume: 52
  start-page: 50
  year: 2016
  end-page: 66
  ident: bb1455
  article-title: Rationale for anti-OX40 cancer Immune-therapy
  publication-title: Eur. J. Cancer (Oxford, England: 1990)
  contributor:
    fullname: Aspeslagh
– volume: 26
  start-page: 8154
  year: 2014
  end-page: 8162
  ident: bb0955
  article-title: Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis
  publication-title: Adv. Mater.
  contributor:
    fullname: Liu
– volume: 58
  start-page: 489
  year: 2017
  end-page: 496
  ident: bb1255
  article-title: Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy
  publication-title: Yonsei Med. J.
  contributor:
    fullname: Sun
– volume: 125
  start-page: 2532
  year: 2015
  end-page: 2546
  ident: bb1000
  article-title: Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants
  publication-title: J. Clin. Invest.
  contributor:
    fullname: Irvine
– volume: 348
  start-page: 74
  year: 2015
  end-page: 80
  ident: bb1660
  article-title: T cell exclusion, immune privilege, and the tumor microenvironment
  publication-title: Science
  contributor:
    fullname: Fearon
– volume: 30
  start-page: 345
  year: 2010
  end-page: 386
  ident: bb0330
  article-title: Tumor antigen presentation by dendritic cells
  publication-title: Crit. Rev. Immunol.
  contributor:
    fullname: Hermans
– volume: 31
  start-page: 636
  year: 2016
  end-page: 642
  ident: bb1925
  article-title: Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B
  publication-title: J. Eur. Acad. Dermatol. Venereol.
  contributor:
    fullname: de Lecea
– volume: 105
  start-page: 63
  year: 2010
  end-page: 98
  ident: bb1465
  article-title: OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology
  publication-title: Adv. Immunol.
  contributor:
    fullname: Sugamura
– volume: 29
  start-page: 4209
  year: 2017
  end-page: 4217
  ident: bb0560
  article-title: Cancer cell lysate entrapment in CaCO3 engineered with polymeric TLR-agonists: immune-modulating microparticles in view of personalized antitumor vaccination
  publication-title: Chem. Mater.
  contributor:
    fullname: De Geest
– volume: 28
  start-page: 383
  year: 2016
  end-page: 391
  ident: bb1115
  article-title: Mechanisms of tumor-escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment
  publication-title: Int. Immunol.
  contributor:
    fullname: Spranger
– volume: 7
  start-page: 3912
  year: 2013
  end-page: 3925
  ident: bb0740
  article-title: pH-responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides
  publication-title: ACS Nano
  contributor:
    fullname: Stayton
– volume: 108
  start-page: E989
  year: 2011
  end-page: E997
  ident: bb0705
  article-title: Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination
  publication-title: Proc. Natl. Acad. Sci.
  contributor:
    fullname: Hubbell
– volume: 211
  start-page: 214
  year: 2006
  end-page: 224
  ident: bb0275
  article-title: CD8+ T-cell memory in tumor immunology and immunotherapy
  publication-title: Immunol. Rev.
  contributor:
    fullname: Restifo
– volume: 6
  start-page: 2136
  year: 2012
  end-page: 2149
  ident: bb0695
  article-title: Polymeric multilayer capsule-mediated vaccination induces protective immunity against cancer and viral infection
  publication-title: ACS Nano
  contributor:
    fullname: De Koker
– volume: 132
  start-page: 61
  year: 2010
  end-page: 68
  ident: bb0215
  article-title: IL-2-deprivation and TGF-β are two non-redundant suppressor mechanisms of CD4+(+)CD25(+) regulatory T cell which jointly restrain CD4+(+)CD25(−) cell activation
  publication-title: Immunol. Lett.
  contributor:
    fullname: Wang
– volume: 89
  start-page: 1736
  year: 2003
  end-page: 1742
  ident: bb1775
  article-title: Clinical significance of immune cell infiltration within gallbladder cancer
  publication-title: Br. J. Cancer
  contributor:
    fullname: Nakakubo
– volume: 2
  start-page: 277
  year: 2002
  end-page: 288
  ident: bb0125
  article-title: Death and anti-death: tumour resistance to apoptosis
  publication-title: Nat. Rev. Cancer
  contributor:
    fullname: Krammer
– volume: 7
  start-page: 13193
  year: 2016
  ident: bb0960
  article-title: Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
  publication-title: Nat. Commun.
  contributor:
    fullname: Liu
– volume: 8
  start-page: 49
  year: 2018
  ident: bb1430
  article-title: Targeting macrophages in cancer: from bench to deside
  publication-title: Front. Oncol.
  contributor:
    fullname: Ernst
– volume: 60
  start-page: 909
  year: 2011
  end-page: 918
  ident: bb1850
  article-title: Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer
  publication-title: Cancer Immunol. Immunother.
  contributor:
    fullname: Ghiringhelli
– volume: 4
  year: 2015
  ident: bb1340
  article-title: Myeloid derived suppressor cells—An overview of combat strategies to increase Immune-therapy efficacy
  publication-title: Oncoimmunology
  contributor:
    fullname: Daemen
– volume: 63
  start-page: 4441
  year: 2003
  end-page: 4449
  ident: bb2060
  article-title: All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination
  publication-title: Cancer Res.
  contributor:
    fullname: Kusmartsev
– volume: 1950
  start-page: 216
  year: 2009
  end-page: 224
  ident: bb2030
  article-title: Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition
  publication-title: J. Immunol. (Baltimore Md.)
  contributor:
    fullname: Mukherjee
– volume: 44
  start-page: 1582
  year: 2014
  end-page: 1592
  ident: bb1050
  article-title: Effect of tumor cells and tumor microenvironment on NK cell function
  publication-title: Eur. J. Immunol.
  contributor:
    fullname: Moretta
– volume: 7
  start-page: 4269
  year: 2012
  end-page: 4283
  ident: bb1350
  article-title: PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells
  publication-title: Int. J. Nanomedicine
  contributor:
    fullname: Su
– volume: 11
  start-page: 2647
  year: 2016
  end-page: 2662
  ident: bb0770
  article-title: Vaccination with trifunctional nanoparticles that address CD8+ dendritic cells inhibits growth of established melanoma
  publication-title: Nanomedicine (London)
  contributor:
    fullname: Bros
– volume: 11
  year: 2016
  ident: bb1785
  article-title: The prognostic value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis
  publication-title: PLoS One
  contributor:
    fullname: Mao
– volume: 8
  start-page: 84
  year: 2010
  ident: bb2005
  article-title: Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402
  publication-title: J. Transl. Med.
  contributor:
    fullname: Tahara
– volume: 10
  start-page: 3332
  year: 2014
  end-page: 3346
  ident: bb0395
  article-title: Antigen-specific vaccines for cancer treatment
  publication-title: Hum. Vaccin. Immunother.
  contributor:
    fullname: Buonaguro
– volume: 10
  start-page: 463
  year: 2017
  end-page: 476
  ident: bb1220
  article-title: Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors
  publication-title: Onco Targets Ther.
  contributor:
    fullname: Asghar
– volume: 8
  start-page: 14595
  year: 2015
  end-page: 14603
  ident: bb1860
  article-title: Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis
  publication-title: Int. J. Clin. Exp. Med.
  contributor:
    fullname: Xu
– volume: 16
  start-page: 900
  year: 2009
  end-page: 911
  ident: bb2040
  article-title: Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based Immune-therapy
  publication-title: Cancer Gene Ther.
  contributor:
    fullname: Nair
– volume: 35
  start-page: 585
  year: 2013
  end-page: 600
  ident: bb0175
  article-title: Tumor-associated macrophages: functional diversity, clinical significance, and open questions
  publication-title: Semin. Immunopathol.
  contributor:
    fullname: Mantovani
– volume: 21
  start-page: 308
  year: 2009
  end-page: 313
  ident: bb0840
  article-title: Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
  publication-title: Curr. Opin. Immunol.
  contributor:
    fullname: Teuwen
– volume: 2013
  year: 2013
  ident: bb1570
  article-title: Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: The underlying mechanisms and clinical management
  publication-title: Australas. Sci.
  contributor:
    fullname: Tarhini
– volume: 1494
  start-page: 145
  year: 2017
  end-page: 152
  ident: bb0875
  article-title: Synthesis of Lymph Node-Targeting Adjuvants
  publication-title: Methods Mol. Biol.
  contributor:
    fullname: Irvine
– volume: 4
  year: 2013
  ident: bb1080
  article-title: Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation
  publication-title: Cell Death Dis.
  contributor:
    fullname: Kiessling
– volume: 5
  start-page: 378
  year: 2015
  end-page: 389
  ident: bb1240
  article-title: HIF-1α pathway: role, regulation and intervention for cancer therapy
  publication-title: Acta Pharm. Sin. B
  contributor:
    fullname: Li
– volume: 30
  start-page: 439
  year: 2014
  end-page: 444
  ident: bb1760
  article-title: Intratumoral immune microenvironment and survival: the immunoscore
  publication-title: Med. Sci.
  contributor:
    fullname: Galon
– volume: 515
  start-page: 568
  year: 2014
  end-page: 571
  ident: bb1625
  article-title: PD-1 blockade induces responses by inhibiting adaptive immune resistance
  publication-title: Nature
  contributor:
    fullname: Tumeh
– volume: 22
  start-page: 132
  year: 2010
  end-page: 143
  ident: bb0520
  article-title: Whole tumor antigen vaccines
  publication-title: Semin. Immunol.
  contributor:
    fullname: Coukos
– volume: 10
  start-page: 205
  year: 2012
  ident: bb1720
  article-title: Cancer classification using the Immunoscore: a worldwide task force
  publication-title: J. Transl. Med.
  contributor:
    fullname: Galon
– volume: 6
  start-page: 1543
  year: 2013
  end-page: 1549
  ident: bb0980
  article-title: Tumor Immune-therapy based on tumor-derived heat shock proteins (Review)
  publication-title: Oncol. Lett.
  contributor:
    fullname: Zheng
– volume: 234
  start-page: 124
  year: 2016
  end-page: 134
  ident: bb0635
  article-title: Orchestrating immune responses: How size, shape and rigidity affect the immunogenicity of particulate vaccines
  publication-title: J. Control. Release
  contributor:
    fullname: Slutter
– volume: 10
  start-page: eaan3682
  year: 2018
  ident: bb1605
  article-title: In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
  publication-title: Sci. Transl. Med.
  contributor:
    fullname: Gu
– volume: 14
  start-page: 561
  year: 2015
  end-page: 584
  ident: bb1490
  article-title: Combination cancer Immune-therapy and new immunomodulatory targets
  publication-title: Nat. Rev. Drug Discov.
  contributor:
    fullname: Freeman
– volume: 36
  start-page: 197
  year: 2011
  end-page: 202
  ident: bb0630
  article-title: Sipuleucel-T (provenge) injection: the first immune-therapy agent (vaccine) for hormone-refractory prostate cancer
  publication-title: Pharmacy Therapeutics
  contributor:
    fullname: Ndefo
– volume: 28
  start-page: 319
  year: 2016
  end-page: 328
  ident: bb0345
  article-title: The present status and future prospects of peptide-based cancer vaccines
  publication-title: Int. Immunol.
  contributor:
    fullname: Nishimura
– volume: 23
  start-page: 445
  year: 2002
  end-page: 449
  ident: bb0155
  article-title: Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?
  publication-title: Trends Immunol.
  contributor:
    fullname: Schuler
– volume: 29
  start-page: 1949
  year: 2011
  end-page: 1955
  ident: bb1780
  article-title: Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer
  publication-title: J. Clin. Oncol.
  contributor:
    fullname: Mahmoud
– volume: 100
  start-page: 8372
  year: 2003
  end-page: 8377
  ident: bb1550
  article-title: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  contributor:
    fullname: Phan
– volume: 28
  start-page: 239
  year: 2009
  end-page: 260
  ident: bb1095
  article-title: Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation
  publication-title: Int. Rev. Immunol.
  contributor:
    fullname: Zhou
– volume: 6
  start-page: 7556
  year: 2015
  ident: bb0575
  article-title: Injectable cryogel-based whole-cell vaccines
  publication-title: Nat. Commun.
  contributor:
    fullname: Mooney
– volume: 17
  start-page: 57
  year: 2016
  ident: bb1575
  article-title: Cutaneous complications of targeted melanoma therapy
  publication-title: Curr. Treat. Options in Oncol.
  contributor:
    fullname: Pugliese
– volume: 468
  start-page: 511
  year: 2016
  end-page: 525
  ident: bb1885
  article-title: Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
  publication-title: Virchows Arch.
  contributor:
    fullname: Hofman
– volume: 6
  start-page: 663
  year: 2016
  ident: bb0995
  article-title: Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines
  publication-title: Front. Immunol.
  contributor:
    fullname: Van Gool
– volume: 109
  start-page: 7841
  year: 2012
  end-page: 7846
  ident: bb1670
  article-title: Tumor-targeted TNFalpha stabilizes tumor vessels and enhances active Immune-therapy
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
  contributor:
    fullname: Ganss
– volume: 57
  start-page: 1569
  year: 2008
  end-page: 1577
  ident: bb0600
  article-title: Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines
  publication-title: Cancer Immunol. Immune-Ther.
  contributor:
    fullname: Scheper
– volume: 6
  year: 2015
  ident: bb1125
  article-title: T-cell exhaustion in the tumor microenvironment
  publication-title: Cell Death Dis.
  contributor:
    fullname: Zhu
– volume: 28
  start-page: 57
  year: 2010
  end-page: 78
  ident: bb1460
  article-title: Control of immunity by the TNFR-related molecule OX40 (CD134)
  publication-title: Annu. Rev. Immunol.
  contributor:
    fullname: Croft
– volume: 61
  start-page: 1359
  year: 2012
  end-page: 1371
  ident: bb1070
  article-title: Implication of the beta2 microglobulin gene in the generation of tumor-escape phenotypes
  publication-title: Cancer Immunol. Immunother.
  contributor:
    fullname: Garrido
– volume: 41
  start-page: 98
  year: 2016
  end-page: 103
  ident: bb1695
  article-title: Neoantigens encoded in the cancer genome
  publication-title: Curr. Opin. Immunol.
  contributor:
    fullname: Hacohen
– volume: 21
  start-page: 847
  year: 2009
  end-page: 867
  ident: bb0475
  article-title: Polymeric materials for gene delivery and dna vaccination
  publication-title: Adv. Mater.
  contributor:
    fullname: Anderson
– volume: 39
  start-page: 98
  year: 2016
  end-page: 106
  ident: bb1585
  article-title: CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition
  publication-title: Am. J. Clin. Oncol.
  contributor:
    fullname: Desai
– volume: 29
  start-page: 440
  year: 2016
  end-page: 451
  ident: bb0080
  article-title: Intratumoral heterogeneity of the epigenome
  publication-title: Cancer Cell
  contributor:
    fullname: Costello
– volume: 17
  start-page: 275
  year: 2007
  end-page: 287
  ident: bb0105
  article-title: Tumor immunoediting and immunosculpting pathways to cancer progression
  publication-title: Semin. Cancer Biol.
  contributor:
    fullname: Knutson
– volume: 1950
  start-page: 2687
  year: 2012
  end-page: 2694
  ident: bb1665
  article-title: Targeting TNF-alpha to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of Immune-therapy
  publication-title: J. Immunol. (Baltimore Md.)
  contributor:
    fullname: Calcinotto
– volume: 16
  start-page: 275
  year: 2016
  end-page: 287
  ident: bb1855
  article-title: Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
  publication-title: Nat. Rev. Cancer
  contributor:
    fullname: Pardoll
– volume: 21
  start-page: 4421
  year: 2013
  end-page: 4442
  ident: bb0420
  article-title: The development of synthetic antitumour vaccines from mucin glycopeptide antigens
  publication-title: Chem. Soc. Rev.
  contributor:
    fullname: Kunz
– volume: 180
  start-page: 7249
  year: 2008
  end-page: 7258
  ident: bb1060
  article-title: Human tumor-derived exosomes down-modulate NKG2D expression
  publication-title: J. Immunol.
  contributor:
    fullname: Tabi
– volume: 17
  start-page: 97
  year: 2017
  end-page: 111
  ident: bb0920
  article-title: Immunogenic cell death in cancer and infectious disease
  publication-title: Nat. Rev. Immunol.
  contributor:
    fullname: Kroemer
– volume: 34
  start-page: 803
  year: 2016
  end-page: 812
  ident: bb1235
  article-title: Hypoxic tumor microenvironment: Opportunities to develop targeted therapies
  publication-title: Biotechnol. Adv.
  contributor:
    fullname: Sant
– volume: 352
  start-page: 658
  year: 2016
  end-page: 660
  ident: bb1740
  article-title: Cancer immunology.The “cancer immunogram”
  publication-title: Science
  contributor:
    fullname: Schumacher
– volume: 23
  start-page: 8968
  year: 2005
  end-page: 8977
  ident: bb1555
  article-title: Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
  publication-title: J. Clin. Oncol.
  contributor:
    fullname: Ribas
– volume: 23
  start-page: 399
  year: 2011
  end-page: 406
  ident: bb0385
  article-title: Tumor vaccination using messenger RNA: prospects of a future therapy
  publication-title: Curr. Opin. Immunol.
  contributor:
    fullname: Sahin
– volume: 363
  start-page: 711
  year: 2010
  end-page: 723
  ident: bb1545
  article-title: Improved survival with ipilimumab in patients with metastatic melanoma
  publication-title: New England J. Med.
  contributor:
    fullname: Hodi
– volume: 39
  start-page: 44
  year: 2016
  end-page: 51
  ident: bb1035
  article-title: The urgent need to recover MHC class I in cancers for effective Immune-therapy
  publication-title: Curr. Opin. Immunol.
  contributor:
    fullname: van Hall
– volume: 2015
  year: 2015
  ident: bb0455
  article-title: RNA-based vaccines in cancer immune-therapy
  publication-title: J Immunol Res
  contributor:
    fullname: Holl
– volume: 15
  start-page: 144
  year: 2012
  end-page: 153
  ident: bb1835
  article-title: CD8+3(+) dendritic cells and Foxp3(+) regulatory T cells in primary lesions and regional lymph nodes are inversely correlated with prognosis of gastric cancer
  publication-title: Gastric Cancer
  contributor:
    fullname: Kashimura
– volume: 56
  start-page: 1687
  year: 2007
  end-page: 1700
  ident: bb0035
  article-title: Dynamic cross-talk between tumor and immune cells in orchestrating the immune-suppressive network at the tumor microenvironment
  publication-title: Cancer Immunol. Immunother.
  contributor:
    fullname: Croci
– volume: 4
  start-page: 28
  year: 2013
  ident: bb0025
  article-title: Mechanisms and insights into drug resistance in cancer
  publication-title: Front. Pharmacol.
  contributor:
    fullname: Borden
– volume: 129
  start-page: 474
  year: 2010
  end-page: 481
  ident: bb1130
  article-title: T-cell exhaustion: characteristics, causes and conversion
  publication-title: Immunology
  contributor:
    fullname: Zajac
– volume: 449
  start-page: 419
  year: 2007
  end-page: 426
  ident: bb0305
  article-title: Taking dendritic cells into medicine
  publication-title: Nature
  contributor:
    fullname: Banchereau
– volume: 16
  start-page: 5504
  year: 2016
  end-page: 5513
  ident: bb0965
  article-title: Acid-activatable versatile micelleplexes for Pd-L1 blockade-enhanced cancer photodynamic immunotherapy
  publication-title: Nano Lett.
  contributor:
    fullname: Li
– volume: 23
  start-page: 6165
  year: 2017
  end-page: 6177
  ident: bb2135
  article-title: Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40
  publication-title: Clin. Cancer Res.
  contributor:
    fullname: Mesenheimer
– volume: 157
  start-page: 1073
  year: 2014
  end-page: 1087
  ident: bb1705
  article-title: Deconstructing the peptide-MHC specificity of T cell recognition
  publication-title: Cell
  contributor:
    fullname: Birnbaum
– volume: 7
  start-page: 8944
  year: 2016
  end-page: 8955
  ident: bb1880
  article-title: Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas
  publication-title: Oncotarget
  contributor:
    fullname: Zeng
– volume: 5
  start-page: 772
  year: 2005
  end-page: 782
  ident: bb0350
  article-title: Central tolerance: learning self-control in the thymus
  publication-title: Nat. Rev. Immunol.
  contributor:
    fullname: Jameson
– volume: 20
  start-page: 4232
  year: 2014
  end-page: 4236
  ident: bb0440
  article-title: A fully synthetic glycopeptide antitumor vaccine based on multiple antigen presentation on a hyperbranched polymer
  publication-title: Chem. Eur. J.
  contributor:
    fullname: Kunz
– volume: 8
  start-page: 96
  year: 2015
  end-page: 100
  ident: bb1520
  article-title: Keytruda (pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma
  publication-title: American Health & Drug Benefits
  contributor:
    fullname: Raedler
– volume: 24
  start-page: 2011
  year: 2017
  end-page: 2032
  ident: bb0885
  article-title: Recent findings on the application of toll-like receptor agonists in cancer therapy
  publication-title: Curr. Med. Chem.
  contributor:
    fullname: Glavan
– volume: 14
  start-page: 1
  year: 2016
  end-page: 18
  ident: bb1715
  article-title: Cancer immune-therapy: the beginning of the end of cancer?
  publication-title: BMC Med.
  contributor:
    fullname: Blasutig
– volume: 71
  start-page: 2488
  year: 2011
  end-page: 2496
  ident: bb1410
  article-title: The efficacy of radiotherapy relies upon induction of type I interferon–dependent innate and adaptive immunity
  publication-title: Cancer Res.
  contributor:
    fullname: Burnette
– volume: 39
  start-page: 7
  year: 2016
  end-page: 13
  ident: bb1750
  article-title: Cancer immune contexture and Immune-therapy
  publication-title: Curr. Opin. Immunol.
  contributor:
    fullname: Fridman
– volume: 107
  start-page: 1563
  year: 2016
  end-page: 1571
  ident: bb1865
  article-title: The up-regulation of PD-L1 promotes the resistant response in non-small cell lung cancer patients with neo-adjuvant chemotherapy
  publication-title: Cancer Sci.
  contributor:
    fullname: Zhang
– volume: 227
  start-page: 234
  year: 2009
  end-page: 247
  ident: bb0720
  article-title: Inflammatory signals in dendritic cell activation and the induction of adaptive immunity
  publication-title: Immunol. Rev.
  contributor:
    fullname: Reise Sousa
– volume: 11
  start-page: 885
  year: 2014
  end-page: 899
  ident: bb0470
  article-title: Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines
  publication-title: Expert Opin. Drug Deliv.
  contributor:
    fullname: Geall
– volume: 33
  start-page: 3193
  year: 2015
  end-page: 3198
  ident: bb1565
  article-title: Immune-related adverse events, need for systemic immune-suppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center
  publication-title: J. Clin. Oncol.
  contributor:
    fullname: Horvat
– volume: 167
  start-page: 4844
  year: 2001
  end-page: 4852
  ident: bb0970
  article-title: Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells
  publication-title: J. Immunol. (Baltimore, Md.: 1950)
  contributor:
    fullname: Somersan
– volume: 9
  start-page: 287
  year: 2009
  end-page: 293
  ident: bb0785
  article-title: Towards an understanding of the adjuvant action of aluminium
  publication-title: Nat. Rev. Immunol.
  contributor:
    fullname: Munks
– volume: 2
  year: 2013
  ident: bb0590
  article-title: Evaluation of RNA amplification methods to improve DC immunotherapy antigen presentation and immune response
  publication-title: Mol. Ther. Nucleic Acids
  contributor:
    fullname: Tcherepanova
– volume: 30
  start-page: 344
  year: 2010
  end-page: 348
  ident: bb2100
  article-title: 1-MT enhances potency of tumor cell lysate-pulsed dendritic cells against pancreatic adenocarcinoma by downregulating the percentage of Tregs
  publication-title: J. Huazhong Univ. Sci. Technol.
  contributor:
    fullname: Wang
– volume: 37
  start-page: 649
  year: 2012
  end-page: 655
  ident: bb1930
  article-title: Indoleamine-pyrrole 2,3-dioxygenase might be a prognostic biomarker for patients with renal cell carcinoma. Zhong nan da xue xue bao. Yi xue ban
  publication-title: J. Central South Univ. Med. Sci.
  contributor:
    fullname: Chen
– volume: 24
  start-page: 217
  year: 2012
  end-page: 224
  ident: bb1450
  article-title: Modulation of GITR for cancer Immune-therapy
  publication-title: Curr. Opin. Immunol.
  contributor:
    fullname: Wolchok
– volume: 198
  start-page: 28
  year: 2013
  end-page: 33
  ident: bb0285
  article-title: Cancer vaccines: Harnessing the potential of anti-tumor immunity
  publication-title: Vet. J.
  contributor:
    fullname: Suckow
– volume: 15
  start-page: 405
  year: 2015
  end-page: 414
  ident: bb1400
  article-title: Type I interferons in anticancer immunity
  publication-title: Nat. Rev. Immunol.
  contributor:
    fullname: Kroemer
– volume: 6
  start-page: 703
  year: 2016
  end-page: 713
  ident: bb1590
  article-title: Personalized oncology meets immunology: The path toward precision immune-therapy
  publication-title: Cancer Discov.
  contributor:
    fullname: Chan
– volume: 94
  start-page: 935
  year: 2016
  end-page: 942
  ident: bb1135
  article-title: T cell exhaustion: Understanding the interface of chronic viral and autoinflammatory diseases
  publication-title: Immunol. Cell Biol.
  contributor:
    fullname: Smith
– volume: 62
  start-page: 909
  year: 2013
  end-page: 918
  ident: bb2045
  article-title: Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer
  publication-title: Cancer Immunol. Immunother.
  contributor:
    fullname: Gabrilovich
– volume: 3
  year: 2014
  ident: bb2115
  article-title: Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response
  publication-title: Oncoimmunology
  contributor:
    fullname: Weir
– volume: 56
  start-page: 227
  year: 2007
  end-page: 236
  ident: bb1040
  article-title: Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunology
  publication-title: Immune-Ther.
  contributor:
    fullname: Ferrone
– volume: 41
  start-page: 843
  year: 2014
  end-page: 852
  ident: bb1415
  article-title: STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors
  publication-title: Immunity
  contributor:
    fullname: Deng
– volume: 3
  start-page: 43
  year: 2015
  ident: bb1635
  article-title: A new paradigm for tumor immune-escape: β-catenin-driven immune exclusion
  publication-title: J. Immune-Therapy of Cancer
  contributor:
    fullname: Gajewski
– volume: 9
  start-page: 2671
  year: 2014
  end-page: 2681
  ident: bb0670
  article-title: The impact of size on particulate vaccine adjuvants
  publication-title: Nanomedicine (London, England)
  contributor:
    fullname: Brito
– volume: 3
  start-page: 49
  year: 2013
  ident: bb1280
  article-title: Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer
  publication-title: Front. Oncol.
  contributor:
    fullname: Finke
– volume: 112
  start-page: 610
  year: 2008
  end-page: 618
  ident: bb2020
  article-title: Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines
  publication-title: Blood
  contributor:
    fullname: Morse
– volume: 72
  start-page: 2162
  year: 2012
  end-page: 2171
  ident: bb0205
  article-title: T-regulatory cells: key players in tumor immune-escape and angiogenesis
  publication-title: Cancer Res.
  contributor:
    fullname: Coukos
– volume: 348
  start-page: 203
  year: 2003
  end-page: 213
  ident: bb1770
  article-title: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
  publication-title: N. Engl. J. Med.
  contributor:
    fullname: Zhang
– volume: 27
  start-page: 2007
  year: 2016
  end-page: 2013
  ident: bb0880
  article-title: Covalent Conjugation of Small-Molecule Adjuvants to Nanoparticles Induces Robust Cytotoxic T Cell Responses via DC Activation
  publication-title: Bioconjug. Chem.
  contributor:
    fullname: Kim
– volume: 28
  start-page: 7897
  year: 2010
  end-page: 7906
  ident: bb0700
  article-title: Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation
  publication-title: Vaccine
  contributor:
    fullname: Swart
– volume: 28
  start-page: 1802540
  year: 2018
  ident: bb1595
  article-title: Toward biomaterials for enhancing immune checkpoint blockade therapy
  publication-title: Adv. Funct. Mater.
  contributor:
    fullname: Liu
– volume: 8121985
  year: 2016
  ident: bb2080
  article-title: Adjuvant autologous melanoma vaccine for macroscopic stage III disease: Survival, biomarkers, and improved response to CTLA-4 blockade
  publication-title: J Immunol Res
  contributor:
    fullname: Lotem
– volume: 1
  start-page: 138
  year: 2006
  end-page: 147
  ident: bb0250
  article-title: Cancer Immune-therapy
  publication-title: Biotechnol. J.
  contributor:
    fullname: Kircheis
– volume: 3
  year: 2014
  ident: bb1215
  article-title: Trial watch: IDO inhibitors in cancer therapy
  publication-title: Oncoimmunology
  contributor:
    fullname: Vacchelli
– volume: 21
  start-page: 4774
  year: 2015
  end-page: 4779
  ident: bb1385
  article-title: Molecular pathways: Targeting the stimulator of interferon genes (STING) in the immune-therapy of cancer
  publication-title: Clin. Cancer Res.
  contributor:
    fullname: Gajewski
– volume: 126
  start-page: 2404
  year: 2016
  end-page: 2411
  ident: bb1380
  article-title: The host STING pathway at the interface of cancer and immunity
  publication-title: J. Clin. Invest.
  contributor:
    fullname: Gajewski
– volume: 125
  start-page: 3356
  year: 2015
  end-page: 3364
  ident: bb1270
  article-title: Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
  publication-title: J. Clin. Invest.
  contributor:
    fullname: Gabrilovich
– volume: 25
  start-page: 37
  year: 2014
  end-page: 48
  ident: bb1395
  article-title: Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses
  publication-title: Cancer Cell
  contributor:
    fullname: Yang
– volume: 15
  start-page: 274
  year: 2016
  end-page: 287
  ident: bb0925
  article-title: Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity
  publication-title: Cell Rep.
  contributor:
    fullname: Aaes
– volume: 106
  start-page: 8623
  year: 2009
  end-page: 8628
  ident: bb1150
  article-title: High antigen levels are the cause of T cell exhaustion during chronic viral infection
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  contributor:
    fullname: Ahmed
– volume: 4
  start-page: 687
  year: 2016
  end-page: 691
  ident: bb2095
  article-title: A transient increase and subsequent sharp decrease of chemo-refractory liver-metastasized uterine cervical small cell carcinoma to autologous formalin-fixed tumor vaccine plus anti-PD-1 antibody
  publication-title: Clin. Case Reports
  contributor:
    fullname: Miyoshi
– volume: 3
  start-page: 991
  year: 2002
  end-page: 998
  ident: bb0030
  article-title: Cancer immunoediting: from immunosurveillance to tumor-escape
  publication-title: Nat. Immunol.
  contributor:
    fullname: Schreiber
– volume: 12
  start-page: 471
  year: 2011
  end-page: 480
  ident: bb1250
  article-title: Advances in the understanding of mechanisms and therapeutic use of bortezomib
  publication-title: Discov. Med.
  contributor:
    fullname: Dou
– volume: 4
  start-page: 522
  year: 2015
  end-page: 527
  ident: bb0445
  article-title: CpG-loaded multifunctional cationic nanohydrogel particles as self-adjuvanting glycopeptide antitumor vaccines
  publication-title: Adv. Healthcare Mater.
  contributor:
    fullname: Zentel
– volume: 3
  start-page: 344
  year: 2015
  end-page: 372
  ident: bb0460
  article-title: Whole tumor antigen vaccines: Where are we?
  publication-title: Vaccine
  contributor:
    fullname: Kandalaft
– volume: 67
  start-page: 11438
  year: 2007
  end-page: 11446
  ident: bb1300
  article-title: Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma
  publication-title: Cancer Res.
  contributor:
    fullname: Colombo
– volume: 1
  start-page: 0011
  year: 2017
  ident: bb1610
  article-title: In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
  publication-title: Nat. Biomed. Eng.
  contributor:
    fullname: Gu
– volume: 1865
  start-page: 72
  year: 2016
  end-page: 82
  ident: bb0360
  article-title: Personalized approaches to active Immune-therapy in cancer
  publication-title: Biochim. Biophys. Acta
  contributor:
    fullname: Kandalaft
– volume: 25
  start-page: 189
  year: 2017
  end-page: 201
  ident: bb1260
  article-title: Recent advances in targeting mTOR signaling pathway using small molecule inhibitors
  publication-title: J. Drug Target.
  contributor:
    fullname: Hojjat-Farsangi
– volume: 39
  year: 2013
  ident: bb0325
  article-title: Dendritic-cell-based therapeutic cancer vaccines
  publication-title: Immunity
  contributor:
    fullname: Banchereau
– volume: 42
  start-page: 663
  year: 2015
  end-page: 671
  ident: bb1485
  article-title: The next hurdle in cancer immune-therapy: overcoming the non-T-cell-inflamed tumor microenvironment
  publication-title: Semin. Oncol.
  contributor:
    fullname: Gajewski
– volume: 127
  start-page: 249
  year: 2010
  end-page: 256
  ident: bb1075
  article-title: "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for Immune-therapy
  publication-title: Int. J. Cancer
  contributor:
    fullname: Aptsiauri
– volume: 4
  start-page: 1643
  year: 2010
  end-page: 1654
  ident: bb1355
  article-title: STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response
  publication-title: Mol. Pharm.
  contributor:
    fullname: Lavasanifar
– volume: 27
  start-page: 1
  year: 2014
  end-page: 7
  ident: bb1435
  article-title: Regulatory T cells in cancer immune-therapy
  publication-title: Curr. Opin. Immunol.
  contributor:
    fullname: Sakaguchi
– volume: 2
  start-page: O15
  year: 2014
  ident: bb1630
  article-title: Melanoma-intrinsic β-catenin signaling prevents T cell infiltration and anti-tumor immunity
  publication-title: J. Immune-Therapy of Cancer
  contributor:
    fullname: Gajewski
– volume: 40
  start-page: 320
  year: 2011
  end-page: 339
  ident: bb0685
  article-title: Designing polymeric particles for antigen delivery
  publication-title: Chem. Soc. Rev.
  contributor:
    fullname: De Koker
– volume: 30
  start-page: 5
  year: 2011
  end-page: 12
  ident: bb1730
  article-title: Tumor immunosurveillance in human cancers
  publication-title: Cancer Metastasis Rev.
  contributor:
    fullname: Galon
– volume: 534
  start-page: 396
  year: 2016
  end-page: 401
  ident: bb0535
  article-title: Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
  publication-title: Nature
  contributor:
    fullname: Kranz
– volume: 3
  start-page: 136
  year: 2015
  end-page: 148
  ident: bb2055
  article-title: Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models
  publication-title: Cancer Immunol. Res.
  contributor:
    fullname: Shen
– volume: 74
  start-page: 4042
  year: 2014
  end-page: 4052
  ident: bb2090
  article-title: Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors
  publication-title: Cancer Res.
  contributor:
    fullname: Fu
– volume: 121
  start-page: 2836
  year: 2013
  end-page: 2844
  ident: bb0730
  article-title: Targeting dendritic cells—why bother?
  publication-title: Blood
  contributor:
    fullname: Figdor
– ident: bb1685
– volume: 1346
  start-page: 33
  year: 2015
  end-page: 44
  ident: bb1245
  article-title: mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging
  publication-title: Ann. N. Y. Acad. Sci.
  contributor:
    fullname: Perl
– volume: 199
  start-page: 251
  year: 2004
  end-page: 263
  ident: bb0595
  article-title: Cancer immunotherapy with mRNA-transfected dendritic cells
  publication-title: Immunol. Rev.
  contributor:
    fullname: Vieweg
– volume: 515
  start-page: 563
  year: 2014
  end-page: 567
  ident: bb1895
  article-title: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
  publication-title: Nature
  contributor:
    fullname: Herbst
– volume: 118
  start-page: 6
  year: 2006
  end-page: 10
  ident: bb1990
  article-title: Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis
  publication-title: Int. J. Cancer
  contributor:
    fullname: Watson
– volume: 23
  start-page: 938
  year: 2016
  end-page: 951
  ident: bb0930
  article-title: Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation
  publication-title: Cell Death Differ.
  contributor:
    fullname: Agostinis
– volume: 24
  start-page: 7139
  year: 2014
  end-page: 7150
  ident: bb0550
  article-title: Bio-hybrid tumor cell-templated capsules: a generic formulation strategy for tumor associated antigens in view of immune therapy
  publication-title: Adv. Funct. Mater.
  contributor:
    fullname: De Geest
– volume: 11
  start-page: 148
  year: 2013
  ident: bb2035
  article-title: Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model
  publication-title: J. Transl. Med.
  contributor:
    fullname: Tan
– volume: 5
  start-page: 6923
  year: 2014
  end-page: 6935
  ident: bb1100
  article-title: Epigenetic regulations in the IFNgamma signalling pathway: IFNgamma-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes
  publication-title: Oncotarget
  contributor:
    fullname: Vlkova
– volume: 19
  start-page: 39
  year: 2012
  end-page: 41
  ident: bb1010
  article-title: Major histocompatibility complex class I and tumour immuno-evasion: how to fool T cells and natural killer cells at one time
  publication-title: Curr. Oncol.
  contributor:
    fullname: Giacomini
– volume: 24
  start-page: 743
  year: 2014
  end-page: 750
  ident: bb1915
  article-title: Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
  publication-title: Genome Res.
  contributor:
    fullname: Brown
– volume: 45
  start-page: 510
  year: 2011
  end-page: 519
  ident: bb1500
  article-title: Ipilimumab: a novel treatment for metastatic melanoma
  publication-title: Ann. Pharmacother.
  contributor:
    fullname: Lowe
– volume: 103
  start-page: 685
  year: 2010
  end-page: 692
  ident: bb1815
  article-title: Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer
  publication-title: British J. Cancer
  contributor:
    fullname: Leffers
– volume: 4
  start-page: 111
  year: 2015
  end-page: 122
  ident: bb1540
  article-title: CD28 co-stimulation in T-cell homeostasis: a recent perspective
  publication-title: Immunotargets and The.
  contributor:
    fullname: Hünig
– volume: 479–480
  start-page: 180
  year: 2015
  end-page: 193
  ident: bb1160
  article-title: T cell exhaustion during persistent viral infections
  publication-title: Virology
  contributor:
    fullname: Zajac
– volume: 25
  start-page: 261
  year: 2013
  end-page: 267
  ident: bb1765
  article-title: From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer
  publication-title: Curr. Opin. Immunol.
  contributor:
    fullname: Galon
– volume: 9
  start-page: 1075
  year: 2014
  end-page: 1085
  ident: bb0850
  article-title: Directing the immune system with chemical compounds
  publication-title: ACS Chem. Biol.
  contributor:
    fullname: Esser-Kahn
– volume: 21
  start-page: 137
  year: 2004
  end-page: 148
  ident: bb0045
  article-title: The immunobiology of cancer immunosurveillance and immunoediting
  publication-title: Immunity
  contributor:
    fullname: Schreiber
– volume: 7
  start-page: 283ra252
  year: 2015
  ident: bb2065
  article-title: STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
  publication-title: Sci. Transl. Med.
  contributor:
    fullname: Fu
– volume: 4
  start-page: 142
  year: 2014
  ident: bb0340
  article-title: Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment
  publication-title: Front. Oncol.
  contributor:
    fullname: Kim
– volume: 7
  start-page: 790
  year: 2007
  end-page: 802
  ident: bb0655
  article-title: Dendritic-cell Immune-therapy: from ex vivo loading to in vivo targeting
  publication-title: Nat. Rev. Immunol.
  contributor:
    fullname: Figdor
– volume: 124
  start-page: 160
  year: 2005
  end-page: 169
  ident: bb0500
  publication-title: Invest. Dermatol.
  contributor:
    fullname: Lori
– volume: 467
  start-page: 127
  year: 2015
  end-page: 135
  ident: bb1735
  article-title: The immune response in cancer: from immunology to pathology to Immune-therapy
  publication-title: Virchows Arch.
  contributor:
    fullname: Fridman
– volume: 33
  start-page: 1201
  year: 2015
  end-page: 1210
  ident: bb0895
  article-title: In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity
  publication-title: Nat. Biotechnol.
  contributor:
    fullname: Lynn
– volume: 24
  start-page: 3724
  year: 2012
  end-page: 3746
  ident: bb0715
  article-title: Engineering nano- and microparticles to tune immunity
  publication-title: Adv. Mater. (Deerfield Beach, Fla.)
  contributor:
    fullname: Irvine
– volume: 5
  year: 2016
  ident: bb0735
  article-title: Toll-like receptors: the swiss army knife of immunity and vaccine development
  publication-title: Clin. Transl. Immunol.
  contributor:
    fullname: Mansell
– volume: 772
  start-page: 189
  year: 2014
  end-page: 204
  ident: bb1960
  article-title: Intratumoral hypoxia as the genesis of genetic instability and clinical prognosis in prostate cancer
  publication-title: Adv. Exp. Med. Biol.
  contributor:
    fullname: Bristow
– volume: 29
  start-page: 235
  year: 2011
  end-page: 271
  ident: bb0050
  article-title: Natural innate and adaptive immunity to cancer
  publication-title: Annu. Rev. Immunol.
  contributor:
    fullname: Smyth
– volume: 26
  start-page: 263
  year: 2005
  end-page: 270
  ident: bb0120
  article-title: Apoptosis in the development and treatment of cancer
  publication-title: Carcinogenesis
  contributor:
    fullname: Vaux
– volume: 34
  start-page: 349
  year: 2016
  end-page: 353
  ident: bb1265
  article-title: Biomedical potential of mTOR modulation by nanoparticles
  publication-title: Trends Biotechnol.
  contributor:
    fullname: Trajkovic
– volume: 125
  start-page: 739
  year: 2015
  end-page: 751
  ident: bb1790
  article-title: Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis
  publication-title: J. Clin. Invest.
  contributor:
    fullname: Reissfelder
– volume: 6
  start-page: 449
  year: 2006
  end-page: 458
  ident: bb0270
  article-title: Metastasis: a question of life or death
  publication-title: Nat. Rev. Cancer
  contributor:
    fullname: Puisieux
– ident: bb0015
– volume: 33
  start-page: 119
  year: 2012
  end-page: 126
  ident: bb0190
  article-title: Differential macrophage programming in the tumor microenvironment
  publication-title: Trends Immunol.
  contributor:
    fullname: Coussens
– volume: 2016
  start-page: 11
  year: 2016
  ident: bb0185
  article-title: Tumor-associated macrophages and neutrophils in tumor microenvironment
  publication-title: Mediat. Inflamm.
  contributor:
    fullname: Bae
– volume: 37
  start-page: 193
  year: 2016
  end-page: 207
  ident: bb1180
  article-title: IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
  publication-title: Trends Immunol.
  contributor:
    fullname: Mellor
– volume: 121
  start-page: 1
  year: 2007
  end-page: 14
  ident: bb0055
  article-title: Cancer immunoediting from immune surveillance to immune escape
  publication-title: Immunology
  contributor:
    fullname: Tanabe
– volume: 21
  start-page: 482
  year: 2015
  end-page: 491
  ident: bb1535
  article-title: Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system
  publication-title: Trends Mol. Med.
  contributor:
    fullname: Kiessling
– volume: 25
  start-page: 267
  year: 2007
  end-page: 296
  ident: bb0095
  article-title: Immune-suppressive strategies that are mediated by tumor cells
  publication-title: Annu. Rev. Immunol.
  contributor:
    fullname: Sotomayor
– volume: 27
  start-page: 462
  year: 2015
  end-page: 472
  ident: bb0195
  article-title: Macrophages and therapeutic resistance in cancer
  publication-title: Cancer Cell
  contributor:
    fullname: Coussens
– volume: 10
  start-page: 48
  year: 2004
  end-page: 54
  ident: bb1675
  article-title: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
  publication-title: Nat. Med.
  contributor:
    fullname: Wang
– volume: 22
  start-page: 679
  year: 2016
  end-page: 684
  ident: bb1845
  article-title: Two FOXP3(+)CD4+(+) T cell subpopulations distinctly control the prognosis of colorectal cancers
  publication-title: Nat. Med.
  contributor:
    fullname: Saito
– volume: 22
  start-page: 105
  year: 2010
  end-page: 112
  ident: bb1025
  article-title: Tumor immunogenicity and responsiveness to cancer vaccine therapy the state of the art
  publication-title: Semin. Immunol.
  contributor:
    fullname: Podack
– volume: 8
  year: 2013
  ident: bb0480
  article-title: Alginic acid-coated chitosan nanoparticles loaded with legumain dna vaccine: effect against breast cancer in mice
  publication-title: PLoS One
  contributor:
    fullname: Tan
– volume: 113
  start-page: 8098
  year: 2016
  end-page: 8103
  ident: bb0905
  article-title: pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune-activation
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  contributor:
    fullname: De Geest
– volume: 72
  start-page: 5435
  year: 2012
  end-page: 5440
  ident: bb1195
  article-title: Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion
  publication-title: Cancer Res.
  contributor:
    fullname: Van den Eynde
– volume: 5
  start-page: 1075
  year: 2013
  end-page: 1087
  ident: bb1420
  article-title: Targeting tumor-infiltrating macrophages to combat cancer
  publication-title: Immunotherapy
  contributor:
    fullname: DeNardo
– volume: 21
  start-page: 712
  year: 2015
  end-page: 720
  ident: bb2085
  article-title: Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma
  publication-title: Clin. Cancer Res.
  contributor:
    fullname: Gibney
– volume: 27
  start-page: 15
  year: 2004
  end-page: 26
  ident: bb0085
  article-title: Biological and therapeutic impact of intratumor heterogeneity in cancer evolution
  publication-title: Cancer Cell
  contributor:
    fullname: Swanton
– volume: 57
  start-page: 1727
  year: 2008
  end-page: 1733
  ident: bb1065
  article-title: Regressing and progressing metastatic lesions: resistance to Immune-therapy is predetermined by irreversible HLA class I antigen alterations
  publication-title: Cancer Immunol. Immune-Ther.
  contributor:
    fullname: Aptsiauri
– volume: 6
  year: 2017
  ident: bb0940
  article-title: Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
  publication-title: Oncoimmunology
  contributor:
    fullname: Galluzzi
– volume: 49
  start-page: 591
  year: 2010
  end-page: 600
  ident: bb1205
  article-title: The selenazal drug ebselen potently inhibits indoleamine 2,3-dioxygenase by targeting enzyme cysteine residues
  publication-title: Biochemistry
  contributor:
    fullname: Terentis
– volume: 134
  start-page: 1247
  year: 2008
  end-page: 1253
  ident: bb1940
  article-title: Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma
  publication-title: J. Cancer Res. Clin. Oncol.
  contributor:
    fullname: Pan
– volume: 55
  start-page: 2894
  year: 2016
  end-page: 2898
  ident: bb0430
  article-title: A Synthetic glycopeptide vaccine for the induction of a monoclonal antibody that differentiates between normal and tumor mammary cells and enables the diagnosis of human pancreatic cancer
  publication-title: Angew. Chem. Int. Ed.
  contributor:
    fullname: Kunz
– volume: 15
  start-page: 486
  year: 2015
  end-page: 499
  ident: bb1170
  article-title: Molecular and cellular insights into T cell exhaustion
  publication-title: Nat. Rev. Immunol.
  contributor:
    fullname: Kurachi
– volume: 1865
  start-page: 35
  year: 2016
  end-page: 48
  ident: bb1275
  article-title: MDSCs in cancer: Conceiving new prognostic and therapeutic targets
  publication-title: Biochim. Biophys. Acta
  contributor:
    fullname: De Sanctis
– volume: 137
  start-page: 1095
  year: 2015
  end-page: 1106
  ident: bb1935
  article-title: Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients
  publication-title: Int. J. Cancer
  contributor:
    fullname: Jia
– volume: 1174
  start-page: 99
  year: 2009
  end-page: 106
  ident: bb1470
  article-title: Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells
  publication-title: Ann. N. Y. Acad. Sci.
  contributor:
    fullname: Vonderheide
– volume: 12
  start-page: 747
  year: 2013
  end-page: 758
  ident: bb0795
  article-title: An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants
  publication-title: Expert Rev. Vaccines
  contributor:
    fullname: Haensler
– volume: 22
  start-page: 329
  year: 2004
  end-page: 360
  ident: bb0040
  article-title: The three Es of cancer immunoediting
  publication-title: Annu. Rev. Immunol.
  contributor:
    fullname: Schreiber
– volume: 11
  start-page: 2723
  year: 2016
  end-page: 2734
  ident: bb0530
  article-title: Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma
  publication-title: Nanomedicine
  contributor:
    fullname: Sahin
– volume: 34
  start-page: 107
  year: 1981
  end-page: 140
  ident: bb0060
  article-title: The tumor dormant state
  publication-title: Adv. Cancer Res.
  contributor:
    fullname: Levich
– volume: 12
  start-page: 779
  year: 2013
  end-page: 791
  ident: bb0815
  article-title: Influenza virosomes as vaccine adjuvant and carrier system
  publication-title: Expert Rev. Vaccines
  contributor:
    fullname: Amacker
– volume: 40
  start-page: 1
  year: 2006
  end-page: 9
  ident: bb0675
  article-title: Pathogen recognition and development of particulate vaccines: does size matter?
  publication-title: Methods (San Diego, Calif.)
  contributor:
    fullname: Xiang
– volume: 21
  start-page: 105
  year: 2009
  end-page: 110
  ident: bb0310
  article-title: Antigen presentation by dendritic cells in vivo
  publication-title: Curr. Opin. Immunol.
  contributor:
    fullname: Villadangos
– volume: 22
  start-page: 1885
  year: 2016
  end-page: 1896
  ident: bb0505
  article-title: Targeting the heterogeneity of cancer with individualized neoepitope vaccines
  publication-title: Clin. Cancer Res.
  contributor:
    fullname: Tureci
– volume: 8
  start-page: 9209
  year: 2014
  end-page: 9218
  ident: bb0410
  article-title: Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity
  publication-title: ACS Nano
  contributor:
    fullname: Shiku
– volume: 10
  start-page: 3261
  year: 2014
  end-page: 3269
  ident: bb0985
  article-title: Tumor cell lysates as immunogenic sources for cancer vaccine design
  publication-title: Hum. Vaccin. Immunother.
  contributor:
    fullname: Gonzalez
– volume: 72
  start-page: 3125
  year: 2012
  end-page: 3130
  ident: bb0200
  article-title: Cellular constituents of immune-escape within the tumor microenvironment
  publication-title: Cancer Res.
  contributor:
    fullname: Restifo
– volume: 67
  start-page: 731
  year: 2015
  end-page: 753
  ident: bb0295
  article-title: Dendritic cells as pharmacological tools for cancer immune-therapy
  publication-title: Pharmacol. Rev.
  contributor:
    fullname: Anguille
– volume: 9
  start-page: 398
  year: 2018
  ident: bb1345
  article-title: Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression
  publication-title: Front. Immunol.
  contributor:
    fullname: Umanski
– volume: 16
  start-page: 2334
  year: 2016
  end-page: 2340
  ident: bb1600
  article-title: Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody
  publication-title: Nano Lett.
  contributor:
    fullname: Gu
– volume: 16
  start-page: 354
  year: 2010
  end-page: 359
  ident: bb1200
  article-title: Indoleamine 2,3-dioxygenase: is it an immune-suppressor?
  publication-title: Cancer J.
  contributor:
    fullname: Antonia
– volume: 109
  start-page: 14604
  year: 2012
  end-page: 14609
  ident: bb0495
  article-title: Self-amplifying RNA vaccines
  publication-title: Proc. Natl. Acad. Sci.
  contributor:
    fullname: Mandl
– volume: 8
  start-page: 274
  year: 2002
  end-page: 281
  ident: bb0130
  article-title: Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax
  publication-title: Nat. Med.
  contributor:
    fullname: LeBlanc
– volume: 351
  start-page: 1463
  year: 2016
  end-page: 1469
  ident: bb1920
  article-title: Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
  publication-title: Science
  contributor:
    fullname: McGranahan
– volume: 3
  start-page: 403
  year: 2004
  end-page: 411
  ident: bb0975
  article-title: Heat shock protein-based cancer vaccines
  publication-title: Expert Rev. Vaccines
  contributor:
    fullname: Younes
– volume: 369
  start-page: 122
  year: 2013
  end-page: 133
  ident: bb1905
  article-title: Nivolumab plus Ipilimumab in Advanced Melanoma
  publication-title: New England J. Med.
  contributor:
    fullname: Wolchok
– volume: 9
  start-page: 798
  year: 2009
  end-page: 809
  ident: bb0135
  article-title: STATs in cancer inflammation and immunity: a leading role for STAT-3
  publication-title: Nat. Rev. Cancer
  contributor:
    fullname: Jove
– volume: 116
  start-page: 685
  year: 2008
  end-page: 694
  ident: bb0070
  article-title: Tumor dormancy and immunoescape
  publication-title: APMIS
  contributor:
    fullname: Quesnel
– volume: 44
  start-page: 973
  year: 2016
  end-page: 988
  ident: bb1530
  article-title: CD28 Costimulation: From Mechanism to Therapy
  publication-title: Immunity
  contributor:
    fullname: Bluestone
– volume: 208
  start-page: 2347
  year: 2011
  end-page: 2349
  ident: bb0845
  article-title: Learning vaccinology from viral infections
  publication-title: J. Exp. Med.
  contributor:
    fullname: Pulendran
– volume: 30
  start-page: 4341
  year: 2012
  end-page: 4348
  ident: bb0790
  article-title: The mechanism of action of MF59 - an innately attractive adjuvant formulation
  publication-title: Vaccine
  contributor:
    fullname: Seubert
– volume: 34
  start-page: 4304
  year: 2016
  end-page: 4312
  ident: bb0890
  article-title: Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants
  publication-title: Vaccine
  contributor:
    fullname: Smith
– volume: 10
  start-page: 9216
  year: 2016
  end-page: 9226
  ident: bb1475
  article-title: Interleukin-2 Functionalized Nanocapsules for T Cell-Based Immunotherapy
  publication-title: ACS Nano
  contributor:
    fullname: Steinbrink
– volume: 4
  start-page: 379
  year: 2014
  ident: bb0990
  article-title: Endoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccines
  publication-title: Front. Oncol.
  contributor:
    fullname: Katsanis
– volume: 22
  start-page: 1856
  year: 2016
  end-page: 1864
  ident: bb1155
  article-title: Reversing T-cell dysfunction and exhaustion in cancer
  publication-title: Clin. Cancer Res.
  contributor:
    fullname: Zarour
– volume: 93
  start-page: 343
  year: 2013
  end-page: 352
  ident: bb1365
  article-title: Tumor microenvironment converts plasmacytoid dendritic cells into immune-suppressive/tolerogenic cells: insight into the molecular mechanisms
  publication-title: J. Leukoc. Biol.
  contributor:
    fullname: Hubert
– ident: bb0005
– volume: 28
  year: 2017
  ident: bb1680
  article-title: Primary PFS and safety analysis of a randomized phase II study of carboplation + paclitaxel +/- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMPOWER150)
  publication-title: Ann. Oncol.
  contributor:
    fullname: Reck
– volume: 59
  start-page: 249
  year: 2011
  end-page: 259
  ident: bb0280
  article-title: Cancer vaccines. Any future?
  publication-title: Arch. Immunol. Ther. Exp.
  contributor:
    fullname: Myc
– volume: 35
  start-page: S185
  year: 2015
  end-page: S198
  ident: bb1020
  article-title: Immune evasion in cancer: Mechanistic basis and therapeutic strategies
  publication-title: Semin. Cancer Biol.
  contributor:
    fullname: Vinay
– volume: 7
  start-page: 835
  year: 2014
  end-page: 844
  ident: bb1285
  article-title: Myeloid lineage-specific deletion of antioxidant system enhances tumor metastasis
  publication-title: Cancer Prev. Res. (Philadelphia, Pa.)
  contributor:
    fullname: Hiramoto
– volume: 12
  start-page: 612
  year: 2016
  end-page: 622
  ident: bb0725
  article-title: Dendritic cell targeted vaccines: recent progresses and challenges
  publication-title: Hum. Vaccin. Immunother.
  contributor:
    fullname: Chen
– volume: 12
  start-page: 252
  year: 2012
  end-page: 264
  ident: bb1495
  article-title: The blockade of immune checkpoints in cancer Immune-therapy
  publication-title: Nat. Rev. Cancer
  contributor:
    fullname: Pardoll
– volume: 13
  start-page: 1
  year: 2015
  end-page: 14
  ident: bb1560
  article-title: Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis
  publication-title: BMC Med.
  contributor:
    fullname: Schaeverbeke
– volume: 5
  start-page: 197
  year: 2014
  ident: bb0090
  article-title: Does the immune system naturally protect against cancer?
  publication-title: Front. Immunol.
  contributor:
    fullname: Corthay
– volume: 206
  start-page: 18
  year: 2010
  ident: bb0100
  article-title: Cancer immunoediting and “spontaneous” tumor regression
  publication-title: Pathol. Res. Pract.
  contributor:
    fullname: Silver
– volume: 131
  start-page: 871
  year: 2012
  end-page: 880
  ident: bb1810
  article-title: A signature of immune function genes associated with recurrence-free survival in breast cancer patients
  publication-title: Breast Cancer Res. Treat.
  contributor:
    fullname: Ascierto
– volume: 13
  start-page: 501
  year: 2012
  end-page: 508
  ident: bb2075
  article-title: Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
  publication-title: Lancet Oncol.
  contributor:
    fullname: Madan
– volume: 34
  start-page: 181
  year: 2016
  end-page: 187
  ident: bb1795
  article-title: The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer
  publication-title: World J. Urol.
  contributor:
    fullname: Horn
– volume: 11
  start-page: 733
  year: 2012
  end-page: 744
  ident: bb0820
  article-title: Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines
  publication-title: Expert Rev. Vaccines
  contributor:
    fullname: Mayorov
– volume: 35
  start-page: 51
  year: 2014
  end-page: 60
  ident: bb1175
  article-title: Tolerance and exhaustion: defining mechanisms of T cell dysfunction
  publication-title: Trends Immunol.
  contributor:
    fullname: Greenberg
– volume: 232
  start-page: 199
  year: 2014
  end-page: 209
  ident: bb1755
  article-title: Towards the introduction of the 'Immunoscore' in the classification of malignant tumours
  publication-title: J. Pathol.
  contributor:
    fullname: Galon
– volume: 28
  start-page: 373
  year: 2016
  end-page: 382
  ident: bb1800
  article-title: Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients
  publication-title: Int. Immunol.
  contributor:
    fullname: Kirilovsky
– volume: 48
  start-page: 7551
  year: 2009
  end-page: 7555
  ident: bb0425
  article-title: A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response
  publication-title: Angew. Chem. Int. Ed.
  contributor:
    fullname: Kunz
– volume: 200
  start-page: 415
  year: 2018
  end-page: 421
  ident: bb1440
  article-title: Unlocking the complexities of tumor-associated regulatory T cells
  publication-title: J. Immunol.
  contributor:
    fullname: Savage
– volume: 11
  start-page: 5417
  year: 2017
  end-page: 5429
  ident: bb1615
  article-title: Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth
  publication-title: ACS Nano
  contributor:
    fullname: Schneck
– volume: 51
  start-page: 3862
  year: 2012
  end-page: 3866
  ident: bb0690
  article-title: Surface-engineered polyelectrolyte multilayer capsules: synthetic vaccines mimicking microbial structure and function
  publication-title: Angew. Chem. Int. Ed.
  contributor:
    fullname: De Koker
– volume: 66
  start-page: 9281
  year: 2006
  end-page: 9289
  ident: bb1980
  article-title: HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker
  publication-title: Cancer Res.
  contributor:
    fullname: Ogino
– volume: 151
  start-page: 458
  year: 2010
  end-page: 465
  ident: bb0235
  article-title: Nanoparticles and the immune system
  publication-title: Endocrinology
  contributor:
    fullname: Dobrovolskaia
– volume: 8
  start-page: 1135
  year: 2012
  end-page: 1140
  ident: bb0335
  article-title: Overview of the cancer vaccine field: Are we moving forward?
  publication-title: Human Vaccin. Immunother.
  contributor:
    fullname: Hanna
– volume: 547
  start-page: 222
  year: 2017
  end-page: 226
  ident: bb0525
  article-title: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
  publication-title: Nature
  contributor:
    fullname: Sahin
– volume: 12
  start-page: 978
  year: 2013
  end-page: 990
  ident: bb0645
  article-title: Engineering synthetic vaccines using cues from natural immunity
  publication-title: Nat. Mater.
  contributor:
    fullname: Szeto
– volume: 258
  start-page: 146
  year: 2017
  end-page: 160
  ident: bb0490
  article-title: Combining reactive triblock copolymers with functional cross-linkers: A versatile pathway to disulfide stabilized-polyplex libraries and their application as pDNA vaccines
  publication-title: J. Control. Release
  contributor:
    fullname: Barz
– volume: 1950
  start-page: 137
  year: 2009
  end-page: 144
  ident: bb2125
  article-title: Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism
  publication-title: J. Immunol. (Baltimore, Md.)
  contributor:
    fullname: Shurin
– volume: 5
  year: 2016
  ident: bb1640
  article-title: Tumor-intrinsic oncogene pathways mediating immune avoidance
  publication-title: Oncoimmunology
  contributor:
    fullname: Gajewski
– volume: 363
  year: 2010
  ident: bb0620
  article-title: Sipuleucel-T Immune-therapy for castration-resistant prostate cancer
  publication-title: N. Engl. J. Med.
  contributor:
    fullname: Kantoff
– volume: 25
  start-page: 1159
  year: 2007
  end-page: 1164
  ident: bb0665
  article-title: Exploiting lymphatic transport and complement activation in nanoparticle vaccines
  publication-title: Nat. Biotechnol.
  contributor:
    fullname: Hubbell
– volume: 21
  start-page: 39
  year: 2015
  end-page: 48
  ident: bb1295
  article-title: Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma
  publication-title: Clin. Cancer Res.
  contributor:
    fullname: Weed
– volume: 8
  year: 2013
  ident: bb2120
  article-title: The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system
  publication-title: PLoS One
  contributor:
    fullname: Salem
– volume: 3
  start-page: 410
  year: 2010
  end-page: 415
  ident: bb0290
  article-title: Vaccine Prevention of Cancer: Can Endogenous Antigens be Targeted?
  publication-title: Cancer Prev. Res. (Philadelphia, Pa.)
  contributor:
    fullname: Murray
– volume: 20
  start-page: 1085
  year: 2013
  end-page: 1092
  ident: bb1310
  article-title: Downregulation of STAT-3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy
  publication-title: Gene Ther.
  contributor:
    fullname: Emeagi
– volume: 22
  start-page: 263
  year: 2010
  end-page: 267
  ident: bb2015
  article-title: Update on castrate-resistant prostate cancer: 2010
  publication-title: Curr. Opin. Oncol.
  contributor:
    fullname: Dawson
– volume: 206
  start-page: 220
  year: 2015
  end-page: 231
  ident: bb0485
  article-title: Feasibility of a subcutaneously administered block/homo-mixed polyplex micelle as a carrier for DNA vaccination in a mouse tumor model
  publication-title: J. Control. Release
  contributor:
    fullname: Nakano
– volume: 8
  start-page: 10633
  year: 2015
  end-page: 10639
  ident: bb1950
  article-title: Association between serum C-reactive protein value and prognosis of patients with non-small cell lung cancer: a meta-analysis
  publication-title: Int. J. Clin. Exp. Med.
  contributor:
    fullname: Jing
– volume: 6
  start-page: 1755
  year: 2000
  end-page: 1766
  ident: bb0610
  article-title: Clinical significance of defective dendritic cell differentation in cancer
  publication-title: Clin. Cancer Res.
  contributor:
    fullname: Almand
– volume: 5
  year: 2016
  ident: bb0615
  article-title: Targeting dendritic cells: a promising strategy to improve vaccine effectiveness
  publication-title: Clin. Trans. Immunol.
  contributor:
    fullname: Mintern
– volume: 72
  start-page: 2990
  year: 2012
  end-page: 2999
  ident: bb1650
  article-title: Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis
  publication-title: Cancer Res.
  contributor:
    fullname: Ihara
– volume: 15
  start-page: 1920
  year: 2016
  end-page: 1930
  ident: bb2050
  article-title: Protection against HPV-16-associated tumors requires the activation of CD8+ effector memory T cells and the control of myeloid-derived suppressor cells
  publication-title: Mol. Cancer Therapeutics
  contributor:
    fullname: Ferreira
– volume: 2016
  year: 2016
  ident: bb0780
  article-title: Adjuvants: classification, modus operandi, and licensing
  publication-title: J Immunol Res
  contributor:
    fullname: Santoro Rosa
– volume: 86
  start-page: 359
  year: 2012
  end-page: 372
  ident: bb0835
  article-title: The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review
  publication-title: Am. J. Trop. Med. Hygiene
  contributor:
    fullname: Williamson
– volume: 103
  start-page: 1219
  year: 2018
  end-page: 1223
  ident: bb1105
  article-title: INF-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression
  publication-title: J. Leukoc. Biol.
  contributor:
    fullname: Mangily
– volume: 547
  start-page: 217
  year: 2017
  end-page: 221
  ident: bb0540
  article-title: An immunogenic personal neoantigen vaccine for patients with melanoma
  publication-title: Nature
  contributor:
    fullname: Ott
– volume: 52
  start-page: 10652
  year: 2013
  end-page: 10656
  ident: bb0435
  article-title: Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines
  publication-title: Angew. Chem. Int. Ed.
  contributor:
    fullname: Kunz
– volume: 59
  start-page: 926
  year: 2010
  end-page: 933
  ident: bb1975
  article-title: Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer
  publication-title: Gut
  contributor:
    fullname: Simpson
– volume: 39
  start-page: 276
  year: 2012
  end-page: 286
  ident: bb0605
  article-title: Whole cell vaccines — past progress and future strategies
  publication-title: Semin. Oncol.
  contributor:
    fullname: Jaffee
– volume: 2
  year: 2013
  ident: bb2110
  article-title: Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas
  publication-title: Oncoimmunology
  contributor:
    fullname: Mattarollo
– volume: 37
  start-page: 855
  year: 2016
  end-page: 865
  ident: bb0710
  article-title: Dendritic cells and cancer immunity
  publication-title: Trends Immunol.
  contributor:
    fullname: Ruffell
– volume: 12
  start-page: 265
  year: 2012
  end-page: 277
  ident: bb0775
  article-title: Cancer Immune-therapy via dendritic cells
  publication-title: Nat. Rev. Cancer
  contributor:
    fullname: Banchereau
– volume: 12
  start-page: 1351
  year: 2013
  end-page: 1368
  ident: bb0830
  article-title: Safety profile of the yellow fever vaccine Stamaril(R): a 17-year review
  publication-title: Expert Rev. Vaccines
  contributor:
    fullname: Domingo
– volume: 348
  start-page: 69
  year: 2015
  end-page: 74
  ident: bb0510
  article-title: Neoantigens in cancer immune-therapy
  publication-title: Science
  contributor:
    fullname: Schreiber
– volume: 515
  start-page: 558
  year: 2014
  end-page: 562
  ident: bb1890
  article-title: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
  publication-title: Nature
  contributor:
    fullname: Powles
– volume: 34
  start-page: 206
  year: 2005
  end-page: 213
  ident: bb1055
  article-title: Exosomes and MICA-NKG2D system in cancer
  publication-title: Blood Cells Mod. Dis.
  contributor:
    fullname: Tabi
– volume: 31
  start-page: 439
  year: 2013
  end-page: 442
  ident: bb0515
  article-title: Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma
  publication-title: J. Clin. Oncol.
  contributor:
    fullname: Schumacher
– volume: 8
  start-page: 1811
  year: 2017
  ident: bb1225
  article-title: Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression
  publication-title: Nat. Commun.
  contributor:
    fullname: Nel
– volume: 94
  start-page: 509
  year: 2016
  end-page: 522
  ident: bb0150
  article-title: Immune-suppressive cells in tumor immune-escape and metastasis
  publication-title: J. Mol. Med. (Berlin, Germany)
  contributor:
    fullname: Cao
– volume: 41
  start-page: 2217
  year: 2011
  end-page: 2228
  ident: bb2130
  article-title: Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity
  publication-title: Eur. J. Immunol.
  contributor:
    fullname: Sierro
– volume: 65
  start-page: 533
  year: 2010
  end-page: 541
  ident: bb0805
  article-title: Safety review: squalene and thimerosal in vaccines
  publication-title: Therapie
  contributor:
    fullname: Montana
– volume: 106
  start-page: 397
  year: 2015
  end-page: 406
  ident: bb2025
  article-title: Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer
  publication-title: Cancer Sci.
  contributor:
    fullname: Mayanagi
– volume: 7
  start-page: 651
  year: 2011
  end-page: 658
  ident: bb0145
  article-title: Dual roles of immune cells and their factors in cancer development and progression
  publication-title: Int. J. Biol. Sci.
  contributor:
    fullname: Chen
– volume: 17
  start-page: 822
  year: 2016
  end-page: 835
  ident: bb0370
  article-title: Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet Oncol.
  contributor:
    fullname: Vansteenkiste
– volume: 203
  start-page: 16
  year: 2015
  end-page: 22
  ident: bb0415
  article-title: Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation
  publication-title: J. Control. Release
  contributor:
    fullname: Ossendorp
– volume: 100
  start-page: 927
  year: 2016
  end-page: 941
  ident: bb0860
  article-title: Molecular mechanisms of regulation of Toll-like receptor signaling
  publication-title: J. Leukoc. Biol.
  contributor:
    fullname: Medvedev
– volume: 122
  start-page: 899
  year: 2012
  end-page: 910
  ident: bb1655
  article-title: Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors
  publication-title: J. Clin. Invest.
  contributor:
    fullname: Salmon
– volume: 1
  start-page: 10
  year: 2013
  ident: bb1335
  article-title: Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer
  publication-title: J. Immune-Ther. Cancer
  contributor:
    fullname: Carson
– volume: 35
  start-page: 1336
  year: 2005
  end-page: 1341
  ident: bb0225
  article-title: Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL-)two to tango
  publication-title: Eur. J. Immunol.
  contributor:
    fullname: Hofer
– volume: 17
  start-page: 343
  year: 2011
  end-page: 350
  ident: bb0375
  article-title: Present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?
  publication-title: Cancer J.
  contributor:
    fullname: The
– volume: 6
  start-page: 1670
  year: 2014
  end-page: 1690
  ident: bb0180
  article-title: Tumor-associated macrophages as major players in the tumor microenvironment
  publication-title: Cancer
  contributor:
    fullname: Itano
– volume: 17
  start-page: 6118
  year: 2011
  end-page: 6124
  ident: bb1110
  article-title: The two faces of interferon-γ in cancer
  publication-title: Clin. Cancer Res.
  contributor:
    fullname: Merlino
– volume: 67
  start-page: 1
  year: 2016
  end-page: 10
  ident: bb1445
  article-title: Rationale for anti-GITR cancer Immune-therapy
  publication-title: Eur. J. Cancer
  contributor:
    fullname: Brogdon
– volume: 5
  start-page: 182
  year: 2014
  ident: bb0650
  article-title: Understanding MHC class I presentation of viral antigens by human dendritic cells as a basis for rational design of therapeutic vaccines
  publication-title: Front. Immunol.
  contributor:
    fullname: Woltman
– volume: 29
  start-page: 2394
  year: 2018
  end-page: 2405
  ident: bb1370
  article-title: Targeting Protumoral Tumor-Associated Macrophages with Nanobody-Functionalized Nanogels through Strain Promoted Azide Alkyne Cycloaddition Ligation
  publication-title: Bioconjug. Chem.
  contributor:
    fullname: De Geest
– volume: 2
  start-page: 578
  year: 2018
  end-page: 588
  ident: bb1375
  article-title: TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy
  publication-title: Nat. Biomed. Eng.
  contributor:
    fullname: Weissleder
– volume: 3
  start-page: 662
  year: 2015
  end-page: 685
  ident: bb0640
  article-title: Nanoparticle drug delivery systems designed to improve cancer vaccines and immune-therapy
  publication-title: Vaccines (Basel)
  contributor:
    fullname: Moon
– volume: 115
  start-page: 3520
  year: 2010
  end-page: 3530
  ident: bb1210
  article-title: Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
  publication-title: Blood
  contributor:
    fullname: Liu
– volume: 22
  start-page: 132
  year: 2010
  end-page: 143
  ident: bb0355
  article-title: Whole tumor antigen vaccines
  publication-title: Semin. Immunol.
  contributor:
    fullname: Coukos
– volume: 6
  start-page: 836
  year: 2006
  end-page: 848
  ident: bb0110
  article-title: Interferons, immunity and cancer immunoediting
  publication-title: Nat. Rev. Immunol.
  contributor:
    fullname: Schreiber
– volume: 4
  start-page: 661
  year: 2015
  end-page: 672
  ident: bb1580
  article-title: CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
  publication-title: Cancer Med.
  contributor:
    fullname: Camacho
– volume: 44
  start-page: 343
  year: 2015
  end-page: 354
  ident: bb1090
  article-title: Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy
  publication-title: Immunity
  contributor:
    fullname: Pfirschke
– volume: 253
  start-page: 402
  year: 2003
  end-page: 410
  ident: bb0390
  article-title: DNA vaccines: a review
  publication-title: J. Intern. Med.
  contributor:
    fullname: Liu
– volume: 11
  year: 2016
  ident: bb0750
  article-title: Targeting cells of the immune system: mannosylated HPMA-LMA block-copolymer micelles for targeting of dendritic cells
  publication-title: Nanomedicine (London)
  contributor:
    fullname: Zentel
– volume: 2
  start-page: 36
  year: 2014
  end-page: 40
  ident: bb0140
  article-title: A bioinspired light induced avenue for the design of patterned functional interfaces
  publication-title: J. Mater. Chem. B
  contributor:
    fullname: Preuss
– volume: 41
  start-page: S3
  year: 2014
  end-page: S13
  ident: bb0265
  article-title: Mechanism of action of immunotherapy
  publication-title: Semin. Oncol.
  contributor:
    fullname: Disis
– volume: 33
  start-page: 1146
  year: 2015
  end-page: 1148
  ident: bb0900
  article-title: Big thinking for adjuvants
  publication-title: Nat. Biotechnol.
  contributor:
    fullname: Irvine
– volume: 6
  year: 2015
  ident: bb1045
  article-title: Critical role of tumor microenvironment in shaping NK cell functions: implication of hypoxic stress
  publication-title: Front. Immunol.
  contributor:
    fullname: Hasmim
– volume: 5
  year: 2015
  ident: bb1510
  article-title: Cancer Discovery
  contributor:
    fullname: Nivolumab approved for Lung Cancer
– volume: 5
  year: 2016
  ident: bb0585
  article-title: Immune reponse and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
  publication-title: Oncoimmunology
  contributor:
    fullname: Kyte
– volume: 20
  start-page: 286
  year: 2008
  end-page: 295
  ident: bb0365
  article-title: Antigens for cancer Immune-therapy
  publication-title: Semin. Immunol.
  contributor:
    fullname: Schmidt
– volume: 5
  start-page: 603
  year: 2014
  ident: bb0170
  article-title: TH1/TH2 paradigm extended: macrophage polarization as an unappreciated pathogen-driven escape mechanism?
  publication-title: Front. Immunol.
  contributor:
    fullname: Moser
– volume: 392
  start-page: 245
  year: 1998
  end-page: 252
  ident: bb0300
  article-title: Dendritic cells and the control of immunity
  publication-title: Nature
  contributor:
    fullname: Steinman
– volume: 2
  start-page: 530
  year: 2014
  end-page: 537
  ident: bb1985
  article-title: Tumor MHC class I expression improves the prognostic value of T cell density in resected colorectal liver metastases
  publication-title: Cancer Immunol. Res.
  contributor:
    fullname: Turcotte
– volume: 8
  start-page: 828
  year: 2017
  ident: bb1360
  article-title: Reprogramming of tumor-associated macrophages with anticancer therapies: radiotherapy versus chemo- and immunotherapies
  publication-title: Front. Immunol.
  contributor:
    fullname: Michiels
– volume: 131
  start-page: 741
  year: 2012
  end-page: 751
  ident: bb1325
  article-title: The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment
  publication-title: Int. J. Cancer
  contributor:
    fullname: Lee
– volume: 4
  start-page: 305
  year: 2013
  end-page: 312
  ident: bb0380
  article-title: Production of recombinant immunotherapeutics for anticancer treatment
  publication-title: Bioengineered.
  contributor:
    fullname: Vieira
– volume: 60
  start-page: 1137
  year: 2011
  end-page: 1146
  ident: bb2070
  article-title: CTLA-4 blockade increases antigen-specific CD8+(+) T cells in prevaccinated patients with melanoma: three cases
  publication-title: Cancer Immunol. Immunother.
  contributor:
    fullname: Yuan
– volume: 98
  start-page: 913
  year: 2016
  end-page: 922
  ident: bb1315
  article-title: Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immune-suppression in cancer
  publication-title: Arch. Pharm. Res.
  contributor:
    fullname: Kim
– volume: 12
  start-page: 180
  year: 2012
  end-page: 190
  ident: bb0220
  article-title: The role of interleukin-2 during homeostasis and activation of the immune system
  publication-title: Nat. Rev. Immunol.
  contributor:
    fullname: Sprent
– volume: 20
  start-page: 241
  year: 2010
  end-page: 246
  ident: bb2010
  article-title: Current status of immunological therapies for prostate cancer
  publication-title: Curr. Opin. Urol.
  contributor:
    fullname: Drake
– volume: 12
  start-page: 298
  year: 2012
  end-page: 306
  ident: bb1745
  article-title: The immune contexture in human tumours: impact on clinical outcome
  publication-title: Nat. Rev. Cancer
  contributor:
    fullname: Galon
– volume: 71
  start-page: 1263
  year: 2011
  end-page: 1271
  ident: bb1805
  article-title: Clinical impact of different classes of infiltrating T cytotoxic and helper cells (TH1, TH2, treg, TH17) in patients with colorectal cancer
  publication-title: Cancer Res.
  contributor:
    fullname: Tosolini
– volume: 24
  start-page: 3724
  year: 2012
  end-page: 3746
  ident: bb0245
  article-title: Engineering nano- and microparticles to tune immunity
  publication-title: Adv. Mater.
  contributor:
    fullname: Irvine
– volume: 63
  start-page: 721
  year: 2014
  end-page: 735
  ident: bb1190
  article-title: Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune-escape in cancer
  publication-title: Cancer Immunol. Immunother.
  contributor:
    fullname: Prendergast
– volume: 222
  start-page: 206
  year: 2008
  end-page: 221
  ident: bb1185
  article-title: Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune-escape
  publication-title: Immunol. Rev.
  contributor:
    fullname: Prendergast
– year: 2018
  ident: bb0945
  article-title: Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy
  publication-title: Angew. Chem. Int. Ed. Eng.
  contributor:
    fullname: Lin
– volume: 33
  start-page: 364
  year: 2012
  end-page: 372
  ident: bb1165
  article-title: The three main stumbling blocks for anticancer T cells
  publication-title: Trends Immunol.
  contributor:
    fullname: Speiser
– volume: 3
  year: 2014
  ident: bb1515
  article-title: Novel immune checkpoint blocker approved for the treatment of advanced melanoma
  publication-title: Oncoimmunology
  contributor:
    fullname: Eggermont
– volume: 2
  start-page: 940
  year: 2013
  end-page: 944
  ident: bb0760
  article-title: Targeting dendritic CELLS: The role of specific receptors in the internalization of polymer capsules
  publication-title: Adv. Healthcare Mater.
  contributor:
    fullname: Johnston
– volume: 21
  start-page: 30
  year: 2015
  end-page: 38
  ident: bb1290
  article-title: Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma
  publication-title: Clin. Cancer Res.
  contributor:
    fullname: Califano
– volume: 2013
  start-page: 764706
  year: 2013
  ident: bb0810
  article-title: Virosome presents multimodel cancer therapy without viral replication
  publication-title: Biomed. Res. Int.
  contributor:
    fullname: Kaneda
– volume: 134
  start-page: 525
  year: 2008
  end-page: 533
  ident: bb2105
  article-title: Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT
  publication-title: J. Cancer Res. Clin. Oncol.
  contributor:
    fullname: Ou
– volume: 2
  start-page: 1700050
  year: 2017
  ident: bb0555
  article-title: Polyelectrolyte-enrobed cancer cells in view of personalized immune-therapy
  publication-title: Adv. Sci.
  contributor:
    fullname: De Geest
– volume: 44
  start-page: 955
  year: 2016
  end-page: 972
  ident: bb1525
  article-title: Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
  publication-title: Immunity
  contributor:
    fullname: Sharpe
– volume: 10
  start-page: 3153
  year: 2014
  end-page: 3164
  ident: bb0450
  article-title: DNA vaccine for cancer immune-therapy
  publication-title: Hum. Vaccin. Immunother.
  contributor:
    fullname: Hung
– volume: 19
  start-page: 447
  year: 2011
  end-page: 459
  ident: bb0855
  article-title: The structural biology of Toll-like receptors
  publication-title: Structure (London, England: 1993)
  contributor:
    fullname: Davies
– volume: 8
  start-page: 479
  year: 2016
  end-page: 488
  ident: bb1900
  article-title: The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis
  publication-title: Immune-Therapy
  contributor:
    fullname: Aguiar
– volume: 371
  start-page: 2189
  year: 2014
  end-page: 2199
  ident: bb1700
  article-title: Genetic basis for clinical response to CTLA-4 blockade in melanoma
  publication-title: N. Engl. J. Med.
  contributor:
    fullname: Snyder
– volume: 13
  start-page: 721
  year: 2014
  end-page: 735
  ident: bb0565
  article-title: Various ways to improve whole cancer cell vaccines
  publication-title: Expert Rev. Vaccines
  contributor:
    fullname: Sanders
– volume: 27
  start-page: 16
  year: 2014
  end-page: 25
  ident: bb0075
  article-title: New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape
  publication-title: Curr. Opin. Immunol.
  contributor:
    fullname: Smyth
– volume: 26
  start-page: 175
  year: 2015
  end-page: 178
  ident: bb1405
  article-title: New perspectives on type I IFNs in cancer
  publication-title: Cytokine Growth Factor Rev.
  contributor:
    fullname: Corrales
– volume: 10
  year: 2015
  ident: bb1945
  article-title: C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review
  publication-title: PLoS One
  contributor:
    fullname: Lorton
– volume: 350
  start-page: h988
  year: 2015
  ident: bb0400
  article-title: Cancer vaccines
  publication-title: BMJ
  contributor:
    fullname: Butterfield
– volume: 21
  start-page: 3771
  year: 2015
  end-page: 3782
  ident: bb1320
  article-title: TLR9-targeted STAT-3 silencing abrogates immune-suppressive activity of myeloid-derived suppressor cells from prostate cancer patients
  publication-title: Clin. Cancer Res.
  contributor:
    fullname: Hossain
– volume: 6
  year: 2015
  ident: bb1140
  article-title: Inhibitory receptors beyond T Cell exhaustion
  publication-title: Front. Immunol.
  contributor:
    fullname: Speiser
– volume: 7
  start-page: 32318
  year: 2016
  end-page: 32328
  ident: bb1875
  article-title: Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants
  publication-title: Oncotarget
  contributor:
    fullname: Chowdhury
– volume: 65
  start-page: 3231
  year: 2008
  end-page: 3240
  ident: bb0825
  article-title: Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant
  publication-title: Cell. Mol. Life Sci.
  contributor:
    fullname: Mitchell
– volume: 31
  start-page: 813
  year: 2011
  end-page: 828
  ident: bb0625
  article-title: Cancer Immune-therapy: Sipuleucel-T and Beyond
  publication-title: Pharmacotherapy
  contributor:
    fullname: Sharma
– volume: 269
  start-page: 64
  year: 2011
  end-page: 73
  ident: bb0315
  article-title: Dendritic cells and immunity against cancer
  publication-title: J. Intern. Med.
  contributor:
    fullname: Banchereau
– volume: 272
  start-page: 97
  year: 2016
  end-page: 108
  ident: bb0680
  article-title: Dendritic cell maturation and cross-presentation: timing matters!
  publication-title: Immunol. Rev.
  contributor:
    fullname: Amigorena
– volume: 4
  year: 2015
  ident: bb1120
  article-title: Reprogramming the tumor microenvironment: tumor-induced immune-suppressive factors paralyze T cells
  publication-title: Oncoimmunology
  contributor:
    fullname: Zheng
– volume: 17
  start-page: 48
  year: 2018
  ident: bb0020
  article-title: Kinase-targeted cancer therapies: progress, challenges and future directions
  publication-title: Mol. Cancer
  contributor:
    fullname: Rupasinghe
– volume: 84
  start-page: 988
  year: 2008
  end-page: 993
  ident: bb0065
  article-title: Immune-mediated dormancy: an equilibrium with cancer
  publication-title: J. Leukoc. Biol.
  contributor:
    fullname: Smyth
– year: 2012
  ident: bb0255
  article-title: Janeway's Immunobiology. (Garland Science)
  contributor:
    fullname: Janeway
– volume: 78
  start-page: 179
  year: 2000
  end-page: 195
  ident: bb0260
  article-title: An overview of cancer Immune-therapy
  publication-title: Immunol. Cell Biol.
  contributor:
    fullname: Davis
– volume: 7
  year: 2016
  ident: bb1230
  article-title: Starved and asphyxiated: How Can CD8+ T Cells within a tumor microenvironment prevent tumor progression
  publication-title: Front. Immunol.
  contributor:
    fullname: Ertl
– volume: 1
  start-page: 908
  year: 2012
  end-page: 916
  ident: bb0115
  article-title: Targeting the MHC calls II antigen presentation pathway in cancer immunotherapy
  publication-title: Oncoimmunology
  contributor:
    fullname: Lapointe
– volume: 5
  year: 2013
  ident: bb1620
  article-title: Up-Regulation of PD-L1, IDO, and T
  publication-title: Sci. Transl. Med.
  contributor:
    fullname: Spranger
– volume: 351
  start-page: 1463
  year: 2016
  end-page: 1469
  ident: bb1690
  article-title: Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
  publication-title: Science (New York, N.Y.)
  contributor:
    fullname: McGranahan
– volume: 146
  start-page: 136
  year: 2017
  end-page: 145
  ident: bb0950
  article-title: DNA nanotechnology-based composite-type gold nanoparticle-immunostimulatory DNA hydrogel for tumor photothermal immunotherapy
  publication-title: Biomaterials
  contributor:
    fullname: Takakura
– volume: 363
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb0620
  article-title: Sipuleucel-T Immune-therapy for castration-resistant prostate cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1001294
  contributor:
    fullname: Kantoff
– volume: 8
  start-page: 1811
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb1225
  article-title: Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-017-01651-9
  contributor:
    fullname: Lu
– volume: 28
  start-page: 373
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1800
  article-title: Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients
  publication-title: Int. Immunol.
  doi: 10.1093/intimm/dxw021
  contributor:
    fullname: Kirilovsky
– volume: 9
  start-page: 2607
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0240
  article-title: The immune system likes nanotechnology
  publication-title: Nanomedicine
  doi: 10.2217/nnm.14.199
  contributor:
    fullname: Toth
– volume: 34
  start-page: 803
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1235
  article-title: Hypoxic tumor microenvironment: Opportunities to develop targeted therapies
  publication-title: Biotechnol. Adv.
  doi: 10.1016/j.biotechadv.2016.04.005
  contributor:
    fullname: Patel
– volume: 30
  start-page: 344
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb2100
  article-title: 1-MT enhances potency of tumor cell lysate-pulsed dendritic cells against pancreatic adenocarcinoma by downregulating the percentage of Tregs
  publication-title: J. Huazhong Univ. Sci. Technol.
  doi: 10.1007/s11596-010-0354-3
  contributor:
    fullname: Li
– volume: 132
  start-page: 2471
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb1085
  article-title: Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immune-therapy
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.27801
  contributor:
    fullname: Nars
– volume: 125
  start-page: 739
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1790
  article-title: Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI74894
  contributor:
    fullname: Reissfelder
– volume: 78
  start-page: 179
  year: 2000
  ident: 10.1016/j.jconrel.2018.09.009_bb0260
  article-title: An overview of cancer Immune-therapy
  publication-title: Immunol. Cell Biol.
  doi: 10.1046/j.1440-1711.2000.00906.x
  contributor:
    fullname: Davis
– volume: 21
  start-page: 482
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1535
  article-title: Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system
  publication-title: Trends Mol. Med.
  doi: 10.1016/j.molmed.2015.05.005
  contributor:
    fullname: Pico de Coana
– volume: 37
  start-page: 855
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0710
  article-title: Dendritic cells and cancer immunity
  publication-title: Trends Immunol.
  doi: 10.1016/j.it.2016.09.006
  contributor:
    fullname: Gardner
– volume: 4
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb1080
  article-title: Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation
  publication-title: Cell Death Dis.
  doi: 10.1038/cddis.2013.207
  contributor:
    fullname: Kono
– volume: 11
  start-page: 5417
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb1615
  article-title: Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth
  publication-title: ACS Nano
  doi: 10.1021/acsnano.6b08152
  contributor:
    fullname: Kosmides
– volume: 65
  start-page: 3231
  year: 2008
  ident: 10.1016/j.jconrel.2018.09.009_bb0825
  article-title: Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant
  publication-title: Cell. Mol. Life Sci.
  doi: 10.1007/s00018-008-8228-6
  contributor:
    fullname: Casella
– volume: 2
  start-page: 578
  year: 2018
  ident: 10.1016/j.jconrel.2018.09.009_bb1375
  article-title: TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy
  publication-title: Nat. Biomed. Eng.
  doi: 10.1038/s41551-018-0236-8
  contributor:
    fullname: Rodell
– volume: 8
  start-page: 2101
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb0230
  article-title: Nanomedicine(s) under the microscope
  publication-title: Mol. Pharm.
  doi: 10.1021/mp200394t
  contributor:
    fullname: Duncan
– volume: 67
  start-page: 731
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb0295
  article-title: Dendritic cells as pharmacological tools for cancer immune-therapy
  publication-title: Pharmacol. Rev.
  doi: 10.1124/pr.114.009456
  contributor:
    fullname: Anguille
– volume: 30
  start-page: 5
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb1730
  article-title: Tumor immunosurveillance in human cancers
  publication-title: Cancer Metastasis Rev.
  doi: 10.1007/s10555-011-9270-7
  contributor:
    fullname: Mlecnik
– volume: 467
  start-page: 127
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1735
  article-title: The immune response in cancer: from immunology to pathology to Immune-therapy
  publication-title: Virchows Arch.
  doi: 10.1007/s00428-015-1787-7
  contributor:
    fullname: Giraldo
– volume: 93
  start-page: 343
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb1365
  article-title: Tumor microenvironment converts plasmacytoid dendritic cells into immune-suppressive/tolerogenic cells: insight into the molecular mechanisms
  publication-title: J. Leukoc. Biol.
  doi: 10.1189/jlb.0812397
  contributor:
    fullname: Demoulin
– volume: 12
  start-page: 180
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb0220
  article-title: The role of interleukin-2 during homeostasis and activation of the immune system
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri3156
  contributor:
    fullname: Boyman
– volume: 13
  start-page: 595
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb1425
  article-title: Tumour-associated macrophages and cancer
  publication-title: Curr. Opin. Pharmacol.
  doi: 10.1016/j.coph.2013.05.017
  contributor:
    fullname: Cook
– volume: 108
  start-page: E989
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb0705
  article-title: Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination
  publication-title: Proc. Natl. Acad. Sci.
  doi: 10.1073/pnas.1104264108
  contributor:
    fullname: Nembri
– volume: 11
  start-page: 733
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb0820
  article-title: Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines
  publication-title: Expert Rev. Vaccines
  doi: 10.1586/erv.12.35
  contributor:
    fullname: Alving
– volume: 72
  start-page: 5435
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1195
  article-title: Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-12-0569
  contributor:
    fullname: Platten
– volume: 22
  start-page: 263
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb2015
  article-title: Update on castrate-resistant prostate cancer: 2010
  publication-title: Curr. Opin. Oncol.
  doi: 10.1097/CCO.0b013e3283380939
  contributor:
    fullname: Lassi
– volume: 105
  start-page: 63
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb1465
  article-title: OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology
  publication-title: Adv. Immunol.
  doi: 10.1016/S0065-2776(10)05003-0
  contributor:
    fullname: Ishii
– volume: 20
  start-page: 1085
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb1310
  article-title: Downregulation of STAT-3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy
  publication-title: Gene Ther.
  doi: 10.1038/gt.2013.35
  contributor:
    fullname: Emeagi
– volume: 71
  start-page: 1263
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb1805
  article-title: Clinical impact of different classes of infiltrating T cytotoxic and helper cells (TH1, TH2, treg, TH17) in patients with colorectal cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-10-2907
  contributor:
    fullname: Tosolini
– volume: 3
  start-page: 991
  year: 2002
  ident: 10.1016/j.jconrel.2018.09.009_bb0030
  article-title: Cancer immunoediting: from immunosurveillance to tumor-escape
  publication-title: Nat. Immunol.
  doi: 10.1038/ni1102-991
  contributor:
    fullname: Dunn
– volume: 2013
  start-page: 764706
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0810
  article-title: Virosome presents multimodel cancer therapy without viral replication
  publication-title: Biomed. Res. Int.
  doi: 10.1155/2013/764706
  contributor:
    fullname: Saga
– volume: 13
  start-page: 501
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb2075
  article-title: Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(12)70006-2
  contributor:
    fullname: Madan
– volume: 4
  start-page: 111
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1540
  article-title: CD28 co-stimulation in T-cell homeostasis: a recent perspective
  publication-title: Immunotargets and The.
  contributor:
    fullname: Beyersdorf
– volume: 55
  start-page: 2894
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0430
  article-title: A Synthetic glycopeptide vaccine for the induction of a monoclonal antibody that differentiates between normal and tumor mammary cells and enables the diagnosis of human pancreatic cancer
  publication-title: Angew. Chem. Int. Ed.
  doi: 10.1002/anie.201509935
  contributor:
    fullname: Palitzsch
– volume: 59
  start-page: 249
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb0280
  article-title: Cancer vaccines. Any future?
  publication-title: Arch. Immunol. Ther. Exp.
  doi: 10.1007/s00005-011-0129-y
  contributor:
    fullname: Myc
– volume: 6
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb0940
  article-title: Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2017.1386829
  contributor:
    fullname: Garg
– volume: 1
  start-page: 908
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb0115
  article-title: Targeting the MHC calls II antigen presentation pathway in cancer immunotherapy
  publication-title: Oncoimmunology
  doi: 10.4161/onci.21205
  contributor:
    fullname: Thibodeau
– volume: 56
  start-page: 227
  year: 2007
  ident: 10.1016/j.jconrel.2018.09.009_bb1040
  article-title: Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunology
  publication-title: Immune-Ther.
  doi: 10.1007/s00262-006-0183-1
  contributor:
    fullname: Chang
– volume: 20
  start-page: 241
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb2010
  article-title: Current status of immunological therapies for prostate cancer
  publication-title: Curr. Opin. Urol.
  doi: 10.1097/MOU.0b013e3283381793
  contributor:
    fullname: Antonarakis
– volume: 107
  start-page: 1563
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1865
  article-title: The up-regulation of PD-L1 promotes the resistant response in non-small cell lung cancer patients with neo-adjuvant chemotherapy
  publication-title: Cancer Sci.
  doi: 10.1111/cas.13072
  contributor:
    fullname: Zhang
– volume: 222
  start-page: 206
  year: 2008
  ident: 10.1016/j.jconrel.2018.09.009_bb1185
  article-title: Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune-escape
  publication-title: Immunol. Rev.
  doi: 10.1111/j.1600-065X.2008.00610.x
  contributor:
    fullname: Katz
– volume: 5
  start-page: 378
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1240
  article-title: HIF-1α pathway: role, regulation and intervention for cancer therapy
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2015.05.007
  contributor:
    fullname: Masoud
– volume: 20
  start-page: 286
  year: 2008
  ident: 10.1016/j.jconrel.2018.09.009_bb0365
  article-title: Antigens for cancer Immune-therapy
  publication-title: Semin. Immunol.
  doi: 10.1016/j.smim.2008.09.006
  contributor:
    fullname: Neller
– volume: 74
  start-page: 4042
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb2090
  article-title: Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-13-2685
  contributor:
    fullname: Fu
– volume: 2
  start-page: 940
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0760
  article-title: Targeting dendritic CELLS: The role of specific receptors in the internalization of polymer capsules
  publication-title: Adv. Healthcare Mater.
  doi: 10.1002/adhm.201200441
  contributor:
    fullname: Mintern
– volume: 547
  start-page: 217
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb0540
  article-title: An immunogenic personal neoantigen vaccine for patients with melanoma
  publication-title: Nature
  doi: 10.1038/nature22991
  contributor:
    fullname: Ott
– volume: 2015
  issue: 9
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb0455
  article-title: RNA-based vaccines in cancer immune-therapy
  publication-title: J Immunol Res
  contributor:
    fullname: McNamara
– volume: 39
  start-page: 7
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1750
  article-title: Cancer immune contexture and Immune-therapy
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2015.11.009
  contributor:
    fullname: Becht
– volume: 3
  start-page: 403
  year: 2004
  ident: 10.1016/j.jconrel.2018.09.009_bb0975
  article-title: Heat shock protein-based cancer vaccines
  publication-title: Expert Rev. Vaccines
  doi: 10.1586/14760584.3.4.403
  contributor:
    fullname: Oki
– volume: 3
  start-page: 49
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb1280
  article-title: Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2013.00049
  contributor:
    fullname: Najjar
– volume: 547
  start-page: 222
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb0525
  article-title: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
  publication-title: Nature
  doi: 10.1038/nature23003
  contributor:
    fullname: Sahin
– volume: 7
  start-page: 4269
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1350
  article-title: PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells
  publication-title: Int. J. Nanomedicine
  doi: 10.2147/IJN.S33666
  contributor:
    fullname: Su
– volume: 117
  start-page: 248
  year: 2005
  ident: 10.1016/j.jconrel.2018.09.009_bb1995
  article-title: Total loss of MHC class I is an independent indicator of good prognosis in breast cancer
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.21163
  contributor:
    fullname: Madjd
– volume: 3
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1515
  article-title: Novel immune checkpoint blocker approved for the treatment of advanced melanoma
  publication-title: Oncoimmunology
  doi: 10.4161/21624011.2014.967147
  contributor:
    fullname: Galluzzi
– volume: 8
  start-page: 84
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb2005
  article-title: Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402
  publication-title: J. Transl. Med.
  doi: 10.1186/1479-5876-8-84
  contributor:
    fullname: Baba
– volume: 21
  start-page: 4774
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1385
  article-title: Molecular pathways: Targeting the stimulator of interferon genes (STING) in the immune-therapy of cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-15-1362
  contributor:
    fullname: Corrales
– volume: 134
  start-page: 525
  year: 2008
  ident: 10.1016/j.jconrel.2018.09.009_bb2105
  article-title: Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT
  publication-title: J. Cancer Res. Clin. Oncol.
  doi: 10.1007/s00432-007-0315-9
  contributor:
    fullname: Ou
– volume: 59
  start-page: 926
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb1975
  article-title: Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer
  publication-title: Gut
  doi: 10.1136/gut.2009.194472
  contributor:
    fullname: Simpson
– volume: 180
  start-page: 7249
  year: 2008
  ident: 10.1016/j.jconrel.2018.09.009_bb1060
  article-title: Human tumor-derived exosomes down-modulate NKG2D expression
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.180.11.7249
  contributor:
    fullname: Clayton
– volume: 21
  start-page: 30
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1290
  article-title: Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-14-1716
  contributor:
    fullname: Califano
– volume: 4
  start-page: 1643
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb1355
  article-title: STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response
  publication-title: Mol. Pharm.
  doi: 10.1021/mp100067u
  contributor:
    fullname: Alshamsan
– volume: 125
  start-page: 2532
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1000
  article-title: Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI79915
  contributor:
    fullname: Hanson
– volume: 16
  start-page: 304
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb0545
  article-title: Cellular vaccine approaches
  publication-title: Cancer J.
  doi: 10.1097/PPO.0b013e3181eb33d7
  contributor:
    fullname: Le
– volume: 7
  start-page: 301
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb0580
  article-title: Significant overall survival advantage for RCC patients treated with autologous tumor lysate vaccine
  publication-title: Nat. Rev. Urol.
  doi: 10.1038/nrurol.2010.71
  contributor:
    fullname: Hutchinson
– volume: 16
  start-page: 900
  year: 2009
  ident: 10.1016/j.jconrel.2018.09.009_bb2040
  article-title: Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based Immune-therapy
  publication-title: Cancer Gene Ther.
  doi: 10.1038/cgt.2009.39
  contributor:
    fullname: Boczkowski
– volume: 129
  start-page: 474
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb1130
  article-title: T-cell exhaustion: characteristics, causes and conversion
  publication-title: Immunology
  doi: 10.1111/j.1365-2567.2010.03255.x
  contributor:
    fullname: Yi
– volume: 27
  start-page: 16
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0075
  article-title: New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2014.01.004
  contributor:
    fullname: Mittal
– volume: 62
  start-page: 909
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb2045
  article-title: Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-013-1396-8
  contributor:
    fullname: Iclozan
– volume: 34
  start-page: 4304
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0890
  article-title: Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2016.06.080
  contributor:
    fullname: Smith
– volume: 132
  start-page: 61
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb0215
  article-title: IL-2-deprivation and TGF-β are two non-redundant suppressor mechanisms of CD4+(+)CD25(+) regulatory T cell which jointly restrain CD4+(+)CD25(−) cell activation
  publication-title: Immunol. Lett.
  doi: 10.1016/j.imlet.2010.06.001
  contributor:
    fullname: Wang
– volume: 29
  start-page: 2394
  year: 2018
  ident: 10.1016/j.jconrel.2018.09.009_bb1370
  article-title: Targeting Protumoral Tumor-Associated Macrophages with Nanobody-Functionalized Nanogels through Strain Promoted Azide Alkyne Cycloaddition Ligation
  publication-title: Bioconjug. Chem.
  doi: 10.1021/acs.bioconjchem.8b00319
  contributor:
    fullname: Nuhn
– volume: 2
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0590
  article-title: Evaluation of RNA amplification methods to improve DC immunotherapy antigen presentation and immune response
  publication-title: Mol. Ther. Nucleic Acids
  contributor:
    fullname: Salgter-Jäger
– volume: 44
  start-page: 1582
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1050
  article-title: Effect of tumor cells and tumor microenvironment on NK cell function
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.201344272
  contributor:
    fullname: Vitale
– volume: 21
  start-page: 3771
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1320
  article-title: TLR9-targeted STAT-3 silencing abrogates immune-suppressive activity of myeloid-derived suppressor cells from prostate cancer patients
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-14-3145
  contributor:
    fullname: Hossain
– volume: 274
  start-page: 105
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb1965
  article-title: Tumour oxygenation: implications for breast cancer prognosis
  publication-title: J. Intern. Med.
  doi: 10.1111/joim.12091
  contributor:
    fullname: Rundqvist
– volume: 188
  start-page: 97
  year: 2002
  ident: 10.1016/j.jconrel.2018.09.009_bb1015
  article-title: Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction
  publication-title: Immunol. Rev.
  doi: 10.1034/j.1600-065X.2002.18809.x
  contributor:
    fullname: Rivoltini
– volume: 84
  start-page: 988
  year: 2008
  ident: 10.1016/j.jconrel.2018.09.009_bb0065
  article-title: Immune-mediated dormancy: an equilibrium with cancer
  publication-title: J. Leukoc. Biol.
  doi: 10.1189/jlb.1107774
  contributor:
    fullname: Teng
– volume: 7
  start-page: 790
  year: 2007
  ident: 10.1016/j.jconrel.2018.09.009_bb0655
  article-title: Dendritic-cell Immune-therapy: from ex vivo loading to in vivo targeting
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri2173
  contributor:
    fullname: Tacken
– volume: 34
  start-page: 181
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1795
  article-title: The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer
  publication-title: World J. Urol.
  doi: 10.1007/s00345-015-1615-3
  contributor:
    fullname: Horn
– volume: 30
  start-page: 345
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb0330
  article-title: Tumor antigen presentation by dendritic cells
  publication-title: Crit. Rev. Immunol.
  doi: 10.1615/CritRevImmunol.v30.i4.30
  contributor:
    fullname: Petersen
– volume: 31
  start-page: 439
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0515
  article-title: Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2012.47.7521
  contributor:
    fullname: van Rooij
– volume: 35
  start-page: 51
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1175
  article-title: Tolerance and exhaustion: defining mechanisms of T cell dysfunction
  publication-title: Trends Immunol.
  doi: 10.1016/j.it.2013.10.001
  contributor:
    fullname: Schietinger
– volume: 72
  start-page: 2162
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb0205
  article-title: T-regulatory cells: key players in tumor immune-escape and angiogenesis
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-11-3687
  contributor:
    fullname: Facciabene
– volume: 272
  start-page: 97
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0680
  article-title: Dendritic cell maturation and cross-presentation: timing matters!
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12432
  contributor:
    fullname: Alloatti
– volume: 5
  start-page: 360
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1030
  article-title: Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune-escape?
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2014.00360
  contributor:
    fullname: Bruttel
– volume: 113
  start-page: 8098
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0905
  article-title: pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune-activation
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1600816113
  contributor:
    fullname: Nuhn
– volume: 24
  start-page: 217
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1450
  article-title: Modulation of GITR for cancer Immune-therapy
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2011.12.011
  contributor:
    fullname: Schaer
– volume: 2
  start-page: 530
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1985
  article-title: Tumor MHC class I expression improves the prognostic value of T cell density in resected colorectal liver metastases
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-13-0180
  contributor:
    fullname: Turcotte
– volume: 2
  start-page: 36
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0140
  article-title: A bioinspired light induced avenue for the design of patterned functional interfaces
  publication-title: J. Mater. Chem. B
  doi: 10.1039/C3TB21317J
  contributor:
    fullname: Preuss
– volume: 1
  start-page: 138
  year: 2006
  ident: 10.1016/j.jconrel.2018.09.009_bb0250
  article-title: Cancer Immune-therapy
  publication-title: Biotechnol. J.
  doi: 10.1002/biot.200500044
  contributor:
    fullname: Schuster
– volume: 67
  start-page: 11438
  year: 2007
  ident: 10.1016/j.jconrel.2018.09.009_bb1300
  article-title: Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-07-1882
  contributor:
    fullname: Melani
– volume: 30
  start-page: 4341
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb0790
  article-title: The mechanism of action of MF59 - an innately attractive adjuvant formulation
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2011.09.061
  contributor:
    fullname: O'Hagan
– volume: 178
  start-page: 643
  year: 2018
  ident: 10.1016/j.jconrel.2018.09.009_bb0910
  article-title: Potent anti-viral vaccine adjuvant based on pH-degradable nanogels with covalently linked small molecule imidazoquinoline TLR7/8 agonist
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2018.03.026
  contributor:
    fullname: Nuhn
– volume: 24
  start-page: 7139
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0550
  article-title: Bio-hybrid tumor cell-templated capsules: a generic formulation strategy for tumor associated antigens in view of immune therapy
  publication-title: Adv. Funct. Mater.
  doi: 10.1002/adfm.201402303
  contributor:
    fullname: Lybaert
– volume: 4
  start-page: 28
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0025
  article-title: Mechanisms and insights into drug resistance in cancer
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2013.00028
  contributor:
    fullname: Zahreddine
– volume: 2016
  issue: 1459394
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0780
  article-title: Adjuvants: classification, modus operandi, and licensing
  publication-title: J Immunol Res
  contributor:
    fullname: de Souza Apostólico
– volume: 1950
  start-page: 2687
  issue: 188
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1665
  article-title: Targeting TNF-alpha to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of Immune-therapy
  publication-title: J. Immunol. (Baltimore Md.)
  contributor:
    fullname: Calcinotto
– volume: 7
  start-page: 32318
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1875
  article-title: Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.8698
  contributor:
    fullname: Chowdhury
– volume: 10
  start-page: eaan3682
  year: 2018
  ident: 10.1016/j.jconrel.2018.09.009_bb1605
  article-title: In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.aan3682
  contributor:
    fullname: Wang
– volume: 2
  start-page: 1700050
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb0555
  article-title: Polyelectrolyte-enrobed cancer cells in view of personalized immune-therapy
  publication-title: Adv. Sci.
  doi: 10.1002/advs.201700050
  contributor:
    fullname: Lybaert
– volume: 8
  start-page: 96
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1520
  article-title: Keytruda (pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma
  publication-title: American Health & Drug Benefits
  contributor:
    fullname: Raedler
– volume: 16
  start-page: 2334
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1600
  article-title: Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody
  publication-title: Nano Lett.
  doi: 10.1021/acs.nanolett.5b05030
  contributor:
    fullname: Wang
– volume: 33
  start-page: 364
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1165
  article-title: The three main stumbling blocks for anticancer T cells
  publication-title: Trends Immunol.
  doi: 10.1016/j.it.2012.02.006
  contributor:
    fullname: Baitsch
– volume: 11
  start-page: 885
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0470
  article-title: Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines
  publication-title: Expert Opin. Drug Deliv.
  doi: 10.1517/17425247.2014.901308
  contributor:
    fullname: Deering
– volume: 5
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1510
  contributor:
    fullname: Nivolumab approved for Lung Cancer
– volume: 22
  start-page: 132
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb0520
  article-title: Whole tumor antigen vaccines
  publication-title: Semin. Immunol.
  doi: 10.1016/j.smim.2010.02.004
  contributor:
    fullname: Chiang
– volume: 12
  start-page: 779
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0815
  article-title: Influenza virosomes as vaccine adjuvant and carrier system
  publication-title: Expert Rev. Vaccines
  doi: 10.1586/14760584.2013.811195
  contributor:
    fullname: Moser
– volume: 10
  start-page: 3261
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0985
  article-title: Tumor cell lysates as immunogenic sources for cancer vaccine design
  publication-title: Hum. Vaccin. Immunother.
  doi: 10.4161/21645515.2014.982996
  contributor:
    fullname: Gonzalez
– volume: 37
  start-page: 649
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1930
  article-title: Indoleamine-pyrrole 2,3-dioxygenase might be a prognostic biomarker for patients with renal cell carcinoma. Zhong nan da xue xue bao. Yi xue ban
  publication-title: J. Central South Univ. Med. Sci.
  contributor:
    fullname: Yuan
– volume: 60
  start-page: 1137
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb2070
  article-title: CTLA-4 blockade increases antigen-specific CD8+(+) T cells in prevaccinated patients with melanoma: three cases
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-011-1011-9
  contributor:
    fullname: Yuan
– volume: 72
  start-page: 2990
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1650
  article-title: Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-11-4062
  contributor:
    fullname: Ihara
– volume: 1950
  start-page: 137
  issue: 183
  year: 2009
  ident: 10.1016/j.jconrel.2018.09.009_bb2125
  article-title: Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism
  publication-title: J. Immunol. (Baltimore, Md.)
  contributor:
    fullname: Shurin
– volume: 11
  issue: 2679-2697
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0750
  article-title: Targeting cells of the immune system: mannosylated HPMA-LMA block-copolymer micelles for targeting of dendritic cells
  publication-title: Nanomedicine (London)
  contributor:
    fullname: Mohr
– volume: 108
  start-page: 1435
  year: 2006
  ident: 10.1016/j.jconrel.2018.09.009_bb0165
  article-title: Tolerogenic dendritic cells: cytokine modulation comes of age
  publication-title: Blood
  doi: 10.1182/blood-2006-03-006403
  contributor:
    fullname: Rutella
– volume: 3
  start-page: 344
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb0460
  article-title: Whole tumor antigen vaccines: Where are we?
  publication-title: Vaccine
  doi: 10.3390/vaccines3020344
  contributor:
    fullname: Chiang
– volume: 350
  start-page: h988
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb0400
  article-title: Cancer vaccines
  publication-title: BMJ
  doi: 10.1136/bmj.h988
  contributor:
    fullname: Butterfield
– volume: 58
  start-page: 489
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb1255
  article-title: Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy
  publication-title: Yonsei Med. J.
  doi: 10.3349/ymj.2017.58.3.489
  contributor:
    fullname: Yu
– volume: 7
  start-page: 283ra252
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb2065
  article-title: STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.aaa4306
  contributor:
    fullname: Fu
– volume: 4
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1120
  article-title: Reprogramming the tumor microenvironment: tumor-induced immune-suppressive factors paralyze T cells
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2015.1016700
  contributor:
    fullname: Wu
– volume: 11
  start-page: 2479
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0755
  article-title: pH-degradable mannosylated nanogels for dendritic cell targeting
  publication-title: Biomacromolecules
  doi: 10.1021/acs.biomac.6b00685
  contributor:
    fullname: De Coen
– volume: 9
  start-page: 2671
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0670
  article-title: The impact of size on particulate vaccine adjuvants
  publication-title: Nanomedicine (London, England)
  doi: 10.2217/nnm.14.193
  contributor:
    fullname: Shah
– volume: 232
  start-page: 199
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1755
  article-title: Towards the introduction of the 'Immunoscore' in the classification of malignant tumours
  publication-title: J. Pathol.
  doi: 10.1002/path.4287
  contributor:
    fullname: Galon
– volume: 39
  start-page: 98
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1585
  article-title: CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition
  publication-title: Am. J. Clin. Oncol.
  doi: 10.1097/COC.0000000000000239
  contributor:
    fullname: Buchbinder
– volume: 8
  start-page: 523
  year: 2008
  ident: 10.1016/j.jconrel.2018.09.009_bb0210
  article-title: How regulatory T cells work
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri2343
  contributor:
    fullname: Vignali
– volume: 137
  start-page: 1095
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1935
  article-title: Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.29481
  contributor:
    fullname: Jia
– volume: 227
  start-page: 234
  year: 2009
  ident: 10.1016/j.jconrel.2018.09.009_bb0720
  article-title: Inflammatory signals in dendritic cell activation and the induction of adaptive immunity
  publication-title: Immunol. Rev.
  doi: 10.1111/j.1600-065X.2008.00718.x
  contributor:
    fullname: Joffre
– volume: 57
  start-page: 1727
  year: 2008
  ident: 10.1016/j.jconrel.2018.09.009_bb1065
  article-title: Regressing and progressing metastatic lesions: resistance to Immune-therapy is predetermined by irreversible HLA class I antigen alterations
  publication-title: Cancer Immunol. Immune-Ther.
  doi: 10.1007/s00262-008-0532-3
  contributor:
    fullname: Aptsiauri
– volume: 14
  start-page: 1
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1715
  article-title: Cancer immune-therapy: the beginning of the end of cancer?
  publication-title: BMC Med.
  doi: 10.1186/s12916-016-0623-5
  contributor:
    fullname: Farkona
– volume: 28
  start-page: 1802540
  year: 2018
  ident: 10.1016/j.jconrel.2018.09.009_bb1595
  article-title: Toward biomaterials for enhancing immune checkpoint blockade therapy
  publication-title: Adv. Funct. Mater.
  doi: 10.1002/adfm.201802540
  contributor:
    fullname: Fan
– volume: 8
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb2120
  article-title: The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0067904
  contributor:
    fullname: Geary
– volume: 67
  start-page: 1
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1445
  article-title: Rationale for anti-GITR cancer Immune-therapy
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2016.06.028
  contributor:
    fullname: Knee
– volume: 22
  start-page: 329
  year: 2004
  ident: 10.1016/j.jconrel.2018.09.009_bb0040
  article-title: The three Es of cancer immunoediting
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev.immunol.22.012703.104803
  contributor:
    fullname: Dunn
– volume: 65
  start-page: 533
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb0805
  article-title: Safety review: squalene and thimerosal in vaccines
  publication-title: Therapie
  doi: 10.2515/therapie/2010069
  contributor:
    fullname: Montana
– volume: 11
  start-page: 2723
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0530
  article-title: Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma
  publication-title: Nanomedicine
  doi: 10.2217/nnm-2016-0275
  contributor:
    fullname: Grabbe
– volume: 41
  start-page: 98
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1695
  article-title: Neoantigens encoded in the cancer genome
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2016.07.005
  contributor:
    fullname: Schumacher
– volume: 103
  start-page: 1219
  year: 2018
  ident: 10.1016/j.jconrel.2018.09.009_bb1105
  article-title: INF-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression
  publication-title: J. Leukoc. Biol.
  doi: 10.1002/JLB.5MIR0917-351R
  contributor:
    fullname: Aqbi
– volume: 17
  start-page: 48
  year: 2018
  ident: 10.1016/j.jconrel.2018.09.009_bb0020
  article-title: Kinase-targeted cancer therapies: progress, challenges and future directions
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-018-0804-2
  contributor:
    fullname: Bhullar
– volume: 21
  start-page: 308
  year: 2009
  ident: 10.1016/j.jconrel.2018.09.009_bb0840
  article-title: Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2009.05.018
  contributor:
    fullname: Barrett
– volume: 68
  start-page: 768
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb1505
  article-title: Ipilimumab approved for metastatic melanoma
  publication-title: Am. J. Health-System Pharmacy
  contributor:
    fullname: Traynor
– volume: 28
  start-page: 22
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0320
  article-title: Cancer Immune-therapy targeting neoantigens
  publication-title: Semin. Immunol.
  doi: 10.1016/j.smim.2015.11.002
  contributor:
    fullname: Lu
– volume: 6
  start-page: 2136
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb0695
  article-title: Polymeric multilayer capsule-mediated vaccination induces protective immunity against cancer and viral infection
  publication-title: ACS Nano
  doi: 10.1021/nn205099c
  contributor:
    fullname: De Geest
– volume: 157
  start-page: 1073
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1705
  article-title: Deconstructing the peptide-MHC specificity of T cell recognition
  publication-title: Cell
  doi: 10.1016/j.cell.2014.03.047
  contributor:
    fullname: Birnbaum
– volume: 33
  start-page: 119
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb0190
  article-title: Differential macrophage programming in the tumor microenvironment
  publication-title: Trends Immunol.
  doi: 10.1016/j.it.2011.12.001
  contributor:
    fullname: Ruffell
– volume: 67
  start-page: 11021
  year: 2007
  ident: 10.1016/j.jconrel.2018.09.009_bb1330
  article-title: Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-07-2593
  contributor:
    fullname: Nefedova
– volume: 10
  start-page: 48
  year: 2004
  ident: 10.1016/j.jconrel.2018.09.009_bb1675
  article-title: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
  publication-title: Nat. Med.
  doi: 10.1038/nm976
  contributor:
    fullname: Wang
– volume: 33
  start-page: 435
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb1840
  article-title: Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoImmune-therapy
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0b013e3181d32f01
  contributor:
    fullname: Correale
– volume: 10
  start-page: 3153
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0450
  article-title: DNA vaccine for cancer immune-therapy
  publication-title: Hum. Vaccin. Immunother.
  doi: 10.4161/21645515.2014.980686
  contributor:
    fullname: Yang
– volume: 23
  start-page: 286
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb1645
  article-title: Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2010.11.013
  contributor:
    fullname: Gajewski
– volume: 7
  start-page: 55765
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1955
  article-title: Elevated serum C-reactive protein level predicts a poor prognosis for recurrent gastric cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.9910
  contributor:
    fullname: Kong
– volume: 41
  start-page: 2217
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb2130
  article-title: Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.201041235
  contributor:
    fullname: Sierro
– volume: 11
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1785
  article-title: The prognostic value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0152500
  contributor:
    fullname: Mao
– volume: 26
  start-page: 175
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1405
  article-title: New perspectives on type I IFNs in cancer
  publication-title: Cytokine Growth Factor Rev.
  doi: 10.1016/j.cytogfr.2015.01.001
  contributor:
    fullname: Gajewski
– volume: 48
  start-page: 7551
  year: 2009
  ident: 10.1016/j.jconrel.2018.09.009_bb0425
  article-title: A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response
  publication-title: Angew. Chem. Int. Ed.
  doi: 10.1002/anie.200902564
  contributor:
    fullname: Kaiser
– volume: 133
  start-page: 509
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb1820
  article-title: BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma
  publication-title: J. Investig. Dermatol.
  doi: 10.1038/jid.2012.283
  contributor:
    fullname: Mann
– volume: 16
  start-page: 5504
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0965
  article-title: Acid-activatable versatile micelleplexes for Pd-L1 blockade-enhanced cancer photodynamic immunotherapy
  publication-title: Nano Lett.
  doi: 10.1021/acs.nanolett.6b01994
  contributor:
    fullname: Wang
– volume: 118
  start-page: 6
  year: 2006
  ident: 10.1016/j.jconrel.2018.09.009_bb1990
  article-title: Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.21303
  contributor:
    fullname: Watson
– volume: 20
  start-page: 4232
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0440
  article-title: A fully synthetic glycopeptide antitumor vaccine based on multiple antigen presentation on a hyperbranched polymer
  publication-title: Chem. Eur. J.
  doi: 10.1002/chem.201400256
  contributor:
    fullname: Glaffig
– volume: 200
  start-page: 415
  year: 2018
  ident: 10.1016/j.jconrel.2018.09.009_bb1440
  article-title: Unlocking the complexities of tumor-associated regulatory T cells
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1701188
  contributor:
    fullname: Chao
– volume: 106
  start-page: 397
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb2025
  article-title: Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer
  publication-title: Cancer Sci.
  doi: 10.1111/cas.12621
  contributor:
    fullname: Mayanagi
– volume: 29
  start-page: 440
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0080
  article-title: Intratumoral heterogeneity of the epigenome
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.03.009
  contributor:
    fullname: Mazor
– volume: 28
  start-page: 383
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1115
  article-title: Mechanisms of tumor-escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment
  publication-title: Int. Immunol.
  doi: 10.1093/intimm/dxw014
  contributor:
    fullname: Spranger
– volume: 98
  start-page: 913
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1315
  article-title: Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immune-suppression in cancer
  publication-title: Arch. Pharm. Res.
  contributor:
    fullname: Ko
– volume: 71
  start-page: 2488
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb1410
  article-title: The efficacy of radiotherapy relies upon induction of type I interferon–dependent innate and adaptive immunity
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-10-2820
  contributor:
    fullname: Burnette
– volume: 2
  start-page: O15
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1630
  article-title: Melanoma-intrinsic β-catenin signaling prevents T cell infiltration and anti-tumor immunity
  publication-title: J. Immune-Therapy of Cancer
  doi: 10.1186/2051-1426-2-S3-O15
  contributor:
    fullname: Spranger
– volume: 17
  start-page: 275
  year: 2007
  ident: 10.1016/j.jconrel.2018.09.009_bb0105
  article-title: Tumor immunoediting and immunosculpting pathways to cancer progression
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2007.06.009
  contributor:
    fullname: Reiman
– volume: 28
  start-page: 7897
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb0700
  article-title: Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2010.09.077
  contributor:
    fullname: Hirosue
– volume: 115
  start-page: 3520
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb1210
  article-title: Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
  publication-title: Blood
  doi: 10.1182/blood-2009-09-246124
  contributor:
    fullname: Liu
– volume: 100
  start-page: 8372
  year: 2003
  ident: 10.1016/j.jconrel.2018.09.009_bb1550
  article-title: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1533209100
  contributor:
    fullname: Phan
– volume: 7
  start-page: 835
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1285
  article-title: Myeloid lineage-specific deletion of antioxidant system enhances tumor metastasis
  publication-title: Cancer Prev. Res. (Philadelphia, Pa.)
  doi: 10.1158/1940-6207.CAPR-14-0094
  contributor:
    fullname: Hiramoto
– volume: 10
  start-page: 3332
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0395
  article-title: Antigen-specific vaccines for cancer treatment
  publication-title: Hum. Vaccin. Immunother.
  doi: 10.4161/21645515.2014.973317
  contributor:
    fullname: Tagliamonte
– volume: 258
  start-page: 146
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb0490
  article-title: Combining reactive triblock copolymers with functional cross-linkers: A versatile pathway to disulfide stabilized-polyplex libraries and their application as pDNA vaccines
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2017.05.012
  contributor:
    fullname: Heller
– volume: 7
  start-page: 13720
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0745
  article-title: The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms13720
  contributor:
    fullname: Laoui
– volume: 4
  start-page: 522
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb0445
  article-title: CpG-loaded multifunctional cationic nanohydrogel particles as self-adjuvanting glycopeptide antitumor vaccines
  publication-title: Adv. Healthcare Mater.
  doi: 10.1002/adhm.201400460
  contributor:
    fullname: Hartmann
– year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb0255
  contributor:
    fullname: Murphy
– volume: 28
  start-page: 57
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb1460
  article-title: Control of immunity by the TNFR-related molecule OX40 (CD134)
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev-immunol-030409-101243
  contributor:
    fullname: Croft
– volume: 17
  start-page: 343
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb0375
  article-title: Present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?
  publication-title: Cancer J.
  doi: 10.1097/PPO.0b013e318233e5b2
  contributor:
    fullname: Slingluff
– volume: 23
  start-page: 399
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb0385
  article-title: Tumor vaccination using messenger RNA: prospects of a future therapy
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2011.03.007
  contributor:
    fullname: Kreiter
– volume: 9
  start-page: 398
  year: 2018
  ident: 10.1016/j.jconrel.2018.09.009_bb1345
  article-title: Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.00398
  contributor:
    fullname: Fleming
– volume: 1865
  start-page: 72
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0360
  article-title: Personalized approaches to active Immune-therapy in cancer
  publication-title: Biochim. Biophys. Acta
  contributor:
    fullname: Ophir
– volume: 134
  start-page: 1247
  year: 2008
  ident: 10.1016/j.jconrel.2018.09.009_bb1940
  article-title: Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma
  publication-title: J. Cancer Res. Clin. Oncol.
  doi: 10.1007/s00432-008-0395-1
  contributor:
    fullname: Pan
– volume: 8
  start-page: 10633
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1950
  article-title: Association between serum C-reactive protein value and prognosis of patients with non-small cell lung cancer: a meta-analysis
  publication-title: Int. J. Clin. Exp. Med.
  contributor:
    fullname: Jing
– volume: 6
  start-page: 1755
  year: 2000
  ident: 10.1016/j.jconrel.2018.09.009_bb0610
  article-title: Clinical significance of defective dendritic cell differentation in cancer
  publication-title: Clin. Cancer Res.
  contributor:
    fullname: Almand
– volume: 16
  start-page: 275
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1855
  article-title: Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2016.36
  contributor:
    fullname: Topalian
– volume: 1174
  start-page: 99
  year: 2009
  ident: 10.1016/j.jconrel.2018.09.009_bb1470
  article-title: Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells
  publication-title: Ann. N. Y. Acad. Sci.
  doi: 10.1111/j.1749-6632.2009.04939.x
  contributor:
    fullname: Rech
– volume: 44
  start-page: 973
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1530
  article-title: CD28 Costimulation: From Mechanism to Therapy
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.04.020
  contributor:
    fullname: Esensten
– volume: 28
  start-page: 319
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0345
  article-title: The present status and future prospects of peptide-based cancer vaccines
  publication-title: Int. Immunol.
  doi: 10.1093/intimm/dxw027
  contributor:
    fullname: Hirayama
– volume: 4
  start-page: 142
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0340
  article-title: Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2014.00142
  contributor:
    fullname: Renovanz
– volume: 72
  start-page: 3125
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb0200
  article-title: Cellular constituents of immune-escape within the tumor microenvironment
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-11-4094
  contributor:
    fullname: Kerkar
– volume: 3
  start-page: 410
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb0290
  article-title: Vaccine Prevention of Cancer: Can Endogenous Antigens be Targeted?
  publication-title: Cancer Prev. Res. (Philadelphia, Pa.)
  doi: 10.1158/1940-6207.CAPR-10-0040
  contributor:
    fullname: Weiner
– volume: 14
  start-page: 237
  year: 2018
  ident: 10.1016/j.jconrel.2018.09.009_bb1005
  article-title: Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy
  publication-title: Nanomedicine (NMB)
  doi: 10.1016/j.nano.2017.10.013
  contributor:
    fullname: Wilson
– volume: 66
  start-page: 9281
  year: 2006
  ident: 10.1016/j.jconrel.2018.09.009_bb1980
  article-title: HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-06-0488
  contributor:
    fullname: Ogino
– volume: 29
  start-page: 235
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb0050
  article-title: Natural innate and adaptive immunity to cancer
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev-immunol-031210-101324
  contributor:
    fullname: Vesely
– volume: 15
  start-page: 1920
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb2050
  article-title: Protection against HPV-16-associated tumors requires the activation of CD8+ effector memory T cells and the control of myeloid-derived suppressor cells
  publication-title: Mol. Cancer Therapeutics
  doi: 10.1158/1535-7163.MCT-15-0742
  contributor:
    fullname: Diniz
– volume: 39
  start-page: 276
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb0605
  article-title: Whole cell vaccines — past progress and future strategies
  publication-title: Semin. Oncol.
  doi: 10.1053/j.seminoncol.2012.02.007
  contributor:
    fullname: Keenan
– volume: 8
  start-page: 9209
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0410
  article-title: Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity
  publication-title: ACS Nano
  doi: 10.1021/nn502975r
  contributor:
    fullname: Muraoka
– volume: 515
  start-page: 563
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1895
  article-title: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
  publication-title: Nature
  doi: 10.1038/nature14011
  contributor:
    fullname: Herbst
– volume: 6
  start-page: 7556
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb0575
  article-title: Injectable cryogel-based whole-cell vaccines
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms8556
  contributor:
    fullname: Bencherif
– volume: 5
  start-page: 1075
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb1420
  article-title: Targeting tumor-infiltrating macrophages to combat cancer
  publication-title: Immunotherapy
  doi: 10.2217/imt.13.102
  contributor:
    fullname: Panni
– volume: 5
  start-page: 603
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0170
  article-title: TH1/TH2 paradigm extended: macrophage polarization as an unappreciated pathogen-driven escape mechanism?
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2014.00603
  contributor:
    fullname: Muraille
– volume: 131
  start-page: 871
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1810
  article-title: A signature of immune function genes associated with recurrence-free survival in breast cancer patients
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-011-1470-x
  contributor:
    fullname: Ascierto
– volume: 5
  start-page: 772
  year: 2005
  ident: 10.1016/j.jconrel.2018.09.009_bb0350
  article-title: Central tolerance: learning self-control in the thymus
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri1707
  contributor:
    fullname: Hogquist
– volume: 17
  start-page: 822
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0370
  article-title: Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(16)00099-1
  contributor:
    fullname: Vansteenkiste
– volume: 25
  start-page: 37
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1395
  article-title: Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2013.12.004
  contributor:
    fullname: Yang
– volume: 371
  start-page: 2189
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1700
  article-title: Genetic basis for clinical response to CTLA-4 blockade in melanoma
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1406498
  contributor:
    fullname: Snyder
– volume: 2011
  start-page: 430394
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb0160
  article-title: The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance
  publication-title: Clin. Dev. Immunol.
  doi: 10.1155/2011/430394
  contributor:
    fullname: Janikashvili
– volume: 28
  start-page: 239
  year: 2009
  ident: 10.1016/j.jconrel.2018.09.009_bb1095
  article-title: Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation
  publication-title: Int. Rev. Immunol.
  doi: 10.1080/08830180902978120
  contributor:
    fullname: Zhou
– volume: 6
  start-page: 836
  year: 2006
  ident: 10.1016/j.jconrel.2018.09.009_bb0110
  article-title: Interferons, immunity and cancer immunoediting
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri1961
  contributor:
    fullname: Dunn
– volume: 63
  start-page: 789
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1825
  article-title: Regulatory T cells are an important prognostic factor in breast cancer: a systematic review and meta-analysis
  publication-title: Neoplasma
  doi: 10.4149/neo_2016_517
  contributor:
    fullname: Wang
– volume: 35
  start-page: 1336
  year: 2005
  ident: 10.1016/j.jconrel.2018.09.009_bb0225
  article-title: Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL-)two to tango
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.200425887
  contributor:
    fullname: Scheffold
– volume: 6
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1045
  article-title: Critical role of tumor microenvironment in shaping NK cell functions: implication of hypoxic stress
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2015.00482
  contributor:
    fullname: Hasmim
– volume: 31
  start-page: 636
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1925
  article-title: Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B
  publication-title: J. Eur. Acad. Dermatol. Venereol.
  doi: 10.1111/jdv.13968
  contributor:
    fullname: de Lecea
– volume: 6
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0935
  article-title: Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2015.00663
  contributor:
    fullname: Vandenberk
– volume: 7
  start-page: 13193
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0960
  article-title: Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms13193
  contributor:
    fullname: Chen
– volume: 468
  start-page: 511
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1885
  article-title: Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
  publication-title: Virchows Arch.
  doi: 10.1007/s00428-016-1910-4
  contributor:
    fullname: Ilie
– volume: 151
  start-page: 458
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb0235
  article-title: Nanoparticles and the immune system
  publication-title: Endocrinology
  doi: 10.1210/en.2009-1082
  contributor:
    fullname: Zolnik
– volume: 94
  start-page: 935
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1135
  article-title: T cell exhaustion: Understanding the interface of chronic viral and autoinflammatory diseases
  publication-title: Immunol. Cell Biol.
  doi: 10.1038/icb.2016.81
  contributor:
    fullname: McKinney
– volume: 7
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1230
  article-title: Starved and asphyxiated: How Can CD8+ T Cells within a tumor microenvironment prevent tumor progression
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2016.00032
  contributor:
    fullname: Zhang
– volume: 234
  start-page: 124
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0635
  article-title: Orchestrating immune responses: How size, shape and rigidity affect the immunogenicity of particulate vaccines
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2016.05.033
  contributor:
    fullname: Benne
– volume: 24
  start-page: 3724
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb0715
  article-title: Engineering nano- and microparticles to tune immunity
  publication-title: Adv. Mater. (Deerfield Beach, Fla.)
  doi: 10.1002/adma.201200446
  contributor:
    fullname: Moon
– volume: 4
  start-page: 687
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb2095
  article-title: A transient increase and subsequent sharp decrease of chemo-refractory liver-metastasized uterine cervical small cell carcinoma to autologous formalin-fixed tumor vaccine plus anti-PD-1 antibody
  publication-title: Clin. Case Reports
  doi: 10.1002/ccr3.596
  contributor:
    fullname: Miyoshi
– volume: 24
  start-page: 3724
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb0245
  article-title: Engineering nano- and microparticles to tune immunity
  publication-title: Adv. Mater.
  doi: 10.1002/adma.201200446
  contributor:
    fullname: Moon
– volume: 4
  start-page: 305
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0380
  article-title: Production of recombinant immunotherapeutics for anticancer treatment
  publication-title: Bioengineered.
  doi: 10.4161/bioe.24666
  contributor:
    fullname: Pranchevicius
– volume: 124
  start-page: 160
  year: 2005
  ident: 10.1016/j.jconrel.2018.09.009_bb0500
  publication-title: Invest. Dermatol.
  doi: 10.1111/j.0022-202X.2004.23535.x
  contributor:
    fullname: Lisziewicz
– volume: 5
  start-page: 6923
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1100
  article-title: Epigenetic regulations in the IFNgamma signalling pathway: IFNgamma-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.2222
  contributor:
    fullname: Vlkova
– volume: 42
  start-page: 663
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1485
  article-title: The next hurdle in cancer immune-therapy: overcoming the non-T-cell-inflamed tumor microenvironment
  publication-title: Semin. Oncol.
  doi: 10.1053/j.seminoncol.2015.05.011
  contributor:
    fullname: Gajewski
– volume: 26
  start-page: 263
  year: 2005
  ident: 10.1016/j.jconrel.2018.09.009_bb0120
  article-title: Apoptosis in the development and treatment of cancer
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgh283
  contributor:
    fullname: Gerl
– volume: 25
  start-page: 189
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb1260
  article-title: Recent advances in targeting mTOR signaling pathway using small molecule inhibitors
  publication-title: J. Drug Target.
  doi: 10.1080/1061186X.2016.1236112
  contributor:
    fullname: Roohi
– volume: 11
  start-page: 2647
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0770
  article-title: Vaccination with trifunctional nanoparticles that address CD8+ dendritic cells inhibits growth of established melanoma
  publication-title: Nanomedicine (London)
  doi: 10.2217/nnm-2016-0174
  contributor:
    fullname: Shen
– volume: 14
  start-page: 561
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1490
  article-title: Combination cancer Immune-therapy and new immunomodulatory targets
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd4591
  contributor:
    fullname: Mahoney
– volume: 1950
  start-page: 216
  issue: 182
  year: 2009
  ident: 10.1016/j.jconrel.2018.09.009_bb2030
  article-title: Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition
  publication-title: J. Immunol. (Baltimore Md.)
  contributor:
    fullname: Mukherjee
– volume: 4
  start-page: 264
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1910
  article-title: DNA damage, tumor mutational load and their impact on immune responses against cancer
  publication-title: Ann. Transl. Med.
  doi: 10.21037/atm.2016.07.11
  contributor:
    fullname: Liontos
– volume: 203
  start-page: 16
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb0415
  article-title: Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2015.02.006
  contributor:
    fullname: Rahimian
– volume: 269
  start-page: 64
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb0315
  article-title: Dendritic cells and immunity against cancer
  publication-title: J. Intern. Med.
  doi: 10.1111/j.1365-2796.2010.02317.x
  contributor:
    fullname: Palucka
– volume: 8121985
  issue: 2016
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb2080
  article-title: Adjuvant autologous melanoma vaccine for macroscopic stage III disease: Survival, biomarkers, and improved response to CTLA-4 blockade
  publication-title: J Immunol Res
  contributor:
    fullname: Lotem
– volume: 4
  start-page: 379
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0990
  article-title: Endoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccines
  publication-title: Front. Oncol.
  contributor:
    fullname: Graner
– volume: 34
  start-page: 349
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1265
  article-title: Biomedical potential of mTOR modulation by nanoparticles
  publication-title: Trends Biotechnol.
  doi: 10.1016/j.tibtech.2016.01.005
  contributor:
    fullname: Hulea
– volume: 12
  start-page: 747
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0795
  article-title: An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants
  publication-title: Expert Rev. Vaccines
  doi: 10.1586/14760584.2013.811188
  contributor:
    fullname: Fox
– volume: 3
  start-page: 43
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1635
  article-title: A new paradigm for tumor immune-escape: β-catenin-driven immune exclusion
  publication-title: J. Immune-Therapy of Cancer
  doi: 10.1186/s40425-015-0089-6
  contributor:
    fullname: Spranger
– volume: 23
  start-page: 6165
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb2135
  article-title: Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-2677
  contributor:
    fullname: Mesenheimer
– volume: 49
  start-page: 591
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb1205
  article-title: The selenazal drug ebselen potently inhibits indoleamine 2,3-dioxygenase by targeting enzyme cysteine residues
  publication-title: Biochemistry
  doi: 10.1021/bi901546e
  contributor:
    fullname: Terentis
– volume: 351
  start-page: 1463
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1690
  article-title: Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
  publication-title: Science (New York, N.Y.)
  doi: 10.1126/science.aaf1490
  contributor:
    fullname: McGranahan
– volume: 27
  start-page: 15
  year: 2004
  ident: 10.1016/j.jconrel.2018.09.009_bb0085
  article-title: Biological and therapeutic impact of intratumor heterogeneity in cancer evolution
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2014.12.001
  contributor:
    fullname: McGranahan
– volume: 6
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1140
  article-title: Inhibitory receptors beyond T Cell exhaustion
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2015.00310
  contributor:
    fullname: Fuertes Marraco
– volume: 21
  start-page: 105
  year: 2009
  ident: 10.1016/j.jconrel.2018.09.009_bb0310
  article-title: Antigen presentation by dendritic cells in vivo
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2009.03.011
  contributor:
    fullname: Segura
– volume: 22
  start-page: 1875
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0405
  article-title: Making better chimeric antigen receptors for adoptive T-cell therapy
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-15-1433
  contributor:
    fullname: Maus
– volume: 534
  start-page: 396
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0535
  article-title: Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
  publication-title: Nature
  doi: 10.1038/nature18300
  contributor:
    fullname: Kranz
– volume: 167
  start-page: 4844
  year: 2001
  ident: 10.1016/j.jconrel.2018.09.009_bb0970
  article-title: Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells
  publication-title: J. Immunol. (Baltimore, Md.: 1950)
  doi: 10.4049/jimmunol.167.9.4844
  contributor:
    fullname: Somersan
– volume: 15
  start-page: 144
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1835
  article-title: CD8+3(+) dendritic cells and Foxp3(+) regulatory T cells in primary lesions and regional lymph nodes are inversely correlated with prognosis of gastric cancer
  publication-title: Gastric Cancer
  doi: 10.1007/s10120-011-0090-9
  contributor:
    fullname: Kashimura
– volume: 35
  start-page: S185
  issue: Supplement
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1020
  article-title: Immune evasion in cancer: Mechanistic basis and therapeutic strategies
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2015.03.004
  contributor:
    fullname: Vinay
– volume: 33
  start-page: 1201
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb0895
  article-title: In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.3371
  contributor:
    fullname: Lynn
– volume: 369
  start-page: 122
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb1905
  article-title: Nivolumab plus Ipilimumab in Advanced Melanoma
  publication-title: New England J. Med.
  doi: 10.1056/NEJMoa1302369
  contributor:
    fullname: Wolchok
– volume: 1
  start-page: 10
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb1335
  article-title: Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer
  publication-title: J. Immune-Ther. Cancer
  doi: 10.1186/2051-1426-1-10
  contributor:
    fullname: Wesolowski
– volume: 6
  start-page: 1670
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0180
  article-title: Tumor-associated macrophages as major players in the tumor microenvironment
  publication-title: Cancer
  doi: 10.3390/cancers6031670
  contributor:
    fullname: Chanmee
– volume: 17
  start-page: 97
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb0920
  article-title: Immunogenic cell death in cancer and infectious disease
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri.2016.107
  contributor:
    fullname: Galluzzi
– volume: 21
  start-page: 1516
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1970
  article-title: The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities
  publication-title: Antioxid. Redox Signal.
  doi: 10.1089/ars.2013.5378
  contributor:
    fullname: Walsh
– volume: 21
  start-page: 39
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1295
  article-title: Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-14-1711
  contributor:
    fullname: Weed
– volume: 44
  start-page: 955
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1525
  article-title: Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.05.002
  contributor:
    fullname: Schildberg
– volume: 515
  start-page: 558
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1890
  article-title: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
  publication-title: Nature
  doi: 10.1038/nature13904
  contributor:
    fullname: Powles
– volume: 121
  start-page: 1
  year: 2007
  ident: 10.1016/j.jconrel.2018.09.009_bb0055
  article-title: Cancer immunoediting from immune surveillance to immune escape
  publication-title: Immunology
  doi: 10.1111/j.1365-2567.2007.02587.x
  contributor:
    fullname: Kim
– volume: 5
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1640
  article-title: Tumor-intrinsic oncogene pathways mediating immune avoidance
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2015.1086862
  contributor:
    fullname: Spranger
– volume: 39
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0325
  article-title: Dendritic-cell-based therapeutic cancer vaccines
  publication-title: Immunity
  doi: 10.1016/j.immuni.2013.07.004
  contributor:
    fullname: Palucka
– volume: 7
  start-page: 3912
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0740
  article-title: pH-responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides
  publication-title: ACS Nano
  doi: 10.1021/nn305466z
  contributor:
    fullname: Wilson
– volume: 15
  start-page: 274
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0925
  article-title: Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2016.03.037
  contributor:
    fullname: Aaes
– volume: 106
  start-page: 8623
  year: 2009
  ident: 10.1016/j.jconrel.2018.09.009_bb1150
  article-title: High antigen levels are the cause of T cell exhaustion during chronic viral infection
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.0809818106
  contributor:
    fullname: Mueller
– volume: 1865
  start-page: 35
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1275
  article-title: MDSCs in cancer: Conceiving new prognostic and therapeutic targets
  publication-title: Biochim. Biophys. Acta
  contributor:
    fullname: De Sanctis
– volume: 7
  start-page: 8944
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1880
  article-title: Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.6884
  contributor:
    fullname: Zeng
– volume: 5
  start-page: 182
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0650
  article-title: Understanding MHC class I presentation of viral antigens by human dendritic cells as a basis for rational design of therapeutic vaccines
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2014.00182
  contributor:
    fullname: van Montfoort
– volume: 3
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb2115
  article-title: Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response
  publication-title: Oncoimmunology
  doi: 10.4161/21624011.2014.953407
  contributor:
    fullname: Weir
– volume: 52
  start-page: 50
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1455
  article-title: Rationale for anti-OX40 cancer Immune-therapy
  publication-title: Eur. J. Cancer (Oxford, England: 1990)
  doi: 10.1016/j.ejca.2015.08.021
  contributor:
    fullname: Aspeslagh
– volume: 3
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1215
  article-title: Trial watch: IDO inhibitors in cancer therapy
  publication-title: Oncoimmunology
  contributor:
    fullname: Vacchelli
– volume: 1
  start-page: 0011
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb1610
  article-title: In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
  publication-title: Nat. Biomed. Eng.
  doi: 10.1038/s41551-016-0011
  contributor:
    fullname: Wang
– volume: 28
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb1680
  article-title: Primary PFS and safety analysis of a randomized phase II study of carboplation + paclitaxel +/- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMPOWER150)
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdx760.002
  contributor:
    fullname: Reck
– volume: 109
  start-page: 14604
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb0495
  article-title: Self-amplifying RNA vaccines
  publication-title: Proc. Natl. Acad. Sci.
  doi: 10.1073/pnas.1209367109
  contributor:
    fullname: Geall
– volume: 352
  start-page: 658
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1740
  article-title: Cancer immunology.The “cancer immunogram”
  publication-title: Science
  doi: 10.1126/science.aaf2834
  contributor:
    fullname: Blank
– volume: 121
  start-page: 2836
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0730
  article-title: Targeting dendritic cells—why bother?
  publication-title: Blood
  doi: 10.1182/blood-2012-09-452078
  contributor:
    fullname: Kreutz
– volume: 12
  start-page: 125
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1390
  article-title: Immunomodulatory functions of type I interferons
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri3133
  contributor:
    fullname: González-Navajas
– volume: 51
  start-page: 3862
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb0690
  article-title: Surface-engineered polyelectrolyte multilayer capsules: synthetic vaccines mimicking microbial structure and function
  publication-title: Angew. Chem. Int. Ed.
  doi: 10.1002/anie.201200048
  contributor:
    fullname: De Geest
– volume: 9
  start-page: 1385
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb0800
  article-title: Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine
  publication-title: Expert Rev. Vaccines
  doi: 10.1586/erv.10.141
  contributor:
    fullname: Walker
– volume: 351
  start-page: 1463
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1920
  article-title: Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
  publication-title: Science
  doi: 10.1126/science.aaf1490
  contributor:
    fullname: McGranahan
– volume: 3
  start-page: 136
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb2055
  article-title: Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-14-0036
  contributor:
    fullname: Shen
– volume: 37
  start-page: 193
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1180
  article-title: IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
  publication-title: Trends Immunol.
  doi: 10.1016/j.it.2016.01.002
  contributor:
    fullname: Munn
– volume: 12
  start-page: 978
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0645
  article-title: Engineering synthetic vaccines using cues from natural immunity
  publication-title: Nat. Mater.
  doi: 10.1038/nmat3775
  contributor:
    fullname: Irvine
– volume: 16
  start-page: 354
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb1200
  article-title: Indoleamine 2,3-dioxygenase: is it an immune-suppressor?
  publication-title: Cancer J.
  doi: 10.1097/PPO.0b013e3181eb3343
  contributor:
    fullname: Soliman
– volume: 23
  start-page: 8968
  year: 2005
  ident: 10.1016/j.jconrel.2018.09.009_bb1555
  article-title: Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2005.01.109
  contributor:
    fullname: Ribas
– volume: 3
  start-page: 662
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb0640
  article-title: Nanoparticle drug delivery systems designed to improve cancer vaccines and immune-therapy
  publication-title: Vaccines (Basel)
  doi: 10.3390/vaccines3030662
  contributor:
    fullname: Fan
– volume: 19
  start-page: 447
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb0855
  article-title: The structural biology of Toll-like receptors
  publication-title: Structure (London, England: 1993)
  doi: 10.1016/j.str.2011.02.004
  contributor:
    fullname: Botos
– volume: 12
  start-page: 1351
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0830
  article-title: Safety profile of the yellow fever vaccine Stamaril(R): a 17-year review
  publication-title: Expert Rev. Vaccines
  doi: 10.1586/14760584.2013.836320
  contributor:
    fullname: Cottin
– volume: 22
  start-page: 679
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1845
  article-title: Two FOXP3(+)CD4+(+) T cell subpopulations distinctly control the prognosis of colorectal cancers
  publication-title: Nat. Med.
  doi: 10.1038/nm.4086
  contributor:
    fullname: Saito
– volume: 41
  start-page: 843
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1415
  article-title: STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors
  publication-title: Immunity
  doi: 10.1016/j.immuni.2014.10.019
  contributor:
    fullname: Deng
– volume: 206
  start-page: 220
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb0485
  article-title: Feasibility of a subcutaneously administered block/homo-mixed polyplex micelle as a carrier for DNA vaccination in a mouse tumor model
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2015.03.029
  contributor:
    fullname: Cui
– volume: 63
  start-page: 4441
  year: 2003
  ident: 10.1016/j.jconrel.2018.09.009_bb2060
  article-title: All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination
  publication-title: Cancer Res.
  contributor:
    fullname: Kusmartsev
– year: 2018
  ident: 10.1016/j.jconrel.2018.09.009_bb0915
  article-title: Nanoparticle-conjugate TLR7/8 agonist localized immunotherapy provokes safe antitumoral responses
  publication-title: Adv. Mater.
  doi: 10.1002/adma.201803397
  contributor:
    fullname: Nuhn
– volume: 41
  start-page: S3
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0265
  article-title: Mechanism of action of immunotherapy
  publication-title: Semin. Oncol.
  doi: 10.1053/j.seminoncol.2014.09.004
  contributor:
    fullname: Disis
– volume: 8
  start-page: 49
  year: 2018
  ident: 10.1016/j.jconrel.2018.09.009_bb1430
  article-title: Targeting macrophages in cancer: from bench to deside
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2018.00049
  contributor:
    fullname: Poh
– volume: 211
  start-page: 214
  year: 2006
  ident: 10.1016/j.jconrel.2018.09.009_bb0275
  article-title: CD8+ T-cell memory in tumor immunology and immunotherapy
  publication-title: Immunol. Rev.
  doi: 10.1111/j.0105-2896.2006.00391.x
  contributor:
    fullname: Klebanoff
– volume: 12
  start-page: 612
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0725
  article-title: Dendritic cell targeted vaccines: recent progresses and challenges
  publication-title: Hum. Vaccin. Immunother.
  doi: 10.1080/21645515.2015.1105415
  contributor:
    fullname: Chen
– volume: 2
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb2110
  article-title: Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas
  publication-title: Oncoimmunology
  doi: 10.4161/onci.27058
  contributor:
    fullname: Sheng Sow
– volume: 6
  start-page: 925
  year: 2007
  ident: 10.1016/j.jconrel.2018.09.009_bb0570
  article-title: Tissue vaccines for cancer
  publication-title: Expert Rev. Vaccines
  doi: 10.1586/14760584.6.6.925
  contributor:
    fullname: Suckow
– volume: 34
  start-page: 206
  year: 2005
  ident: 10.1016/j.jconrel.2018.09.009_bb1055
  article-title: Exosomes and MICA-NKG2D system in cancer
  publication-title: Blood Cells Mod. Dis.
  doi: 10.1016/j.bcmd.2005.03.003
  contributor:
    fullname: Clayton
– volume: 52
  start-page: 10652
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0435
  article-title: Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines
  publication-title: Angew. Chem. Int. Ed.
  doi: 10.1002/anie.201304212
  contributor:
    fullname: Nuhn
– volume: 8
  start-page: 108
  year: 2008
  ident: 10.1016/j.jconrel.2018.09.009_bb0465
  article-title: DNA vaccines: precision tools for activating effective immunity against cancer
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc2326
  contributor:
    fullname: Rice
– volume: 772
  start-page: 189
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1960
  article-title: Intratumoral hypoxia as the genesis of genetic instability and clinical prognosis in prostate cancer
  publication-title: Adv. Exp. Med. Biol.
  doi: 10.1007/978-1-4614-5915-6_9
  contributor:
    fullname: Taiakina
– volume: 13
  start-page: 721
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0565
  article-title: Various ways to improve whole cancer cell vaccines
  publication-title: Expert Rev. Vaccines
  doi: 10.1586/14760584.2014.911093
  contributor:
    fullname: Cicchelero
– volume: 63
  start-page: 721
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1190
  article-title: Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune-escape in cancer
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-014-1549-4
  contributor:
    fullname: Prendergast
– volume: 15
  start-page: 405
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1400
  article-title: Type I interferons in anticancer immunity
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri3845
  contributor:
    fullname: Zitvogel
– volume: 28
  start-page: 35
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1145
  article-title: Reprogramming away from the exhausted T cell state
  publication-title: Semin. Immunol.
  doi: 10.1016/j.smim.2015.10.007
  contributor:
    fullname: Karagiannis
– volume: 19
  start-page: 39
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1010
  article-title: Major histocompatibility complex class I and tumour immuno-evasion: how to fool T cells and natural killer cells at one time
  publication-title: Curr. Oncol.
  doi: 10.3747/co.19.945
  contributor:
    fullname: Fruci
– volume: 5
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0735
  article-title: Toll-like receptors: the swiss army knife of immunity and vaccine development
  publication-title: Clin. Transl. Immunol.
  doi: 10.1038/cti.2016.22
  contributor:
    fullname: Dowling
– volume: 103
  start-page: 685
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb1815
  article-title: Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer
  publication-title: British J. Cancer
  doi: 10.1038/sj.bjc.6605820
  contributor:
    fullname: Leffers
– volume: 94
  start-page: 509
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0150
  article-title: Immune-suppressive cells in tumor immune-escape and metastasis
  publication-title: J. Mol. Med. (Berlin, Germany)
  doi: 10.1007/s00109-015-1376-x
  contributor:
    fullname: Liu
– volume: 348
  start-page: 74
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1660
  article-title: T cell exclusion, immune privilege, and the tumor microenvironment
  publication-title: Science
  doi: 10.1126/science.aaa6204
  contributor:
    fullname: Joyce
– volume: 12
  start-page: 252
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1495
  article-title: The blockade of immune checkpoints in cancer Immune-therapy
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3239
  contributor:
    fullname: Pardoll
– volume: 9
  start-page: 119
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1725
  article-title: Has the new TNM classification for colorectal cancer improved care?
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/nrclinonc.2011.157
  contributor:
    fullname: Nagtegaal
– volume: 33
  start-page: 3193
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1565
  article-title: Immune-related adverse events, need for systemic immune-suppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2015.60.8448
  contributor:
    fullname: Horvat
– volume: 6
  start-page: 1543
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0980
  article-title: Tumor Immune-therapy based on tumor-derived heat shock proteins (Review)
  publication-title: Oncol. Lett.
  doi: 10.3892/ol.2013.1616
  contributor:
    fullname: Zhang
– volume: 21
  start-page: 847
  year: 2009
  ident: 10.1016/j.jconrel.2018.09.009_bb0475
  article-title: Polymeric materials for gene delivery and dna vaccination
  publication-title: Adv. Mater.
  doi: 10.1002/adma.200801478
  contributor:
    fullname: Nguyen
– volume: 206
  start-page: 18
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb0100
  article-title: Cancer immunoediting and “spontaneous” tumor regression
  publication-title: Pathol. Res. Pract.
  doi: 10.1016/j.prp.2009.10.001
  contributor:
    fullname: Sengupta
– volume: 146
  start-page: 136
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb0950
  article-title: DNA nanotechnology-based composite-type gold nanoparticle-immunostimulatory DNA hydrogel for tumor photothermal immunotherapy
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2017.09.014
  contributor:
    fullname: Yata
– volume: 253
  start-page: 402
  year: 2003
  ident: 10.1016/j.jconrel.2018.09.009_bb0390
  article-title: DNA vaccines: a review
  publication-title: J. Intern. Med.
  doi: 10.1046/j.1365-2796.2003.01140.x
  contributor:
    fullname: Liu
– volume: 12
  start-page: 298
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1745
  article-title: The immune contexture in human tumours: impact on clinical outcome
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3245
  contributor:
    fullname: Fridman
– volume: 25
  start-page: 267
  year: 2007
  ident: 10.1016/j.jconrel.2018.09.009_bb0095
  article-title: Immune-suppressive strategies that are mediated by tumor cells
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev.immunol.25.022106.141609
  contributor:
    fullname: Rabinovich
– volume: 6
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1125
  article-title: T-cell exhaustion in the tumor microenvironment
  publication-title: Cell Death Dis.
  doi: 10.1038/cddis.2015.162
  contributor:
    fullname: Jiang
– volume: 98
  start-page: 69
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1870
  article-title: Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)
  publication-title: Lung Cancer (Amsterdam, Netherlands)
  doi: 10.1016/j.lungcan.2016.04.021
  contributor:
    fullname: Shimoji
– volume: 27
  start-page: 2007
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0880
  article-title: Covalent Conjugation of Small-Molecule Adjuvants to Nanoparticles Induces Robust Cytotoxic T Cell Responses via DC Activation
  publication-title: Bioconjug. Chem.
  doi: 10.1021/acs.bioconjchem.6b00277
  contributor:
    fullname: Kim
– volume: 127
  start-page: 249
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb1075
  article-title: "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for Immune-therapy
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.25270
  contributor:
    fullname: Garrido
– volume: 116
  start-page: 685
  year: 2008
  ident: 10.1016/j.jconrel.2018.09.009_bb0070
  article-title: Tumor dormancy and immunoescape
  publication-title: APMIS
  doi: 10.1111/j.1600-0463.2008.01163.x
  contributor:
    fullname: Quesnel
– volume: 21
  start-page: 137
  year: 2004
  ident: 10.1016/j.jconrel.2018.09.009_bb0045
  article-title: The immunobiology of cancer immunosurveillance and immunoediting
  publication-title: Immunity
  doi: 10.1016/j.immuni.2004.07.017
  contributor:
    fullname: Dunn
– volume: 39
  start-page: 44
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1035
  article-title: The urgent need to recover MHC class I in cancers for effective Immune-therapy
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2015.12.007
  contributor:
    fullname: Garrido
– volume: 57
  start-page: 1569
  year: 2008
  ident: 10.1016/j.jconrel.2018.09.009_bb0600
  article-title: Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines
  publication-title: Cancer Immunol. Immune-Ther.
  doi: 10.1007/s00262-008-0536-z
  contributor:
    fullname: de Gruijl
– volume: 22
  start-page: 1885
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0505
  article-title: Targeting the heterogeneity of cancer with individualized neoepitope vaccines
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-15-1509
  contributor:
    fullname: Tureci
– volume: 112
  start-page: 610
  year: 2008
  ident: 10.1016/j.jconrel.2018.09.009_bb2020
  article-title: Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines
  publication-title: Blood
  doi: 10.1182/blood-2008-01-135319
  contributor:
    fullname: Morse
– volume: 109
  start-page: 7841
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1670
  article-title: Tumor-targeted TNFalpha stabilizes tumor vessels and enhances active Immune-therapy
  contributor:
    fullname: Johansson
– volume: 9
  start-page: 287
  year: 2009
  ident: 10.1016/j.jconrel.2018.09.009_bb0785
  article-title: Towards an understanding of the adjuvant action of aluminium
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri2510
  contributor:
    fullname: Marrack
– volume: 6
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0870
  article-title: Rational design of small molecules as vaccine adjuvants
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.3009980
  contributor:
    fullname: Wu
– volume: 22
  start-page: 132
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb0355
  article-title: Whole tumor antigen vaccines
  publication-title: Semin. Immunol.
  doi: 10.1016/j.smim.2010.02.004
  contributor:
    fullname: Chiang
– volume: 14
  start-page: 1411
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1480
  article-title: Induced regulatory T cells in inhibitory microenvironments created by cancer
  publication-title: Expert. Opin. Biol. Ther.
  doi: 10.1517/14712598.2014.927432
  contributor:
    fullname: Whiteside
– volume: 60
  start-page: 909
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb1850
  article-title: Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-011-1046-y
  contributor:
    fullname: Ladoire
– volume: 100
  start-page: 927
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0860
  article-title: Molecular mechanisms of regulation of Toll-like receptor signaling
  publication-title: J. Leukoc. Biol.
  doi: 10.1189/jlb.2MR0316-117RR
  contributor:
    fullname: Leifer
– volume: 4
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1340
  article-title: Myeloid derived suppressor cells—An overview of combat strategies to increase Immune-therapy efficacy
  publication-title: Oncoimmunology
  doi: 10.4161/21624011.2014.954829
  contributor:
    fullname: Draghiciu
– volume: 36
  start-page: 197
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb0630
  article-title: Sipuleucel-T (provenge) injection: the first immune-therapy agent (vaccine) for hormone-refractory prostate cancer
  publication-title: Pharmacy Therapeutics
  contributor:
    fullname: Anassi
– volume: 8
  start-page: 274
  year: 2002
  ident: 10.1016/j.jconrel.2018.09.009_bb0130
  article-title: Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax
  publication-title: Nat. Med.
  doi: 10.1038/nm0302-274
  contributor:
    fullname: LeBlanc
– volume: 20
  start-page: 12405
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0765
  article-title: Selective uptake of cylindrical Poly(2-Oxazoline) brush-AntiDEC205 antibody-OVA antigen conjugates into DEC-positive dendritic cells and subsequent T-Cell activation
  publication-title: Chem. Eur. J.
  doi: 10.1002/chem.201403942
  contributor:
    fullname: Bühler
– volume: 8
  start-page: 479
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1900
  article-title: The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis
  publication-title: Immune-Therapy
  doi: 10.2217/imt-2015-0002
  contributor:
    fullname: Aguiar
– volume: 2
  start-page: 277
  year: 2002
  ident: 10.1016/j.jconrel.2018.09.009_bb0125
  article-title: Death and anti-death: tumour resistance to apoptosis
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc776
  contributor:
    fullname: Igney
– volume: 40
  start-page: 320
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb0685
  article-title: Designing polymeric particles for antigen delivery
  publication-title: Chem. Soc. Rev.
  doi: 10.1039/B914943K
  contributor:
    fullname: De Koker
– volume: 348
  start-page: 69
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb0510
  article-title: Neoantigens in cancer immune-therapy
  publication-title: Science
  doi: 10.1126/science.aaa4971
  contributor:
    fullname: Schumacher
– volume: 5
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0615
  article-title: Targeting dendritic cells: a promising strategy to improve vaccine effectiveness
  publication-title: Clin. Trans. Immunol.
  doi: 10.1038/cti.2016.6
  contributor:
    fullname: Macri
– volume: 122
  start-page: 899
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1655
  article-title: Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI45817
  contributor:
    fullname: Salmon
– volume: 61
  start-page: 1373
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1305
  article-title: Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-011-1178-0
  contributor:
    fullname: Porembka
– volume: 6
  start-page: 703
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1590
  article-title: Personalized oncology meets immunology: The path toward precision immune-therapy
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-16-0146
  contributor:
    fullname: Mandal
– volume: 5
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb1620
  article-title: Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.3006504
  contributor:
    fullname: Spranger
– volume: 10
  start-page: 205
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1720
  article-title: Cancer classification using the Immunoscore: a worldwide task force
  publication-title: J. Transl. Med.
  doi: 10.1186/1479-5876-10-205
  contributor:
    fullname: Galon
– volume: 10
  start-page: 9216
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1475
  article-title: Interleukin-2 Functionalized Nanocapsules for T Cell-Based Immunotherapy
  publication-title: ACS Nano
  doi: 10.1021/acsnano.5b07973
  contributor:
    fullname: Frick
– volume: 33
  start-page: 1146
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb0900
  article-title: Big thinking for adjuvants
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.3398
  contributor:
    fullname: Dane
– volume: 125
  start-page: 3356
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1270
  article-title: Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI80005
  contributor:
    fullname: Marvel
– volume: 21
  start-page: 4421
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0420
  article-title: The development of synthetic antitumour vaccines from mucin glycopeptide antigens
  publication-title: Chem. Soc. Rev.
  doi: 10.1039/c3cs35470a
  contributor:
    fullname: Gaidzik
– volume: 14
  start-page: 486
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1830
  article-title: Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-14-486
  contributor:
    fullname: Reimers
– volume: 5
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0585
  article-title: Immune reponse and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2016.1232237
  contributor:
    fullname: Kyte
– volume: 22
  start-page: 1856
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1155
  article-title: Reversing T-cell dysfunction and exhaustion in cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-15-1849
  contributor:
    fullname: Zarour
– volume: 27
  start-page: 462
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb0195
  article-title: Macrophages and therapeutic resistance in cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2015.02.015
  contributor:
    fullname: Ruffell
– volume: 25
  start-page: 1159
  year: 2007
  ident: 10.1016/j.jconrel.2018.09.009_bb0665
  article-title: Exploiting lymphatic transport and complement activation in nanoparticle vaccines
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt1332
  contributor:
    fullname: Reddy
– volume: 515
  start-page: 568
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1625
  article-title: PD-1 blockade induces responses by inhibiting adaptive immune resistance
  publication-title: Nature
  doi: 10.1038/nature13954
  contributor:
    fullname: Tumeh
– volume: 479–480
  start-page: 180
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1160
  article-title: T cell exhaustion during persistent viral infections
  publication-title: Virology
  doi: 10.1016/j.virol.2014.12.033
  contributor:
    fullname: Kahan
– volume: 7
  start-page: 651
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb0145
  article-title: Dual roles of immune cells and their factors in cancer development and progression
  publication-title: Int. J. Biol. Sci.
  doi: 10.7150/ijbs.7.651
  contributor:
    fullname: Zamarron
– volume: 6
  start-page: 449
  year: 2006
  ident: 10.1016/j.jconrel.2018.09.009_bb0270
  article-title: Metastasis: a question of life or death
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc1886
  contributor:
    fullname: Mehlen
– volume: 22
  start-page: 105
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb1025
  article-title: Tumor immunogenicity and responsiveness to cancer vaccine therapy the state of the art
  publication-title: Semin. Immunol.
  doi: 10.1016/j.smim.2010.02.001
  contributor:
    fullname: Schreiber
– volume: 24
  start-page: 743
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1915
  article-title: Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
  publication-title: Genome Res.
  doi: 10.1101/gr.165985.113
  contributor:
    fullname: Brown
– volume: 9
  start-page: 798
  year: 2009
  ident: 10.1016/j.jconrel.2018.09.009_bb0135
  article-title: STATs in cancer inflammation and immunity: a leading role for STAT-3
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc2734
  contributor:
    fullname: Yu
– volume: 12
  start-page: 265
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb0775
  article-title: Cancer Immune-therapy via dendritic cells
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3258
  contributor:
    fullname: Palucka
– volume: 112
  start-page: 26
  year: 2006
  ident: 10.1016/j.jconrel.2018.09.009_bb0660
  article-title: In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2006.01.006
  contributor:
    fullname: Reddy
– volume: 208
  start-page: 2347
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb0845
  article-title: Learning vaccinology from viral infections
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20112321
  contributor:
    fullname: Ahmed
– volume: 61
  start-page: 1359
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1070
  article-title: Implication of the beta2 microglobulin gene in the generation of tumor-escape phenotypes
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-012-1321-6
  contributor:
    fullname: Bernal
– volume: 29
  start-page: 1949
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb1780
  article-title: Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2010.30.5037
  contributor:
    fullname: Mahmoud
– volume: 8
  start-page: 14595
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1860
  article-title: Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis
  publication-title: Int. J. Clin. Exp. Med.
  contributor:
    fullname: Xu
– volume: 35
  start-page: 585
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0175
  article-title: Tumor-associated macrophages: functional diversity, clinical significance, and open questions
  publication-title: Semin. Immunopathol.
  doi: 10.1007/s00281-013-0367-7
  contributor:
    fullname: Biswas
– volume: 2016
  start-page: 11
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0185
  article-title: Tumor-associated macrophages and neutrophils in tumor microenvironment
  publication-title: Mediat. Inflamm.
  doi: 10.1155/2016/6058147
  contributor:
    fullname: Kim
– volume: 27
  start-page: 1
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1435
  article-title: Regulatory T cells in cancer immune-therapy
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2013.12.005
  contributor:
    fullname: Nishikawa
– volume: 21
  start-page: 712
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb2085
  article-title: Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-14-2468
  contributor:
    fullname: Gibney
– volume: 44
  start-page: 343
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1090
  article-title: Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy
  publication-title: Immunity
  doi: 10.1016/j.immuni.2015.11.024
  contributor:
    fullname: Pfirschke
– volume: 89
  start-page: 1736
  year: 2003
  ident: 10.1016/j.jconrel.2018.09.009_bb1775
  article-title: Clinical significance of immune cell infiltration within gallbladder cancer
  publication-title: Br. J. Cancer
  doi: 10.1038/sj.bjc.6601331
  contributor:
    fullname: Nakakubo
– volume: 45
  start-page: 510
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb1500
  article-title: Ipilimumab: a novel treatment for metastatic melanoma
  publication-title: Ann. Pharmacother.
  doi: 10.1345/aph.1P651
  contributor:
    fullname: Culver
– volume: 31
  start-page: 813
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb0625
  article-title: Cancer Immune-therapy: Sipuleucel-T and Beyond
  publication-title: Pharmacotherapy
  doi: 10.1592/phco.31.8.813
  contributor:
    fullname: Hammerstrom
– volume: 40
  start-page: 1
  year: 2006
  ident: 10.1016/j.jconrel.2018.09.009_bb0675
  article-title: Pathogen recognition and development of particulate vaccines: does size matter?
  publication-title: Methods (San Diego, Calif.)
  doi: 10.1016/j.ymeth.2006.05.016
  contributor:
    fullname: Xiang
– volume: 8
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0480
  article-title: Alginic acid-coated chitosan nanoparticles loaded with legumain dna vaccine: effect against breast cancer in mice
  publication-title: PLoS One
  contributor:
    fullname: Liu
– volume: 9
  start-page: 1075
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0850
  article-title: Directing the immune system with chemical compounds
  publication-title: ACS Chem. Biol.
  doi: 10.1021/cb500079s
  contributor:
    fullname: Mancini
– volume: 12
  start-page: 471
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb1250
  article-title: Advances in the understanding of mechanisms and therapeutic use of bortezomib
  publication-title: Discov. Med.
  contributor:
    fullname: Mujtaba
– volume: 11
  start-page: 148
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb2035
  article-title: Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model
  publication-title: J. Transl. Med.
  doi: 10.1186/1479-5876-11-148
  contributor:
    fullname: Tan
– volume: 6
  start-page: 663
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0995
  article-title: Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines
  publication-title: Front. Immunol.
  contributor:
    fullname: Vandenberck
– volume: 131
  start-page: 741
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb1325
  article-title: The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.26411
  contributor:
    fullname: Lee
– volume: 86
  start-page: 359
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb0835
  article-title: The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review
  publication-title: Am. J. Trop. Med. Hygiene
  doi: 10.4269/ajtmh.2012.11-0525
  contributor:
    fullname: Thomas
– volume: 8
  start-page: 1135
  year: 2012
  ident: 10.1016/j.jconrel.2018.09.009_bb0335
  article-title: Overview of the cancer vaccine field: Are we moving forward?
  publication-title: Human Vaccin. Immunother.
  doi: 10.4161/hv.20474
  contributor:
    fullname: Kudrin
– volume: 42
  start-page: 4859
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0865
  article-title: Targeting Toll-like receptors with small molecule agents
  publication-title: Chem. Soc. Rev.
  doi: 10.1039/c3cs60039d
  contributor:
    fullname: Wang
– volume: 23
  start-page: 938
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb0930
  article-title: Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation
  publication-title: Cell Death Differ.
  doi: 10.1038/cdd.2016.5
  contributor:
    fullname: Garg
– volume: 1494
  start-page: 145
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb0875
  article-title: Synthesis of Lymph Node-Targeting Adjuvants
  publication-title: Methods Mol. Biol.
  doi: 10.1007/978-1-4939-6445-1_10
  contributor:
    fullname: Hanson
– volume: 4
  start-page: 661
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1580
  article-title: CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
  publication-title: Cancer Med.
  doi: 10.1002/cam4.371
  contributor:
    fullname: Camacho
– volume: 5
  start-page: 197
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0090
  article-title: Does the immune system naturally protect against cancer?
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2014.00197
  contributor:
    fullname: Corthay
– volume: 363
  start-page: 711
  year: 2010
  ident: 10.1016/j.jconrel.2018.09.009_bb1545
  article-title: Improved survival with ipilimumab in patients with metastatic melanoma
  publication-title: New England J. Med.
  doi: 10.1056/NEJMoa1003466
  contributor:
    fullname: Hodi
– volume: 199
  start-page: 251
  year: 2004
  ident: 10.1016/j.jconrel.2018.09.009_bb0595
  article-title: Cancer immunotherapy with mRNA-transfected dendritic cells
  publication-title: Immunol. Rev.
  doi: 10.1111/j.0105-2896.2004.00139.x
  contributor:
    fullname: Gilboa
– volume: 17
  start-page: 57
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1575
  article-title: Cutaneous complications of targeted melanoma therapy
  publication-title: Curr. Treat. Options in Oncol.
  doi: 10.1007/s11864-016-0434-0
  contributor:
    fullname: de Golian
– volume: 348
  start-page: 124
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1710
  article-title: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
  publication-title: Science
  doi: 10.1126/science.aaa1348
  contributor:
    fullname: Rizvi
– volume: 23
  start-page: 445
  year: 2002
  ident: 10.1016/j.jconrel.2018.09.009_bb0155
  article-title: Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?
  publication-title: Trends Immunol.
  doi: 10.1016/S1471-4906(02)02281-0
  contributor:
    fullname: Lutz
– volume: 348
  start-page: 203
  year: 2003
  ident: 10.1016/j.jconrel.2018.09.009_bb1770
  article-title: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa020177
  contributor:
    fullname: Zhang
– volume: 15
  start-page: 486
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1170
  article-title: Molecular and cellular insights into T cell exhaustion
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri3862
  contributor:
    fullname: Wherry
– volume: 25
  start-page: 261
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb1765
  article-title: From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2013.03.004
  contributor:
    fullname: Angell
– volume: 34
  start-page: 107
  year: 1981
  ident: 10.1016/j.jconrel.2018.09.009_bb0060
  article-title: The tumor dormant state
  publication-title: Adv. Cancer Res.
  doi: 10.1016/S0065-230X(08)60240-7
  contributor:
    fullname: Wheelock
– volume: 1346
  start-page: 33
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1245
  article-title: mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging
  publication-title: Ann. N. Y. Acad. Sci.
  doi: 10.1111/nyas.12756
  contributor:
    fullname: Perl
– volume: 8
  start-page: 828
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb1360
  article-title: Reprogramming of tumor-associated macrophages with anticancer therapies: radiotherapy versus chemo- and immunotherapies
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2017.00828
  contributor:
    fullname: Genard
– volume: 26
  start-page: 8154
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb0955
  article-title: Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis
  publication-title: Adv. Mater.
  doi: 10.1002/adma.201402996
  contributor:
    fullname: Wang
– volume: 10
  start-page: 909
  year: 2004
  ident: 10.1016/j.jconrel.2018.09.009_bb2000
  article-title: Cancer immunotherapy: moving beyond current vaccines
  publication-title: Nat. Med.
  doi: 10.1038/nm1100
  contributor:
    fullname: Rosenberg
– volume: 17
  start-page: 6118
  year: 2011
  ident: 10.1016/j.jconrel.2018.09.009_bb1110
  article-title: The two faces of interferon-γ in cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-11-0482
  contributor:
    fullname: Raza Zaidi
– volume: 449
  start-page: 419
  year: 2007
  ident: 10.1016/j.jconrel.2018.09.009_bb0305
  article-title: Taking dendritic cells into medicine
  publication-title: Nature
  doi: 10.1038/nature06175
  contributor:
    fullname: Steinman
– volume: 126
  start-page: 2404
  year: 2016
  ident: 10.1016/j.jconrel.2018.09.009_bb1380
  article-title: The host STING pathway at the interface of cancer and immunity
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI86892
  contributor:
    fullname: Corrales
– volume: 56
  start-page: 1687
  year: 2007
  ident: 10.1016/j.jconrel.2018.09.009_bb0035
  article-title: Dynamic cross-talk between tumor and immune cells in orchestrating the immune-suppressive network at the tumor microenvironment
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-007-0343-y
  contributor:
    fullname: Croci
– volume: 24
  start-page: 2011
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb0885
  article-title: Recent findings on the application of toll-like receptor agonists in cancer therapy
  publication-title: Curr. Med. Chem.
  doi: 10.2174/0929867324666170320114359
  contributor:
    fullname: Mikulandra
– year: 2018
  ident: 10.1016/j.jconrel.2018.09.009_bb0945
  article-title: Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy
  publication-title: Angew. Chem. Int. Ed. Eng.
  contributor:
    fullname: Duan
– volume: 392
  start-page: 245
  year: 1998
  ident: 10.1016/j.jconrel.2018.09.009_bb0300
  article-title: Dendritic cells and the control of immunity
  publication-title: Nature
  doi: 10.1038/32588
  contributor:
    fullname: Banchereau
– volume: 13
  start-page: 1
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1560
  article-title: Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis
  publication-title: BMC Med.
  doi: 10.1186/s12916-015-0455-8
  contributor:
    fullname: Bertrand
– volume: 198
  start-page: 28
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb0285
  article-title: Cancer vaccines: Harnessing the potential of anti-tumor immunity
  publication-title: Vet. J.
  doi: 10.1016/j.tvjl.2013.06.005
  contributor:
    fullname: Suckow
– volume: 10
  year: 2015
  ident: 10.1016/j.jconrel.2018.09.009_bb1945
  article-title: C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0143080
  contributor:
    fullname: Shrotriya
– volume: 10
  start-page: 463
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb1220
  article-title: Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors
  publication-title: Onco Targets Ther.
  doi: 10.2147/OTT.S119362
  contributor:
    fullname: Zulfiqar
– volume: 2013
  year: 2013
  ident: 10.1016/j.jconrel.2018.09.009_bb1570
  article-title: Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: The underlying mechanisms and clinical management
  publication-title: Australas. Sci.
  contributor:
    fullname: Tarhini
– volume: 30
  start-page: 439
  year: 2014
  ident: 10.1016/j.jconrel.2018.09.009_bb1760
  article-title: Intratumoral immune microenvironment and survival: the immunoscore
  publication-title: Med. Sci.
  contributor:
    fullname: Galon
– volume: 29
  start-page: 4209
  year: 2017
  ident: 10.1016/j.jconrel.2018.09.009_bb0560
  article-title: Cancer cell lysate entrapment in CaCO3 engineered with polymeric TLR-agonists: immune-modulating microparticles in view of personalized antitumor vaccination
  publication-title: Chem. Mater.
  doi: 10.1021/acs.chemmater.6b05062
  contributor:
    fullname: Lybaert
SSID ssj0005347
Score 2.4762986
SecondaryResourceType review_article
Snippet During the last decade anti-tumor immune-therapy has opened novel opportunities to efficiently combat cancer progression. The introduction of DC- and CAR...
SourceID proquest
crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 125
Title Immunoengineering through cancer vaccines – A personalized and multi-step vaccine approach towards precise cancer immunity
URI https://dx.doi.org/10.1016/j.jconrel.2018.09.009
https://www.ncbi.nlm.nih.gov/pubmed/30223044
https://search.proquest.com/docview/2109335395
Volume 289
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9wwEBUhufRS2vRrmw9UKDlFu7Ily9JxCQmbFkKgCeQmZFmG3YPXrJ3ChlL6H_IP80sykq1sCi2FHm3LtpgZzzyjeU8IfRYVZMVCKEJNnhLueEUMFxURVlRJUCS3Qe3zQsyu-Zeb7GYLnUQujG-rHHJ_n9NDth7OTAZrTpr5fPINwIpkIlMQlDRLpSeacyh_ENPjn8_aPBjvKdNCEj96w-KZLMYL-OdcOb8Ckcggd-r7Ev9cn_6GP0MdOnuFXg4AEk_7Ob5GW67eRUeXvQL1-hhfbQhV7TE-wpcbber1G_Tj3PNBlm6jQoiHnXqw9f5f4e_G-rX2Fj_8usdT3ESwfudKbOoShw5EArHRxKE46pLjLvTgtrjxkhmti4-cBw5Kt36Lrs9Or05mZNiAgVgwVUeclAkrTOIAJrjClrkT0soSIFwKMNAoUUgqDEuto1LZzKjCXwGTV3mpBACJd2i7XtbuA8KMKmN4ZUpalDynSeEEz41Sng7HrCpHaBzNrpteZ0PHBrSFHvykvZ80VRr8NEIyOkf_FjAaasG_bv0UnanhY_IrJKZ2y9tWp15ci2VMZSP0vvfy02wYoB1GOf_4_y_eQy_8EQldhPtou1vdugPANF1xGIL2EO1Mz7_OLh4Bh035ew
link.rule.ids 315,783,787,4509,24128,27936,27937,45597,45691
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9wwEB3S9NBeSvqZTfqhQskp2pUtWZaOITRs2jQEuoHchCzLsHvwmrVT2FBK_kP-YX9JJdnqttBS6NWSbTEzHj0z854A3vHKZcWCS0x0nmJmWYU14xXmhldJUCQ3Qe3znE8v2Yer7GoLjiMXxrdVDrm_z-khWw9XJoM1J818PvnswIqgPJMuKEmWiuwe3GceH7ugHn_7pc-Dsp4zzQX20zc0nslivHA_nSvrSxCJCHqnvjHxzxvU3wBo2IhOduDRgCDRUb_Ix7Bl6ydwcNFLUK8P0WzDqGoP0QG62IhTr5_C11NPCFnajQwhGo7qQcYHwAp90cYX21v0_fYOHaEmovUbWyJdlyi0IGIXHE2ciqIwOepCE26LGq-Z0dr4yHkgoXTrZ3B58n52PMXDCQzYOFN12AqR0EIn1uEEW5gyt1wYUToMlzocqCUvBOGapsYSIU2mZeFHnMmrvJTcIYnnsF0va7sLiBKpNat0SYqS5SQpLGe5ltLz4aiR5QjG0eyq6YU2VOxAW6jBT8r7SRGpnJ9GIKJz1G8Ro9xm8K9b30ZnKvc1-RKJru3yulWpV9eiGZXZCF70Xv65GurgDiWM7f3_i9_Ag-ns05k6Oz3_uA8P_QgOLYUvYbtbXdtXDuB0xesQwD8AUFr7FA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunoengineering+through+cancer+vaccines+-+A+personalized+and+multi-step+vaccine+approach+towards+precise+cancer+immunity&rft.jtitle=Journal+of+controlled+release&rft.au=Lybaert%2C+Lien&rft.au=Vermaelen%2C+Karim&rft.au=De+Geest%2C+Bruno+G&rft.au=Nuhn%2C+Lutz&rft.date=2018-11-10&rft.eissn=1873-4995&rft.volume=289&rft.spage=125&rft.epage=145&rft_id=info:doi/10.1016%2Fj.jconrel.2018.09.009&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0168-3659&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0168-3659&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0168-3659&client=summon